EpSSG
NRSTS 2005

a protocol for
Localized Non-Rhabdomyosarcoma
Soft Tissue Sarcomas

VERSION 1.1 INTERNATIONAL
JUNE 2005
## Contents

1. Protocol sponsor .............................................................. p. 3
2. Protocol co-ordination ...................................................... p. 3
3. EpSSG structure ............................................................... p. 4
4. Administrative organisation .............................................. p. 5
5. Signatures ................................................................ p. 9
6. Abbreviations ................................................................. p.10
7. Summary .................................................................... p.11
8. Background ................................................................. p.16
9. Study structure ............................................................... p.22
10. Patient eligibility ........................................................... p.22
11. Pre-treatment investigation ........................................... p.23
  11.1. Histological diagnosis ................................................ p.23
  11.2. Clinical assessment .................................................... p.23
  11.3. Laboratory investigations ........................................... p.23
  11.4. Radiological investigations ....................................... p.24
  11.5. Tumour measurements .............................................. p.25
  11.6. Lung lesions ............................................................... p.25
12. Staging system ................................................................. p.26
13. Surgical guidelines ......................................................... p.27
  13.1. Definitions ............................................................... p.27
  13.2. Biopsy ................................................................ p.28
  13.3. Primary resection ...................................................... p.29
  13.4. Primary re-operation ................................................ p.30
  13.5. Secondary re-operation ............................................ p.30
  13.6. Reconstructive surgery and local control ................. p.31
  13.7. Lymph nodes ............................................................ p.31
  13.8. Specific sites ............................................................ p.32
  13.9. Surgery for relapse .................................................... p.34
  13.10. Marker clips ............................................................ p.34
  13.11. Histology ............................................................... p.34
14. Radiotherapy guidelines ................................................ p.37
  14.1. Equipment ............................................................... p.37
  14.2. Treatment planning .................................................... p.37
  14.3. Fractionation ............................................................ p.38
  14.4. Target volume definition for primary tumour ............ p.38
  14.5. Target volume definition for lymph nodes ............... p.38
  14.6. Timing of radiotherapy ............................................ p.39
  14.7. Indications and doses ............................................... p.40
  14.8. Normal tissue tolerance guidelines ......................... p.41
  14.9. Treatment guidelines for special sites ...................... p.41
  14.10. Quality assurance of radiotherapy ......................... p.42
15. Chemotherapy guidelines ............................................... p.44
  15.1. Chemotherapy regimen ............................................ p.45
  15.2. Chemotherapy administration and drugs information ... p.46
  15.3. Chemotherapy toxicity ........................................... p.47
  15.4. Supportive care ...................................................... p.50
16. Investigation during and at the end of treatment .......... p.53
  16.1. Investigation during treatment ................................... p.53
  16.2. Tumour reassessment .............................................. p.53
16.3. Response evaluation criteria       p.54
16.4. Investigations at the end of treatment       p.54
16.5. Investigations during follow-up       p.54

17. Synovial sarcoma       p.58
  17.1. Chemotherapy       p.58
  17.2. Radiotherapy       p.61
  17.3. Risk-adapted treatment program       p.66
  17.4. Stopping rules       p.68

18. Adult-type soft tissue sarcomas       p.71
  18.1. Chemotherapy       p.71
  18.2. Radiotherapy       p.76
  18.3. Risk-adapted treatment program       p.79

19. Other histotypes       p.83
  19.1. Infantile fibrosarcoma       p.83
  19.2. Extracranial rhabdoid tumour       p.86
  19.3. Desmoplastic small round cell tumour       p.92
  19.4. Undifferentiated sarcoma of the liver       p.95
  19.5. Malignant ectomesenchymoma       p.96
  19.6. Epithelioid hemangioendothelioma       p.96
  19.7. Myofibroblastic lesions and aggressive fibromatosis       p.97

20. Second-line therapies       p.100
  20.1. Vinorelbine       p.100
  20.2. High-dose ifosfamide       p.101
  20.3. Gemcitabine in leiomyosarcoma       p.103
  20.4. Paclitaxel in angiosarcoma       p.103
  20.5. Isolated limb perfusion       p.104

21. Statistical considerations       p.107

22. Organisational and administrative issues       p.112

Appendix

TNM classification and grouping       p.117
IRS clinical grouping classification       p.118
Definition of sites       p.120
Regional lymph nodes definition       p.122
Toxicity grading       p.127
Radiological guidelines       p.128
Pathology guidelines       p.133

  1. General remarks       p.142
  2. Classification and diagnosis
    2.1. WHO classification       p.144
    2.2. Histotypes       p.148
  3. Immunohistochemistry       p.152
  4. Common translocations       p.154
  5. The grading of NRSTS       p.155
  6. Handling of specimens       p.159
  7. The pathology report       p.163
  8. Material to be sent to national coordinator       p.165

Biological aspects       p.167
Declaration of Helsinki       p.170
Information sheet/consent forms       p.173
1 Protocol Sponsor

It is responsibility of each participating national Group or Institutions to arrange sponsorship in line with the requirements of the European Union directive on Good Clinical Practice in Clinical Trials.

2 Protocol Co-ordination

This protocol is co-ordinated by the European paediatric Soft Tissue Sarcoma Study Group (in its abbreviated form EpSSG). This new collaborative structure has been founded by

- The Co-operative Weichteilsarkom Studie (CWS)
- The AIEOP Soft Tissue Sarcoma Committee (AIEOP STSC)
  (former ICG: Italian Cooperative Group for paediatric soft tissue sarcoma)
- The SIOP Malignant Mesenchymal Tumour Committee (SIOP MMT)

These Groups decided to join forces to design and implement a portfolio of pan-European studies addressed at children and adolescents affected by soft tissue sarcoma.

The three cooperative Groups act on behalf of the following Societies:
- GPOH - Gesellschaft für pädiatrische Onkologie und Hämatologie (Germany, Austria)
- AIEOP - Associazione Italiana di Ematologia e Oncologia Pediatrica (Italy)
- UKCCSG - United Kingdom Children’s Cancer Study Group (United Kingdom)
- SFCE - Société Francaise des Cancers d’Enfants (France)
- SEOP - Sociedad Espanola de Oncologia Pediátrica (Spain)
- NOPHO - Nordic Organisation of Pediatric Hematology and Oncology (Denmark, Norway, Sweden)
- DCOG – Dutch Childhood Oncology Group (The Netherlands)
- BSPHO - Belgian Society of Paediatric Hematology Oncology (Belgium)

This study will not introduce or try to license chemotherapeutic agents for treatment of paediatric sarcoma. Treatment will rely on already licensed and introduced chemotherapeutic drugs. Therefore, chemotherapeutic agents and other therapeutic substances needed for treatment in ESSG NRSTS 2005 will not be paid for by the study nor will these substances be provided by pharmaceutical companies.

**Important note:**

It is emphasised that no legal responsibility for possible consequences resulting from the application of recommendations from this protocol will be taken by the members of the ESSG. Treatment and follow-up of patients with soft tissue sarcoma requires a high degree of medical competence and humane presence existing only in hospitals with adequate infra-structure. A state of emergency due to complications from the underlying disease or from its treatment can develop in every patient at any time. Children with soft tissue sarcomas should thus be treated by an experienced team with multidisciplinary competences.
3 EpSSG Structure

EpSSG Chairmen
Prof. Joern Treuner (Chair, CWS Study Group)
Prof. Modesto Carli (Chair, ICG Study Group)
Dr. Odile Oberlin (Co Chair AIEOP STSC, SIOP MMT Study Group)
Prof. Michael Stevens (Co Chair, SIOP MMT Study Group)

Committee for EpSSG NRSTS 2004 Protocol
Dr. Andrea Ferrari (Coordinator) (Italy)
Dr. Bernadette Brennan (United Kingdom)
Dr. Ewa Koscielniak (Germany)
Dr. Ines Brecht (Germany)
Dr. Michela Casanova (Italy)
Dr. Max Van Noesel (The Netherlands)
Dr. Daniel Orbach (France)
Dr. Gustaf Ljungman (Sweden)
Dr. Nadine Francotte (Belgium)

Radiotherapy Committee Coordinator
Dr. Andreas Schuck (Germany)

Surgical Committee Coordinator
Prof. Helene Martelli (France)

Pathology Committee Coordinators
Dr. Anna Kelsey (United Kingdom)
Prof. Vito Ninfo (Italy)

Biology Committee Coordinator
Dr. Angelo Rosolen (Italy)

Radiology Committee Coordinators
Dr. Hervé Brisse (France)
Kieran McHugh (UK)

Statistical & Data Management Committee Coordinator
Dr. Gian Luca De Salvo (Italy)

Other collaborators:
Dr. Christophe Bergeron
Dr. Gianni Bisogno
4 Protocol EpSSG 2005 – Administrative organisation

The protocol is co-ordinated by the Committee for EpSSG NRSTS 2005 protocol under the supervision of EpSSG Chairmen. The Committee will meet at least twice a year to monitor the progress of the study. The Pathology, Surgical and Radiotherapy Committees will normally meet at the same time as the main Committee.

Cooperative Groups and EpSSG Chairmen:

<table>
<thead>
<tr>
<th>Group</th>
<th>Chair</th>
<th>Institution</th>
<th>Address</th>
<th>Phone</th>
<th>Fax</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIEOP STSC</td>
<td>Prof. Modesto Carli</td>
<td>AIEOP STS Data Centre</td>
<td>Hematology/Oncology Division, Department of Pediatric, Padova, Via Giustiniani, 35128 Padova, Italy</td>
<td>+39 049 8213565</td>
<td>+39 049 8211462</td>
<td><a href="mailto:modesto.carli@unipd.it">modesto.carli@unipd.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CWS Study Data Centre</td>
<td>Hematology/Oncology Division, Department of Pediatric, Padova, Via Giustiniani, 35128 Padova, Italy</td>
<td>+39 049 8211475</td>
<td>+39 049 8211462</td>
<td><a href="mailto:ilaria.zanetti@unipd.it">ilaria.zanetti@unipd.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SIOP MMT Data Centres</td>
<td>Paediatric Oncology, Institut Gustave Roussy, Rue Camille Desmoulins, 94805 Villejuif Cedex, France</td>
<td>+33 1 45 59 41 42</td>
<td>+33 1 45 59 70 19</td>
<td><a href="mailto:oberlin@igr.fr">oberlin@igr.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>United Kingdom Children’s Cancer Study Group</td>
<td>3rd Floor, Hearts of Oak House, 9 Princess Road West, Leicester LE1 6TH, United Kingdom</td>
<td>+44-116-249 4460</td>
<td>+44-116-254 9504</td>
<td><a href="mailto:ukccsg@le.ac.uk">ukccsg@le.ac.uk</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EpSSG NRSTS 2004 Committee

Dr. Andrea Ferrari (Protocol Coordinator)
Paediatric Oncology Unit,
Istituto Nazionale Tumori, Milano
Via G. Venezian 1, 20133 Milano, Italy
Tel.: +39 02 23902588, Fax: +39 02 2665642
e-mail: andrea.ferrari@istitutotumori.mi.it

Dr. Bernadette Brennan
Consultant Paediatric Oncologist
Royal Manchester Children's Hospital,
Hospital Road, Manchester, M27 4HA
Tel: +44 161 727 2227, Fax: +44 161 728 3529
e-mail: bernadette.brennan@cmmc.nhs.uk

Dr. Ewa Koscielniak
Olgahospital
Bismarckstrasse 8
70176 Stuttgart Germany
e-mail: e.Koscielniak@olghospital.de

Dr. Ines Brecht
Olgahospital, Bismarckstrasse 8
70176 Stuttgart Germany
Tel.: +49-711-992-3870, Fax: +49-711-992-2749
e-mail: cws.study@olghospital.s.shuttle.de
i.brecht@olghospital.de

Dr. Michela Casanova
Pediatric Oncology Unit,
Istituto Nazionale Tumouri, Milano
Via G. Venezian 1, 20133 Milano, Italy
Tel.: +39 02 23902588, Fax: +39 02 2665642
e-mail: michela.casanova@istitutotumori.mi.it

Dr. Max Van Noesel
Erasmus MC/Sophia Children's Hospital
Dept. of Paediatric Oncology-Hematology
Dr. Molewaterplein60
3015 GJ Rotterdam, The Netherlands
Tel: +31-10-463 2073/6691, Fax: +31-10-463 6801
e-mail: m.vannoesel@erasmus.nl

Dr. Daniel Orbach
Institut Curie, Département de pédiatrie
26 rue d’Ulm, 75995 Paris
Tel.: +33 0144324601, Fax: 0153104005
e-mail: daniel.orbach@curie.net

Dr. Gustaf Ljungman
Department of Paediatric Hematology Oncology
Children’s University Hospital, SE-75185 Uppsala,
Sweden - Tel +46-186115586, Fax +46-18500949
e-mail: gustaf.ljungman@kbh.uu.se

Dr. Nadine Francotte
Pediatre Hemato-oncologue, Département de Pédiatre
CHC-Clin Espérance - rue Saint Nicolas
B.4420 MONTEGNEE – tel : 3242249111 / 3242249139
nadine.francotte@chc.be
Surgery Panel Coordinator
Dr. Helene Martelli
Service de Chirurgie Pédiatrique,
Hôpital de BICETRE
78, RUE DU GÉNÉRAL LECLERC
94275 LE KREMLIN-BICETRE Cedex, Paris
Tel: 33 (0)145212 92. Fax: 33 (0)145213189
e-mail: helene.martelli@bct.ap-hop-paris.fr

Radiotherapy Panel Coordinator
Dr. Andreas Schuck
Radiotherapy Department, University Hospital, Muenster,
Germany
Tel +49 2518347384
e-mail: schuck@uni-muenster.de

Pathology Panel Coordinators
Dr. Anna Kelsey
Royal Manchester Children's Hospital
Hospital Road. Pendlebury
Manchester, M27 4HA, UK
Tel: +44 161 727 2247
FAX:+44 161 727 2249
e-mail: crcpfcrg@man.ac.uk

Dr. Anna Covezzoli
Clinical Epidemiology Unit
Regional Cancer Centre
Via Gattamelata 64, 35128 Padova, Italy
Tel: +39-0498215704
Fax: +39-0498215706
e-mail: cor.epiclin@unipd.it

Remote Data Entry System
Dr. Marisa De Rosa, Dr. Anna Covezzoli
Sistemi Informativi e Servizi per la Sanità CINECA
Via Magnanelli 6/3,
40033 Casalecchio di Reno, Bologna, Italy
Tel.: +39 051 6171411
Fax : +39 051 6132198
e-mail: covezzoli@cineca.it

Biostatistic and Data-management coordinator
Dr. Kieran McHugh
Radiology Department, Great Ormond Street Hospital for Children, London, WC1N 3JH (UK)
Tel: 0044207 4059200
e-mail : kmchugh@gosh.nhs.uk

Prof. Vito Ninfo
Istituto di Anatomia Patologica
Via Gabelli, 61 – 35100 Padova
Tel +39 049 8272262
Fax + 39 049 8272265
e-mail: vito.ninfo@unipd.it

Dr. Gian Luca De Salvo
Clinical Epidemiology Unit
Regional Cancer Centre
Via Gattamelata 64, 35128 Padova, Italy
Tel: +39-0498215704
Fax: +39-0498215706
e-mail: cor.epiclin@unipd.it

Biostatistic and Data-management coordinator
Dr. Gian Luca De Salvo
Clinical Epidemiology Unit
Regional Cancer Centre
Via Gattamelata 64, 35128 Padova, Italy
Tel: +39-0498215704
Fax: +39-0498215706
e-mail: cor.epiclin@unipd.it

Remote Data Entry System
Dr. Marisa De Rosa, Dr. Anna Covezzoli
Sistemi Informativi e Servizi per la Sanità CINECA
Via Magnanelli 6/3,
40033 Casalecchio di Reno, Bologna, Italy
Tel.: +39 051 6171411
Fax : +39 051 6132198
e-mail: covezzoli@cineca.it
### 4.1 ORGANISATION BY COUNTRY

<table>
<thead>
<tr>
<th>Country</th>
<th>Coordinating Centre for ESSG studies</th>
<th>National Coordinator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>CWS Stuttgart</td>
<td>Ruth Ladenstein</td>
</tr>
<tr>
<td>Belgium</td>
<td>French Data Centre</td>
<td>Nadine Francotte</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>ICG Data Centre, Padova - Department of Pediatric, Padova - Via Giustinian, 3 - 35128 Padova, Italy - Tel.: +39 049 8211475 Fax:+39 0498211462 e-mail: <a href="mailto:ilaria.zanetti@unipd.it">ilaria.zanetti@unipd.it</a></td>
<td>Andrea Ferrari Mutica Michela Casanova</td>
</tr>
<tr>
<td>Denmark</td>
<td>NOPHO</td>
<td>Catherine Rechnitzer</td>
</tr>
<tr>
<td>Italy</td>
<td>ICG Data Centre, Padova - Department of Pediatric, Padova - Via Giustinian, 3 - 35128 Padova, Italy - Tel.: +39 049 8211475 Fax:+39 0498211462 e-mail: <a href="mailto:ilaria.zanetti@unipd.it">ilaria.zanetti@unipd.it</a></td>
<td>Andrea Ferrari Mutica Michela Casanova</td>
</tr>
<tr>
<td>France</td>
<td>French Data Centre (Curie) - Paediatric Oncology - Institut Curie, 26 rue d’Ulm 75005 Paris, France.Tel.: +33 144324550 - Fax.:+33 153104005</td>
<td>Daniel Orbach</td>
</tr>
<tr>
<td>Germany</td>
<td>CWS Stuttgart CWS Study Data Centre Olghospital,Bismarckstrasse 8, 70176 Stuttgart Germany, Tel.: +49-711-992-3870 Fax: +49-711-992-2749 e-mail: <a href="mailto:cws.study@olgahospital.s.shuttle.de">cws.study@olgahospital.s.shuttle.de</a></td>
<td>Ewa Koscieleniak Ines Brecht</td>
</tr>
<tr>
<td>Israel</td>
<td></td>
<td>Myriam Ben Arush</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>DCOG (Dutch Childhood Oncology Group) Leyweg 299 - 2545 CJ The Hague, The Netherlands - Tel: +31-70-367 4545 Fax: +31-70-3670868 - Email: <a href="mailto:info@skion.nl">info@skion.nl</a></td>
<td>Max Van Noesel</td>
</tr>
<tr>
<td>Norway</td>
<td>NOPHO</td>
<td>Ingebjorg Stom-Mathiesen</td>
</tr>
<tr>
<td>Poland</td>
<td>Stuttgart</td>
<td>Bernarda Kazanowka</td>
</tr>
<tr>
<td>Portugal</td>
<td></td>
<td>Nuno Jorge Farinha</td>
</tr>
<tr>
<td>Spain</td>
<td>SEOP Data Centre, Hospital Universitari Vall d’Hebron, p.Vall d’Ebron 119 – 08035, Barcelona, Spain – tel:+34 934893089, fax:+34 934893089 – Email: <a href="mailto:jossanchez@vhebron.net">jossanchez@vhebron.net</a></td>
<td>Soledad Gallego</td>
</tr>
<tr>
<td>Sweden</td>
<td>NOPHO</td>
<td>Gustaf Ljungman</td>
</tr>
<tr>
<td>Switzerland</td>
<td></td>
<td>Felix Niggli</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>United Kingdom Children’s Cancer Study Group (UKCCSG) Leicester – 3rd Floor, Hearts of Oak House, 9 Princess Road West, Leicester LE1 6TH, United Kingdom – tel:+44 1162494460, fax:+44 1162549504 – email: <a href="mailto:ukccsg@le.ac.uk">ukccsg@le.ac.uk</a></td>
<td>Bernadette Brennan</td>
</tr>
<tr>
<td>New Centres / New Countries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5 Signatures

__________________________________________
Prof. Joern Treuner                        Prof. Modesto Carli

__________________________________________
Dr. Odile Oberlin                          Prof. Michael Stevens

__________________________________________
Dr. Andrea Ferrari                         Dr. Bernadette Brennan

__________________________________________
Dr. Michela Casanova                       Dr. Ines Brecht

__________________________________________
Dr. Ewa Koscielniak                        Dr. Max Van Noesel

__________________________________________
Dr. Daniel Orbach                          Dr. Andreas Schuk

__________________________________________
Prof. Helene Martelli                      Dr. Anna Kelsey

__________________________________________
Prof. Vito Ninfo                           Dr. Gian Luca De Salvo

__________________________________________
Dr. Gianni Bisogno                         Dr. Angelo Rosolen

__________________________________________
Dr. Christoph Bergeron                     Dr. Gustaf Ljungman

__________________________________________
Dr. Hervè Brisse                           Dr. Nadine Francotte

__________________________________________
Dr. Kieran McHugh
6 Abbreviations

EpSSG = European paediatric Soft Tissue Sarcoma Study Group
CWS, GPOH = Co-operative Weichteilsarkom Studie, Gesellschaft für pädiatrische Onkologie und Hämatologie
ICG, AIEOP-STSC = Italian Cooperative Group, Associazione Italiana Ematologia Oncologia Pediatrica – Soft Tissue Sarcoma Committee
SIOP-MMT = Societé Internationale d’Oncologie Pédiatrique / International Society of Paediatric Oncology - Malignant Mesenchimal Tumour Committee
UKCCSG = United Kingdom Children’s Cancer Study Group
SFCE = Société Française des Cancers d’Enfants
SEOP = Sociedad Espanola de Oncologia Pediátrica
NOPHO = Nordic Organisation of Pediatric Hematology and Oncology
BSPO = Belgian Society of Paediatric Hematology Oncology
DCOG = Dutch Childhood Oncology Group
IRS = Intergroup Rhabdomyosarcoma Study
POG = Pediatric Oncology Group
COG = Children Oncology Group
NCI = National Cancer Institute

RMS = rhabdomyosarcoma
NRSTS = non-rhabdomyosarcoma soft tissue sarcomas
STS = soft tissue sarcomas
pPNET = peripheral primitive neuroectodermal tumour
MPNST = malignant peripheral nerve sheath tumour
NF1 = neurofibromatosis type 1
GIST = gastro-intestinal stromal tumour
DSRCT = desmoplastic small round cell tumour

TNM = tumour – node – metastasis
FNCLCC = French Federation of Cancer Centers Sarcoma Group
OS = overall survival
EFS = event-free survival
LRFS = local relapse-free survival
MFS = metastases-free survival
CR = complete response
PR = partial response
SD = stable disease
PD = progressive disease

S = surgery
RT / RXT = radiotherapy
GTV = gross tumour volume
CTV = clinical target volume
PTV = planning target volume
CT= chemotherapy
IFO = ifosfamide
DOXO = doxorubicin
G-CSF =granulocyte colony stimulating factor
VA = vincristine-actinomycin
VAC = vincristine-actinomycin-cyclophosphamide
VAdr = vincristine-adriamycin-cyclophosphamide
VACA = vincristine-actinomycin-cyclophosphamide-adriamycin
VAIA = vincristine-actinomycin-ifosfamide-adriamycin
CEVAIE = carboplatin-etoposide-vincristine-actinomycin-ifosfamide-epirubicin

CT-scan = computed tomography scan
MRI = magnetic resonance imaging
CTC = common toxicity criteria
IDMC = International Data Monitoring Committee
RDE = Remote Data Entry
7 Summary

Three Cooperative Groups have been working in Europe on paediatric soft tissue sarcoma for the last twenty years: 1) the SIOP MMT (International Society of Paediatric Oncology - Malignant Mesenchymal Tumours) Committee, 2) the CWS (German Co-operative Soft Tissues Sarcoma Group) Committee, and 3) the AIEOP STSC (Associazione Italiana Ematologia Oncologia Pediatrica - Soft Tissue Sarcoma Committee) (former ICG, Italian Cooperative Group for paediatric soft tissue sarcoma).

Cooperation has intensified over the last few years and has led to the foundation of the European paediatric Soft Tissue Sarcoma Study Group (EpSSG). This collaboration will allow the recruitment of patients from all over Europe to the same protocol and thus be able to answer more rapidly some still unanswered questions regarding the treatment of children with soft tissue sarcomas.

The NRSTS protocol addresses the treatment of children and young people presenting with non-metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). It parallels the EpSSG protocol addressed paediatric patients with rhabdomyosarcomas (RMS). Patients with metastatic soft tissue sarcomas will be treated according to different protocols elaborated within the framework of EpSSG.

Soft tissue sarcomas (STS) are rare, with an annual incidence around 2.3/100,000; they account for less than 1% of all malignant tumours and 2% of all cancer-related deaths. In paediatric age, however, about 8% of all malignancies are STS, with RMS representing approximately 55-60% of them. The so called “non-rhabdomyosarcoma” soft tissue sarcomas (NRSTS) account for about 3-4% of paediatric cancers and constitute a very heterogeneous group of tumours with a variety of histotypes with different origins, biology and natural history, some of which are more common in adults.

Most of the experience of treatment for paediatric NRSTS derives from the experience of managing the same diseases in adults or is based on the principles derived from the management of RMS. Despite the global incidence of NRSTS is not so far from that of RMS, the large heterogeneity of this group and the rarity of each single histotype prevents the performance of clinical trials on a single tumour type, and NRSTS consequently have to be treated and studied as a group.

The EpSSG NRSTS protocol is completely dedicated to NRSTS. Given the heterogeneity of these tumours, clinical studies should target diagnostic subgroup as specific as possible. To create more homogeneous subsets, the protocol considers three separate sections:
1 – synovial sarcoma
2 – “adult-type” soft tissue sarcomas
3 – “other histotypes”

?? For synovial sarcoma and “adult-type” soft tissue sarcomas, the protocol comprises two prospective non-randomized historically-controlled trials (as “therapeutic recommendations” and not as “investigational trial”). For patients with synovial sarcoma and “adult-type” soft tissue sarcomas, full data as described in the forms are required.
For the so-called “other histotypes” (as well as for the section on “second-line therapies”) only general considerations and suggestions are reported. However, patients with “other histotypes” will be registered in the protocol. Patients with undifferentiated sarcomas will be registered in the NRSTS protocol, but they will be treated according to the EpSSG RMS 2005 protocol. These patients should be treated according to the RMS guidelines, but they should not be included in the RMS protocol (i.e., they should not be randomized).

Patients with extrasosseous pPNET/Ewing sarcomas will not be registered in the EpSSG NRSTS 2005 study.

7.1 Objectives:

First objective of the study is to make uniform the treatment of NRSTS patients in Europe. Patients will be treated with a risk-adapted multidisciplinary treatment approach. In particular, the protocol aims to investigate, as main objectives:

- the survival rates (event-free survival EFS and overall survival OS) and the pattern of treatment failure in patients with synovial sarcoma and adult-type sarcomas
- the role of an ifosfamide-doxorubicin regimen in improving the response rate in patients with unresectable (measurable disease) synovial sarcoma and adult-type sarcomas

Secondary objectives will be:

- the prospective evaluation of clinical/pathological prognostic factors, in particular: a) the radiological and pathological response to neo-adjuvant treatment, b) the tumour grade, assessed according to the POG and the FNCLCC, and to the new prospective EpSSG grading system
- the impact of the omission of adjuvant chemotherapy in patients with low-risk synovial sarcoma (IRS group I, tumour smaller than 5 cm)
- the role of adjuvant chemotherapy in IRS group I-II, G3, size > 5 cm adult-type STS patients in improving the metastases-free survival (MRS) and the OS

Moreover, the study aims to improve the biological studies and samples collection of these malignancies.

7.2 Patients eligibility

Registration is recommended for all patients with diagnosis of NRSTS observed in Paediatric Oncology Center.

Inclusion in the prospective non-randomized historically-controlled trial require:

- Pathologically proven diagnosis of synovial sacomas or adult-type soft tissue sarcomas
- Age less than 21 years
- No evidence of metastatic disease
EpSSG NRSTS 2005 protocol

- No previous treatment except for primary surgery
- Diagnostic specimens available for pathological review
- Written consent

7.3 Patients stratification

Adult Oncology Groups utilised different staging systems for soft tissue sarcomas, including histological grading, tumour size, tumour depth, degree of surgical resection and sometimes age. In agreement with previous paediatric studies, stage of disease will be defined according to both

1. the clinical tumour-node-metastases (TNM) staging classification
2. the Intergroup Rhabdomyosarcoma Study (IRS) post-surgical grouping system.

For adult-type NRSTS, patients stratification needs to be performed according to IRS group, tumour size and tumour grade (tumour grade must be available in all cases and should be guide in particular the indication to adjuvant chemotherapy). Given that synovial sarcoma has to be considered as a high grade tumour in all cases, the stratification follows IRS group and tumour size alone.

7.4 Pathology and biology

The sample collection of NRSTS needs to be improved and this is one of the aim of this protocol. For the pathologists, one of the most debated and complex subject on NRSTS concerns the definition of tumour grade, which is predictive for clinical outcome and essential to guide the treatment choice. It is well know that different grading systems are available (NCI, POG, FNCLCC), but unfortunately an universally accepted system does not exist still today.

For the EpSSG NRSTS protocol, the FNCLCC grading system will be adopted to give to the clinicians the tumour grade essential to define the treatment choice. Prospectively, a new grading system will be evaluated and compared to the FNCLCC and the POG system.

Translational research on NRSTS will be strengthened. Several chromosomal translocations are present in NRSTS: most of the specific recurrent translocations have been cloned and most of the resulting fusion genes have been identified. These translocations may represent the ideal targets for new molecular therapies, since the success of imatinib mesylate (Glivec) in the treatment of GIST provides important lessons for the development of new therapies specifically designated for targets identified as critical to tumour’s biology.

7.5 Statistical considerations

The study on synovial sarcomas and “adult-type” soft tissue sarcomas is a prospective, non-randomised, observational, international, multi-institutional, and historically-controlled study. Stopping rules has been defined to monitor throughout the study the survival rates of patients with synovial sarcomas.

For “other histotypes”, only general considerations and suggestions are provided.
7.6 Organization of the study

The EpSSG is an inter-group structure which is based on the already existing national and international organisations built with the efforts of the participants to CWS, ICG and SIOP MMT studies over many years. The existing national coordinating centers will continue their work ensuring pathology review, clinical advice and data quality control. All clinical centres previously part of the SIOP, CWS or STSC Co-operative Group are expected to participate in the EpSSG study. New clinical centres, whose national group does not take part as a whole, who wish to participate must demonstrate their ability to participate in the study and must link to one of the existing co-operative Groups. The EpSSG Co-ordinating Centre will supervise the data collection and data quality and will be responsible for the statistical analysis within the trial at given time periods in collaboration with the panel of statisticians from individual groups.

7.7 Data mangement and analysis

The EpSSG NRSTS trial will be managed via a web based system provided by CINECA (Casalecchio, Italy). At the moment it has not yet established if the Co-ordinating centres will allow their local sites to enter directly the data into the electronic data base via Internet or if they will choose the traditional paper based flow of data within their group. Standard Operative Procedures for the electronic data management will be agreed on and followed by the Co-ordinating Centres. Reports on the study progress will be prepared twice yearly, describing accrual of the patients, group allocations, local therapy modalities and toxicity of the treatments given. This report will be circulated to the Principal Investigators. The international study committee shall meet as appropriate to consider patient accrual, eligibility, treatment allocation and outcome and ensure a smooth conduct of the study. An International Data Monitoring Committee (IDMC) is not required because the trial is not an investigational trial.

7.8 Ethical considerations

The EpSSG NRSTS 2005 protocol follows the EU Clinical Directive 2001/20/EC for non-commercial clinical trials, in according to the Good Clinical Practice guidelines. National implementation of the directives is a matter of current debate, and possibly divergent views between Member States could be present. As a consequence, different national groups may need deal differently with the protocol in order to address relevant ethical and insurance requirements. The protocol is not an investigational trial: therefore, the decision to submit it, before patients enrolment, to the Ethics Committee of each centre for review and approval according to in force law depends to the each national group. The patient’s and/or parent’s written consent is required for data management and for collecting samples for biological studies (sending diagnostic material to reference institutions, which in all participating countries has to conform to the national data protection legislation). The need for a written consent for participating in the study depends on the indication of each national group.
# TREATMENT SUMMARY

## SYNOVIAL SARCOMA

| IRS group I, = 5 cm | surgery only |
| IRS group I, > 5 cm | IFO-DOXO x 4 |
| IRS group II, = 5 cm | IFO-DOXO x 3 – RXT 50.4 Gy * |
| IRS group II, > 5 cm | IFO-DOXO x 3 – IFO x 2 + RXT 54 Gy* – IFO-DOXO x 1 |
| IRS group III / N1 | IFO-DOXO x 3 - local treatment (S/RXT+IFO x 2) + IFO-DOXO x1 |

* RXT could be avoided in selected cases (i.e. age < 10 years)

## ADULT-TYPE STS

| group I, = 5cm | surgery alone |
| group I, > 5 cm | |
| G1 | surgery alone |
| G2 | RXT 50.4 Gy |
| G3 | IFO-DOXO x 3 – IFO x 2 + RXT 50.4 Gy – IFO-DOXO x 1 |

| IRS Group II / N0 | surgery alone |
| G1 | |
| G2-G3, = 5 cm | RXT 54 Gy |
| G2, > 5 cm | RXT 54 Gy |
| G3, > 5 cm | IFO-DOXO x 3 – IFO x 2 + RXT 54 Gy - IFO-DOXO x 1 |

| IRS III & N1 | IFO-DOXO x 3 - local treatment (S/RXT+IFO x 2) + IFO-DOXO x2 |
8 Background

Soft tissue sarcomas are a very heterogeneous group of non-epithelial extraskeletal malignancies that are classified on a histogenic basis according to the adult tissue they resemble. Different histotypes with different biology and clinical behaviour are included in the group of NRSTS. Some of these tumours are more frequently found in adult age and many of which are very rare in childhood.

NRSTS can arise, generally as a soft part enlarging mass, anywhere in the body (most frequently in the muscles of extremities, less usually in the trunk or head and neck region). They occur at any age, but some subtypes are particularly typical of adolescents, i.e. synovial sarcoma, malignant peripheral nerve sheath tumours (MPNST) and fibrosarcoma (liposarcoma and malignant fibrous histiocytoma the most common histotypes in adult age).

Usually, they are characterized by local aggressiveness; their propensity to metastasize is directly correlated to their grade of malignancy. Different histotypes with the same grade of malignancy could display the same clinical behaviour. Generally, low-grade tumours usually may have local aggressiveness but low tendency to metastatic spread. High-grade tumours are more frequent and have a more invasive behaviour with high propensity to metastasize (in particular at the lung).

Overall, the survival rate for soft tissue sarcomas averages 60%, with substantial differences according to the different histotypes, the degree of malignancy, and the stage of the disease. The treatment of patients with soft tissue sarcomas is complex and necessitates multidisciplinary approach.

Surgery is the mainstay of treatment in NRSTS. Quality of surgery is critical, and it is felt that soft tissue sarcoma patients should be referred to specialist centers for local treatment, preferably prior to undergoing biopsy. In particular, deep and large (i.e. in excess of 5 cm) soft tissue lesions are highly suspicious for sarcomas, and they should be referred to centers of excellence.

Inadequate surgical margins adversely affect the local outcome, and - as a consequence - the overall survival, although some experiences in adult soft tissue sarcomas failed to find a strong correlation between quality of surgery and final outcome (various studies showed that what was relevant for distant metastases and therefore disease-specific survival was the intrinsic biological aggressiveness of the tumour, as defined by size, depth, malignancy grade and histotype, whereas, in this sense, the quality of surgical margins and the local recurrence might be well regarded as an additional biological marker of aggressiveness, i.e. a result rather than a cause).

With the exception of pPNET/Ewing sarcomas (and partially of synovial sarcomas), NRSTS are generally considered poorly chemosensitive tumours. However, knowledge regarding chemotherapy responsiveness is clearly incomplete and must be improved. In addition, prognostic factors in paediatric NRSTS are not completely defined and it is uncertain whether they are the same of those identified in adult sarcomas.

Despite the global incidence of NRSTS being not so far from that of RMS, the published studies available on paediatric NRSTS are definitely less than those on RMS.

The only published multicenter study is that of Pediatric Oncology Group (POG) that reported the results of a prospective randomised trial of adjuvant chemotherapy in patients with surgically resected NRSTS. The trial was conducted from 1986 to 1992: IRS group I patients were randomized to be observed or to receive adjuvant chemotherapy (VAC/VAdrC), group II patients received radiotherapy and then were randomly assigned to receive or not chemotherapy. Unfortunately, only 30 out of the 81 eligible patients accepted randomization: therefore, only 15 patients were assigned to each arm. For the whole series, 5-year EFS and OS were 72.2% and 84.5%, respectively. No statistically significant differences were observed between patients treated
or not treated with chemotherapy. Tumour grade was identified as the most important predictor of outcome (Pratt CB, 1999).

The St Jude Children’s Research Hospital reported a large single-institution experience with surgically-resected (Spunt SL, 1999) and initially unresected non-metastatic NRSTS (Spunt SL, 2002). In the series of 121 IRS group I-II patients, 5-year EFS and OS were 77% and 89% respectively. Statistical analysis confirmed the prognostic role of surgical margins, local invasiveness, tumour grade and, in particular, tumour size (Spunt SL, 1999).

In the series of 40 initially-unresected patients, 5-year EFS and OS were 33% and 56% respectively. These patients presented high-risk features at diagnosis. Response rate to primary chemotherapy was 37%, but the response to therapy did not predict the outcome. Most treatment failures were local, and post-relapse survival was poor (19%) (Spunt SL, 2002).

More recently, the retrospectively-analysed single-institution series from the Istituto Nazionale Tumori of Milan, Italy, parallels the two studies reported by the St Jude (Ferrari A, J Clin Oncol, 2005).

The series includes 182 patients aged less than 18 years treated between 1977 and 2003: the most frequent histotype was synovial sarcoma (32% of cases), followed by MPNST (17%). Overall, 102 patients received complete resection at diagnosis. Radiotherapy was given to 73 patients. Chemotherapy was administered to 114 patients, 70 of them as adjuvant therapy. Reported survival rates at 5 years were as follow: EFS 63%, LRFS 75%, MFS 72%, OS 76%. Local invasiveness and tumour size represented the most significant prognostic factors.

In patients with grossly-resected disease (136 patients, 5-year EFS and OS 72% and 86%), adjuvant chemotherapy was given to 52% of cases. The authors reported the analysis of patients with adult-type STS (excluding synovial sarcomas) at high risk of metastatic failure (i.e. IRS group I-II, size > 5 cm, G3): in this subset of 15 patients, 5-year MFS was 36%, and it was 53% in patients treated with adjuvant chemotherapy (11 cases) and 0% in those treated without chemotherapy (4 cases). Post-operative radiotherapy seemed to have an impact on local control and outcome in IRS group I patients considered at high-risk of local control due to large tumour size and in IRS group II patients.

In patients with initially unresected disease (40 cases – EFS and OS 45% and 52%, respectively), the overall response rate was 39% in terms of complete and partial response (CR+PR), but it was 58% when minor responses were included (some cases - initially considered unresectable - had complete delayed surgery after minor response to chemotherapy; in these tumours, generally regarded as poor responders to chemotherapy, also minor tumour shrinkage may have a significant value). Response rate was better in those cases treated with regimens including ifosfamide and antracyclines. The outcome was directly influenced by the response to primary chemotherapy and the possibility to obtain complete tumour resection (Ferrari A, J Clin Oncol, 2005).

The general attitude in the reported studies has been to analyse NRSTS as a whole group, despite heterogeneity.

With the aim to understand more on the different histotypes, in the last year CWS and AIEOP STSC groups cooperated in performing selective retrospective analysis for any single histotype. Table 1 briefly summarizes the results obtained in these studies.

Overall, these retrospective studies showed: 1) better results when compared with adult counterparts, 2) concerning treatment: together with the unquestionable role of surgery and the effectiveness of radiotherapy in improving local control in patients with microscopical residual disease, these analyses would suggest some unexpected responses to chemotherapy in some histotypes, 3) tumour size and surgery (IRS grouping) are the most significant prognostic factors.
### Table 1. NRSTS: Retrospective analysis for single histotypes from Italian and German Groups (1).

<table>
<thead>
<tr>
<th>histotype</th>
<th>pts</th>
<th>groups</th>
<th>treatment</th>
<th>results</th>
<th>Conclusions, comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SYNOVIAL SARCOMA</strong></td>
<td>220</td>
<td>MD Anderson, St. Jude, CWS, INT Milan</td>
<td>82% received CT, 60% RT</td>
<td>5yr EFS = 72%, 5yr OS = 80%</td>
<td>CT: no impact on survival in Group I-II pts</td>
</tr>
<tr>
<td>Ocku et al. J Clin Oncol 2003;21:1601-1612</td>
<td></td>
<td></td>
<td></td>
<td>CT response rate = 61%</td>
<td>RT improved LRFS and OS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prognostic factors: SIZE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICG, CWS</td>
<td>80% CT, 40% RT</td>
<td>10yr OS = 45%, (5% in NF1)</td>
<td></td>
</tr>
<tr>
<td><strong>MALIGNANT PERIPHERAL NERVE SHEATH TUMOUR</strong></td>
<td>166</td>
<td>ICG, CWS</td>
<td>80% CT, 40% RT</td>
<td>CT response = 47%</td>
<td>Local control is the main challenge</td>
</tr>
<tr>
<td>Carli et al. SIOP Meeting 2001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RT improve local control IRS I-II pts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICG, CWS</td>
<td>72% CT, 24% RT</td>
<td>5yr OS 78% for infantile type, 51% adult type</td>
<td>Unexpected response to CT</td>
</tr>
<tr>
<td><strong>FIBROSARCOMA</strong></td>
<td>25</td>
<td>ICG</td>
<td>72% CT, 24% RT</td>
<td>CT response 3/8</td>
<td>Infants: better outcome, surgery alone</td>
</tr>
<tr>
<td>Cecchetto et al. J Surg Oncol 2001;78:255-231</td>
<td></td>
<td></td>
<td></td>
<td>5yr OS 92% for infantile type, 60% adult type</td>
<td>Adult type: SIZE and IRS group as prognostic factors</td>
</tr>
<tr>
<td>Ladenstein et al. SIOP Meeting 2001</td>
<td>52</td>
<td>CWS</td>
<td>54% CT, 10% RT</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPITHELIOID SARCOMA</strong></td>
<td>44</td>
<td>CWS, ICG</td>
<td>not reported</td>
<td>OS = 89% for IRS Group I, 41% II-III, 0% IV</td>
<td>Prognostic factors: IRS group, T, SIZE</td>
</tr>
<tr>
<td>Matke et al. SIOP Meeting 2001</td>
<td></td>
<td></td>
<td></td>
<td>81% &lt;5cm, 33% &gt;5cm</td>
<td>Surgery mainstay of treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICG, CWS</td>
<td></td>
<td>CT response 3/8</td>
<td></td>
</tr>
<tr>
<td><strong>LEIOMYOSARCOMA</strong></td>
<td>16</td>
<td>ICG</td>
<td>56% CT, 19% RT</td>
<td>5yr OS = 73% (SIZE 100% vs 45%)</td>
<td>Role for RT</td>
</tr>
<tr>
<td>Kanz et al. SIOP Meeting 2001</td>
<td>54</td>
<td>CWS, ICG</td>
<td>60% CT, 18% RT</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MALIGNANT FIBROUS HISTIOCYTOMA</strong></td>
<td>45</td>
<td>CWS, ICG</td>
<td>55% CT, 33% RT</td>
<td>5yr OS = 89%, 100% in IRS Group I-II</td>
<td>Gross surgical is the treatment of choice</td>
</tr>
<tr>
<td>Kanz et al. SIOP Meeting 2001</td>
<td></td>
<td></td>
<td></td>
<td>CT response 3/7</td>
<td></td>
</tr>
<tr>
<td><strong>LIPOSARCOMA</strong></td>
<td>34</td>
<td>CWS, ICG</td>
<td>65% CT, 50% RT</td>
<td>5yr OS: 100% IRS I, 67% II, 22% III, 33% IV</td>
<td>Prognostic factors: surgery, SIZE, age (?)</td>
</tr>
<tr>
<td>Mattke et al. SIOP Meeting 2001</td>
<td></td>
<td></td>
<td></td>
<td>100% &lt;5cm</td>
<td>Quite good response to CT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICG, CWS</td>
<td></td>
<td>CT response 7/13</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. NRSTS: Retrospective analysis for single histotypes from Italian and German Groups (2).

<table>
<thead>
<tr>
<th>histotype</th>
<th>pts</th>
<th>groups</th>
<th>treatment</th>
<th>results</th>
<th>Conclusions, comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLEAR CELL SARCOMA</td>
<td>28</td>
<td>ICG, CWS</td>
<td>71% CT 25% RT</td>
<td>5yr OS = 69% CT response 1/7</td>
<td>Only surgery for small resected tumour</td>
</tr>
<tr>
<td>Ferrari et al. Cancer 2002;94:3269-3276</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Uncertain role for CT and RT</td>
</tr>
<tr>
<td>ANGIOSARCOMA</td>
<td>18</td>
<td>ICG, CWS</td>
<td>78% CT 33% RT</td>
<td>5yr OS = 31%, EFS = 21% CT response 3/9</td>
<td>Poor prognosis – high rate of metastatic relapses</td>
</tr>
<tr>
<td>HEMANGIOPERICYTOMA</td>
<td>27</td>
<td>ICG, CWS</td>
<td>85% CT 55% RT</td>
<td>Infants: 5/6 CT response, OS 85% Adult-type: CT response 70%, OS 69%</td>
<td>Infants: myofibroblastic lesions? Adult-type: CT and RT seem effective, SIZE as prognostic factor</td>
</tr>
<tr>
<td>Ferrari et al. Cancer 2001;92:2692-2698</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEMANGIOHENDOTELIOMA</td>
<td>18</td>
<td>ICG, CWS</td>
<td>72% CT (4 pts received ?-IFN)</td>
<td>OS = 83%, EFS 60% No response to CT 2 PR + 2 SD with ?-IFN</td>
<td>Heterogeneous group CT completely uneffective, role for ?-IFN</td>
</tr>
<tr>
<td>ALVEOLAR SOFT PART SARCOMA</td>
<td>19</td>
<td>ICG</td>
<td>79% CT 42% RT</td>
<td>5yr OS = 80%, 92% for localized disease, 100% &lt;5 cm, 31% &gt;5 cm CT response 2/7</td>
<td>More favourable prognosis than adults Surgery mainstay of therapy SIZE strongly correlates with outcome</td>
</tr>
<tr>
<td>DESMOPLASTIC SMALL ROUND CELL TUMOUR</td>
<td>6</td>
<td>ICG</td>
<td>All pts received CT</td>
<td>Alive in CR 4/18 (with short follow-up)</td>
<td>Disappointing survival Complete resection + intensive CT ± RT crucial for good prognosis</td>
</tr>
<tr>
<td>DESMOPLASTIC SMALL ROUND CELL TUMOUR</td>
<td>12</td>
<td>CWS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
8.1 References


9 Study structure

The protocol contains three separate sections:

1 – synovial sarcoma
2 – “adult-type” soft tissue sarcomas
3 – “other histotypes”

10 Patient eligibility

Eligibility criteria for the prospective non-randomized historically-controlled trial are the following:

- A pathologically proven diagnosis of synovial sarcoma and adult-type soft tissue sarcomas
- No evidence of metastatic lesions
- Age less than 21 years (20 years and 364 days) of age
- No previous treatment except for primary surgery
- For patients who require adjuvant chemotherapy according to protocol guidelines, no more than an 8 week-interval between the diagnostic surgical approach and the start of chemotherapy
- For patients who require adjuvant chemotherapy according to protocol guidelines, no pre-existing illness preventing treatment (in particular renal function must be equivalent to grade 0-1 nephrotoxicity, no prior history of cardiac disease and normal shortening fraction (> 28%) and ejection fraction (> 47%))
- No previous malignancy
  Patients with post-irradiation soft part sarcomas could be registered and treated according to the protocol guidelines, but they will be analysed separately
- Diagnostic material available for pathology review
- Available for long term follow up through the treatment centre
- Written informed consent for treatment available.
11 Pre-treatment investigations

With the pre-treatment investigations a patient will be tested for eligibility and staging criteria. The pre-treatment investigations must be performed no more than 4 weeks before the beginning of chemotherapy; otherwise they need to be repeated.

11.1 Histological diagnosis

The diagnosis must be established pathologically. Open surgical biopsy is the preferred approach as this maximises the tissue available for diagnostic procedures, biological studies and central pathology review. Open biopsy is essential if initial needle biopsy is non-diagnostic or equivocal. (See the paragraph of Surgical Guidelines for biopsy techniques and of Pathology Guidelines for details about tissue handling and diagnostic pathology techniques)

11.2 Clinical assessment

?? Weight, Height and Body Surface Area
?? Blood pressure, pulse
?? Site and clinical extent of the tumour
?? Regional lymph node involvement should be clinico-radiologically assessed and recorded in all cases. Lymph node biopsy is required when nodal involvement is suspected.

11.3 Laboratory investigations

?? Blood: Full Blood Count, Differential WBC and Platelet Count, Creatinine (and formal GFR measurement if possible), Na, K, Ca, Mg, PO4, Cl and HCO3 or Total CO2, LDH, Liver function including ALT / AST, Bilirubin and Alkaline Phosphatase
?? Early Morning Urine sample for Phosphate, Creatinine, Osmolarity and routine urinalysis (included as baseline for Ifosfamide nephrotoxicity evaluation)
?? Bone Marrow: the evaluation of bone marrow (bilateral aspirates and trephines) is required only for patients with extraossues pPNET/Ewing sarcoma.
?? Cerebrospinal fluid examination for cytospin and cell count is required only for patients with parameningeal tumours with high risk of meningeal involvement (i.e. cranial nerve palsy, skull base bone erosion, intracranial tumour extension)

And
?? **Echocardiogram**: baseline assessment is required in all patients who are to receive chemotherapy according to protocol guidelines

### 11.4 Radiological investigations

?? Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. **Volume estimation** should be attempted by providing the maximum sagittal, coronal and axial diameters.  
MRI: Intravenous **gadolinium** administration (0.2 ml/kg - 0.1 mmol/kg) is mandatory for all MRI examinations (post-contrast T1-weighted sequences should ideally be performed with fat saturation). MRI is particularly recommended for limb, head/neck, pelvic and paraspinal masses. MRI appears to be superior to CT scan in defining soft tissue extension. CT scan: it is superior to MRI in the evaluation of possible bone erosion and could be indicated for nasopharyngeal masses, and also for the assessment of abdominal lymphadenopathy and pulmonary metastases. It is generally advised to follow treatment response with the same imaging technique (CT or MRI) particularly where measurement is required. Imaging of the primary site should include examination of regional lymph nodes if not evaluable clinically or if clinically suspicious.

?? It is important to note that radiological primary tumour assessment should precede the biopsy (this can significantly modify initial tumour volume).

?? All imaging data should be **stored in DICOM** format for further review (on CDROM if PACS is not locally available)

?? **Chest CT scan**: the presence of lung metastases must be evaluated by CT scan. Chest CT scan is mandatory for all patients.  
?? **Chest X-Ray Postero-Anterior and Lateral**  
?? **Tc Bone Scan** (with plain X rays and / or MRI of any isolated abnormal site): it can be avoided in G1 tumours  
?? **Bone plain films** (± CT/MRI): for differential diagnosis if isolated bone uptake on bone scan.  
?? **Abdominal Ultrasonography (US)**  
?? **Abdomen-pelvic CT scan** with intravenous contrast enhancement: for abdominal-paratesticular-lower limbs primaries, to evaluate the lymph nodes. Lower Limb tumours must have evaluation of pelvic lymph nodes by CT scan, even if femoral nodes are clinically/radiologically (including ultrasound) normal.  
?? Upper Limb tumours must have radiological evaluation (US) of axillary nodes.

?? **Optional pre-treatment examinations**

- Pulmonary function test  
- Hormonal status in patients with tumours close to endocrine organs (thyroid gland, adrenal gland, hypophysis etc)  
- PET
(Semen storage should be considered in post-pubertal boys before commencing chemotherapy).

11.5 Tumour measurements

Tumour dimensions should be recorded in three diameters choosing, as far as possible, the three maximum diameters.

With MRI, tumour measurements should be performed on post-gadolinium T1 or T2-weighted sequences (but not on STIR or non-enhanced T1-weighted sequences).

The tumour volume will be calculated according to the following:

<table>
<thead>
<tr>
<th>Tumour volume (V) calculation:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a= length (in cm)</td>
</tr>
<tr>
<td>b= width (in cm)</td>
</tr>
<tr>
<td>c= thickness (in cm)</td>
</tr>
<tr>
<td>V = ( \frac{a \times b \times c}{6} = 0.52 \times a \times b \times c ) in cm³</td>
</tr>
</tbody>
</table>

11.6 Lung lesions

Chest CT scan is mandatory in all patients. Is the radiologist, expert in such problems, that gives the interpretation of lung lesions, discussing with the oncologist.

Similarly to what recommended for other solid tumours (i.e. Ewing’s sarcoma, RMS), one pulmonary/pleural nodule of 1 cm, or lesions > 0.5 cm in more than one site, are considered evidence of pulmonary metastases, as long as there is no other clear medical explanation for these lesions.

Smaller solitary nodules (0.5-1 cm) are questionable evidence of metastatic disease unless the radiologist is reasonable sure to consider them as metastatic lesions. In such cases a biopsy may be performed but it is not recommended.
12. Staging Systems

Adult Oncology Groups utilised different staging systems for soft tissue sarcomas, including histological grading, tumour size, tumour depth, degree of surgical resection and sometimes age (Wunder JS, 2000).

In agreement with previous pediatric studies, stage of disease will be defined according to both

1. the clinical tumour-node-metastases (TNM) staging classification (Harmer MH, 1982)
2. the Intergroup Rhabdomyosarcoma Study (IRS) post-surgical grouping system (Maurer HM, 1988).

The TNM T1 definition applies to tumours confined to the organ or tissue of origin, while T2 lesions invade contiguous structures; T1 and T2 groups are further classified as A or B according to tumour diameter, ≤5 cm or >5 cm respectively.

Regional node involvement was designated as N1 (no node involvement - N0)
Distant metastases at onset as M1 (no metastases - M0).

After initial surgery, patients were classified according to the IRS system:

?? group I includes completely-excised tumours
?? group II indicates grossly-resected tumours with microscopic residual disease and/or regional lymph nodal spread
?? group III includes patients with gross residual disease after incomplete resection or biopsy
?? group IV comprises patients with metastases at onset.

12.1 References

13 Surgical guidelines

Local treatment is essential in non-metastatic NRSTS as chemosensitivity is uncertain for most of them. It can be achieved by surgery, radiotherapy or both.

The aim of local treatment is to cure the patient with no or minimal long term sequelae. The choice of local treatment will depend on the site and the size of the primary tumour, the age of the patient and the possible response to neoadjuvant chemotherapy. Surgical planning should include all reconstructive procedures with optimal timing of possible additional radiotherapy.

Surgical guidelines for NRSTS are necessarily partially different from those proposed for RMS, due to some relevant differences between the two subsets of tumours. In particular, surgical discussion for NRSTS would be influenced (in comparison to those for RMS) by the higher proportion of tumours localized at extremities, the median higher age of patients, the lower chemo-radio-responsiveness and the lower tendency to lymph-nodal spread (NRSTS patients are often adolescents with localized extremities tumours with uncertain possibilities to obtain tumour shrinkage with pre-operative chemotherapy).

In this group of patients, the mainstay of therapy, as in adults, remains conservative surgical resection. The possibility to achieve a surgical complete excision of the tumour is the most critical prognostic factor.

13.1 Definitions

The quality of the resection is defined by its worst margin and is usually classified as follows for extremity tumours but definitions can be extended to other sites whenever possible.

?? **R0 resection** (= microscopically complete resection = radical resection)

- **Wide**
  It is an en-bloc resection through normal tissue, beyond the reactive zone, with the removal of the tumour with its pseudocapsule and a margin of normal tissue; a resection could be defined as “wide” when the tumour is covered at every point by healthy tissue (muscle, subcutaneous tissue, thick fascia or intermuscular septum) according to the growth pattern of the tumour. When the tumour involves more than one anatomical compartment, the wide resection may include adjacent muscle compartment, bone, blood vessels or nerves and should be immediately followed by reconstructive surgery.

?? **Compartmental surgery**

When the tumour is removed en-bloc with the entire muscular or anatomical compartment and is covered by intact deep fascia. This surgery is feasible when tumour is entirely anatomically confined.

?? **R1 resection** (= microscopically incomplete resection = marginal resection)
When the tumour surface emerges macroscopically at the resection surface (e.g. surgical plane through the reactive zone or pseudo-capsule), or when microscopic tumour extension is present at the margin of resection, but without evidence of macroscopic disease residue.

Surgery is defined **contaminated** when accidental rupture of the tumour pseudocapsule with spillage of material into the operating field occurs, and also when the pseudocapsule has simply emerged at the margin of resection. In these cases spillage of material must be controlled by all means, and then the operating field must be rapidly washed and the resection margins widened. The contamination must be reported in the description of the surgical procedure and will be followed by complementary radiotherapy.

?? **R2 resection** (= macroscopically incomplete resection = intralesional resection)

When macroscopic tumour residue is left in situ.

**Primary resection** is recommended when complete and non-mutilating resection is considered feasible, otherwise a biopsy is absolutely required.

### 13.2 Biopsy

**Aim:** to provide enough material for histology, grading, immunochemistry, cytogenetics, central pathology review and spare of tissues for biological studies and frozen storage.

Biopsy should be the initial surgical procedure in all patients. Also when primary excision with adequate margins seems possible, the biopsy could be considered to avoid inadequate surgery performed according to a mistaken presumptive clinical diagnosis.

**Open biopsy** is recommended and should be **incisional**, although ultrasound or CT scan guided core needle biopsies (tru-cut) may be appropriate in difficult or inaccessible sites.

Fine needle aspiration biopsy is not recommended. Endoscopic biopsies are appropriate for bladder, prostate or vaginal tumours.

In planning the surgical approach for biopsy it must be kept in mind that:

**- Incisional biopsy:**
  - The scar and the biopsy track must be included en bloc in the subsequent definitive surgical procedure (this also applies to needle biopsy)
  - In case of sarcoma of the extremities, the incision must always be longitudinal to the limb (transverse and inappropriately placed incisions that traverse multiple tissue compartments must be avoided, because they interfere with the further delayed surgery)
  - Very careful hemostasis must be ensured, to avoid post-surgical hematoma. If drains are used (not recommended), the tract of the drain must be in-line with the skin incision and as close as possible from it.
- **Tru-cut biopsy:**
  - The biopsy track must always go directly to the tumour, through the muscle fibers with minimal use of retractors.
  - The biopsy track must contaminate only the anatomical compartment in which the tumour is situated, avoiding major neurovascular structures.

Tissue should always be sent fresh to the laboratory if possible. If fixative has to be used it should be formalin based.

### 13.3 Primary resection

**Aim:** to achieve complete resection (R0: microscopically complete resection), without danger or mutilation.

Primary resection is indicated:
1. if there is no clear clinical evidence of lymph node or metastatic disease
2. if the tumour can be excised with adequate margins and without danger or mutilation.

**Adequate margins**

The pathologic assessment of the quality of resection margin status is regarded as the benchmark, though imperfect, for determining the quality of local treatment.

A layer of healthy tissue between tumour and resection margins should exist. This layer of healthy tissue is defined as a “safety distance”, and depends on the type of the tissue.

In the recent Milan Consensus Conference on Adult Soft Tissue Sarcomas (June 2004), *adequate margins* have been defined as: **> 1 cm of healthy tissue around the tumour in all directions (when the tissue is a muscle), > 1 mm of healthy tissue around the tumour when the tissue is periostium, vessel sheath, epineurium, muscular fascia.**

The metric definition of the safety distance cannot be easily used in paediatric tumour surgery. However, it is important to have well-defined criteria to standardize the language and the definitions. Therefore, for the EpSSG NRSTS protocol, we decide to arbitrarily adopt the above mentioned definition of *adequate margins*, as those more commonly adopted in adult surgical oncology.

It is important to note that the layer of healthy tissue can show a shrinkage from *in vivo* to the subsequent pathological evaluation. Surgeons and pathologists must take this possibility into account.

The kind of tumour growth has to be settled as well-defined with pseudocapsule or locally infiltrating, and should be documented. These information are important to characterize the biological behaviour of the tumour, and thus contribute to the evaluation of further local therapeutical measures.

In order to ensure the evaluation concerning complete resection, the risk stratification, and therefore further treatment, a close cooperation between surgeon and pathologist is necessary. The surgeon should perform an exact drawing of the tumour, including resection margins being important for the evaluation of safety distance (also marked at the tumour). It should be possible for the pathologist to reconstruct the tumour and biopsies taken from the resection margins according to the surgeon’s drawing and information. An agreement between surgeon and pathologist concerning TNM-status should be achieved. It will be important for the pathologist to examine the specimen with the surgeon so that correct orientation is ensured for accurate evaluation of the margins. The surgeon must help the pathologist to identify the most critical resection margin and likewise must ensure
that points where the tumour emerges only due to muscle retraction following surgical removal are not identified as critical margins.

According to adult oncology orthopedic surgical guidelines, only R0 resections, as above defined, are considered adequate. The feasibility of primary resection should be carefully evaluated with radiologists. Irrespective of the site, surgery will be largely planned on the basis of imaging findings (CT, MRI) and the least favorable intraoperative situations will be hypothesized.

Extensive, “mutilating” operations should never be considered at primary resection.

“Mutilating” is defined as: leading to significant long term anatomical, functional or cosmetic impairment; e.g. extremity amputation or extensive muscular resection, orbital exenteration, major resection of the face, pneumonectomy, pelvic exenteration with definitive intestinal or urinary diversion, total cystectomy, total prostatectomy, hysterectomy.

However, the terms “resectability” and “mutilation” have to be understood under consideration of the possible reconstructive techniques of plastic surgery, microsurgery and the cooperation of different surgical disciplines in tumour surgery.

It is of note that in some younger cases, amputation may be preferable to radiotherapy, given the severe radiotherapy late-effects on growth and function.

13.4 Primary re-operation

**Aim:** To achieve complete resection (R0) in patients with microscopic (certain or doubtful) residue after primary operation, before other therapies, if this can be done without danger or mutilation

If a primary marginal excision or excisional biopsy (not recommended) has already been done, or where histological evaluation is inadequate, then primary re-excision should be considered (Hays, 1989; Cecchetto, 2001). This applies particularly to trunk, limb and paratesticular tumours.

The interval between initial surgical approach and primary reexcision should be as short as possible, and should never exceed 8 weeks. Similarly, the interval between the “adequate” surgery (first surgery or primary re-excision) should not exceed 8 weeks. In case of adequate margins (or no tumour) on specimen from primary re-excision, patient should be classified as IRS Group I only if the description of first surgery allows to be confident that no tumour spill and contamination has occurred.

13.5 Secondary operation (delayed surgery, post-chemotherapy)

**Aim:** to achieve complete resection (R0) of a residual mass after neoadjuvant chemotherapy.

Secondary operations and even multiple biopsies for verification of local control are not indicated if clinically, endoscopically and on CT or MRI scanning there is no visible tumour (Godzinski, 1994).

Where a residual mass is demonstrated or in cases of doubt, surgical resection should be done, although there may be certain anatomical sites, particularly in the head and neck, where this may not be feasible and the final indication in these cases is left to the decision of the individual surgeon.
It should however be remembered that negative biopsies of the residual mass, even if multiple, may be unrepresentative. It is important to note that in patients considered unresectable at diagnosis, the outcome strongly correlate with the achievement of complete delayed resection. In the series from INT Milan (40 IRS group III patients with adult-type STS), 5-year OS was 80% and 86% in patients who underwent complete delayed surgery and complete delayed surgery plus radiotherapy, whereas it was 36% and 14% in those who did not undergo complete resection (with or without radiotherapy, respectively) (Ferrari A, 2004)

Marginal resections (R1 resections) in sites where R0 resection is not possible may also be acceptable, provided they are always followed by radiotherapy. If residual mass is not completely resected, radiotherapy should be given.

Secondary operations should, as a rule, be conservative, anticipating local radiotherapy for residual disease, but “mutilating” operations may be appropriate in certain circumstances, after unsuccessful neo-adjuvant chemotherapy or radiotherapy or in patients under 3 years. “Debulking” procedures are not recommended.

13.6 Reconstructive surgery and local control

Reconstructive measures have to be included early enough in the planning of the resection and can be most often performed during the same operation as the resection of the tumour. Pre or post operative irradiation has to be considered depending on the necessary reconstructive measures:
- Bone reconstruction (microvascular transfers of fibula or iliac bone is incompatible with post-operative irradiation)
- Free flaps for soft tissue replacement can help lymphatic reconstruction only if they are not irradiated (proximal part of arm or thigh tumours)
- The integration of metal implants in general for joint replacement may be disturbed by radiation.

13.7 Lymph nodes

Aim: to confirm nodal involvement with nodal sampling, avoiding radical lymph node dissection.

Clinically or radiologically suspicious regional lymph nodes should be sampled on initial presentation and at relapse. Cytology may be useful to confirm nodal involvement but only if a conventional biopsy of the primary tumour has been obtained for diagnostic purposes.

Nodal spread is less frequent in NRSTS as compared to RMS, and therefore surgical recommendations are partially different. In RMS arising at extremities, systematic biopsy of regional nodes may be recommended and a technique of sentinel lymph node mapping may be useful (McMulkin, 2003). This procedure is not standardized in adult soft tissue sarcomas (with partial exception for some particular histotypes, i.e.
epithelioid sarcomas, clear cell sarcomas or vascular sarcomas). Therefore, also in paediatric adult-type sarcomas systematic biopsy would be not required in absence of clinico-radiological suspicion.
In RMS, radical lymph node dissections are not indicated and involved lymph nodes should be irradiated. In NRSTS (generally less sensitive to chemotherapy and radiotherapy), lymph node dissection may be considered.
It should be remembered that the combination of radiation therapy and radical lymph node dissection should be avoided as it can induce severe lymphoedema.

13.8 Specific sites

**Parameningeal site**
Complete surgical resection is difficult and generally not possible. Radiotherapy is always necessary in patients over 3 years and should be given at week 9 regardless of response to initial chemotherapy.
An initial resection will not be accepted if permanent severe functional dysfunction or mutilation results. In all cases where resectability is uncertain a resection should not be attempted and only a biopsy taken. Neck dissections should not be performed initially.
Only after radiotherapy a secondary resection is acceptable. Secondary resections in this site should only be performed in centres with experience in this field. A combination of surgery and brachytherapy (‘AMORE’ technique) is practised in some Centres (*Buwalda 2003*).

**Orbit**
Biopsy is usually the only surgical procedure required for orbital tumours. Secondary resections are not recommended. Enucleation or exenteration are very rarely indicated (*Oberlin, 2001*).
Depending on the age of the child microsurgical reconstruction with a free flap or forearm flap in combination with an appropriate prosthetic device are recommended after exenteration of the orbit.

**Head and Neck**
Complete surgical excision is difficult but major resections with reconstruction may be appropriate in some circumstances, after neoadjuvant chemotherapy. Such operations should only be realised in centres with an interdisciplinary surgical team and with experience in microsurgical free flap reconstruction.
The ‘AMORE’ technique could be considered in some Centres (*Buwalda 2003*).

**Bladder/Prostate**
Cystoscopy should be done at diagnosis and during follow up.
Initial resection (rather than biopsy alone) should only be done in the case of very small tumours arising in the fundus of the bladder, far from the trigone.

Secondary operations:
Conservative surgery of bladder /prostate tumours could be done where feasible (partial cystectomy and/or partial prostatectomy) in conjunction with brachytherapy particularly in very young boys (*Haie-Meder, 2000; Martelli, 2003*) or external beam radiotherapy.
Partial prostatectomy, without radiotherapy, carries a high risk of local relapse (Audry, 1998). Where conservative treatment is not feasible, the treatment will include total cystectomy and/or total prostatectomy with or without post-operative radiotherapy.

**Vagina**
Partial vaginectomy may be feasible after chemotherapy but brachytherapy is often preferable after ovarian transposition (Martelli, 1999).

**Paratesticular**
These should be excised via an inguinal incision, first ligating the cord at the internal inguinal ring. Orchidectomy is essential. In rare cases, if the tumour is very large and delivery into the groin would be difficult or traumatic, it is better to make a scrotal incision (keeping the tunica vaginalis intact) and deliver the testis and cord via this. Retroperitoneal lymphadenectomy or nodal sampling at diagnosis is not recommended unless there is uncertainty on imaging (Olive, 1984; Ferrari A, 2002).

If the initial operation before referral was scrotal then primary re-operation should be done to excise the cord at the internal ring. When there is a doubt about scrotal contamination, hemiscrotectomy should be performed.

**Extremities**
At secondary operation, formal compartmental resection (en bloc resection of the tumour and the entire compartment of origin, where tumour was entirely anatomically confined) may be appropriate for some tumours but less “anatomical” wide resections (en bloc resection through normal tissue, beyond the reactive zone, with the removal of the tumour with its pseudocapsule and a margin of normal tissue) is usually sufficient, providing an adequate margin of normal tissue.

A wide cutaneous incision will be made along traditional lines (along the major axis of the tumour-bearing anatomical compartment), and must include en bloc the scar and the holes-track of previous biopsies or surgery. Once the skin-fat flaps have been prepared the tumour will be isolated within the tumour-bearing structure, with prompt recognition and careful dissection of the main vascular structures and motor nerves (femoral, sciatic, external/internal sciatic-popliteal, median, ulnar and radial). These structures must not show tumour infiltration. Should doubt arise about a possible edema or suspect thickening of the delimiting fascia (vascular external tunica, perineurium), it will be prudent to perform frozen section biopsy.

Care must be taken to avoid contamination of the surgical field, which can also occur if the tumour is allowed to emerge on the surface of resection. When minimal contamination has occurred at primary surgery, the patient will be classified as IRS group II, and complementary radiation therapy will have to be planned in any case. Once the malignancy has been isolated, it must be removed en bloc with the surrounding soft tissue, covered at every point by at least one centimeter of healthy tissue.

Compartmental operations will be performed only if made necessary by the site and dimensions of the tumour. If the lesion is near structures such as the vascular-nervous fascia or bone, it must be cautiously prepared by also removing the fascia covering said structures (vascular external tunica, perineurium or periostium). If these structures are also found to be infiltrated, they must be resected.
en bloc with the tumour, assessing the possibility of performing vascular, neurological or bone reconstruction as an alternative to mutilating procedures.

Specific problems which can arise from the combination with the irradiation should be considered already at the operation planning. These are:

- disturbance of growth because of irradiation of growth plates
- pathological fractures after marginal bone resection
- lymph edema after marginal lymph node dissection and nevertheless necessary irradiation, especially in the region of the shoulder and groin
- scarred contracture.

When considering radiotherapy, it should be remembered that amputation may be preferable in young children, bearing in mind the serious effects of radiations on growth and function.

**Abdomen/Pelvis**

If radiotherapy is anticipated for pelvic tumour the surgeon should consider exclusion of the ovaries from the radiotherapy field by transposition and could consider exclusion of small bowel from the pelvis by insertion of a tissue expander or absorbable mesh.

**13.9 Surgery for relapse**

This depends on the treatment used during primary treatment, but “mutilating” operations may be justified, particularly if radiotherapy options have already been exhausted. It is to note that the long term salvage in relapsing patients is generally confined to those patients who can undergo surgical resection of relapsing disease (Zagars, 2003).

**13.10 Marker clips**

If it is considered necessary to mark the tumour bed for post operative radiotherapy, titanium rather than stainless steel clips should be used so as not to interfere with CT or MRI scans.

**13.11 Histology**

Whenever possible, the case should be discussed with the pathologist pre-operatively and the tissue sent fresh from the operating theatre to the laboratory. Marker sutures should be inserted to help in orientation and show crucial resection margins. If the tissue has to be sent fixed rather than fresh, a formalin based fixative is preferred.
NRSTS Surgery Committee

?? Helene Martelli (France) – coordinator

?? Giovanni Cecchetto (Italy)
?? Jan Godzinski (Poland)
?? Michael Greulich (Germany)
?? Alessandro Gronchi (Italy)
?? Helmut Lochbueler (Germany)
?? Eric Mascard (France)
?? Richard Spicer (UK)

References


Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft tissue sarcoma of the extremities: prospective randomized evaluation of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196: 305-315; 1982


14 Radiotherapy guidelines

Radiotherapy is an essential component of the treatment strategy for NRSTS. The use of radiotherapy is a balance between the prognostic improvement due to radiotherapy and the potential side effects of the treatment. In adults, radiotherapy is required in most patients after wide excision, especially in large tumours, and irradiation is considered always unnecessary only after compartment resection. The situation in children and adolescents is different: the morbidity of radiotherapy is clearly much greater than in adults (depending on the site that require irradiation) since these patients are growing and physical development can be disturbed.

In adult studies, relatively high total dose of conventional fractionated external beam irradiation are recommended to achieve local control: doses of 60-64 Gy are used, sometimes with 50 Gy on a large first volume and a boost on a smaller one. Radiotherapy is usually delivered following surgery (post-operative radiotherapy), but excellent results have been reported with pre-operative irradiation. For children and adolescents, so far lower radiation doses of about 50 Gy have been used in the CWS-trials.

The rationale, indications and doses of radiotherapy in synovial sarcoma and adult type NRSTS are given below.

14.1 Equipment

? Megavoltage equipment
All patients will be treated with megavoltage equipment (4-20 MV linear accelerator preferably). For extremity tumours photons of 4 to 6 MV are recommended. Care must be taken to ensure an adequate skin dose in high risk areas when high energy photons are used. For tumours of the trunk, photons of 6 to 20 MV energy are recommended.

? Electrons
Electrons are allowed for superficial and moderately infiltrating tumours (to a maximum depth of 5 cm) either as an electron field matching on, or as boost to, linear accelerator planned fields. The use of electron fields alone should be avoided because of the late effects.

? Brachytherapy
Brachytherapy may be used in cases of incompletely resected tumours of vagina, perineum, bladder, prostate and orbit. It may be used as boost technique before or after external beam irradiation or may in some cases replace external beam irradiation. This must be discussed with the reference centre for each individual patient. The dose for brachytherapy and external beam radiotherapy must take into account radiation-tolerance of adjacent tissue and should be calculated individually in each case.

14.2 Treatment planning

3-D-conformal radiotherapy planning is recommended when critical structures lie in or nearby the target volume. The dose is prescribed according to ICRU 50.
14.3 Fractionation

Treatment is applied in conventional fractionation with 1.8 Gy per day, 5 day per week. In patients with large fields, smaller fractions may be used. In patients < 3 years of age, smaller fractions may be given as well (1.6 Gy). The radiation dose is prescribed according to ICRU 50.

Compensation for treatment breaks

Standard fractionation is 5 days per week. If there is a treatment interruption, 2 fractions with an interval of at least 6 hours between fractions should be given to enable completion of treatment within the same overall time, if feasible from the surrounding critical structures.

14.4 Target volume definition for primary tumour

The target volume is chosen according to the initial tumour volume (gross tumour volume - GTV). The pre-therapeutic T1 MRI image with contrast is usually the optimal imaging study.

 Exceptions: intrathoracic or pelvic tumour bulk

The clinical target volume (CTV) is defined as the GTV + 1 cm

 Exceptions: limbs: 2 cm in longitudinal direction

Additionally, scars of the biopsy, of the initial surgery, of the second look surgery and of drain sites have to be included in the CTV. Furthermore all tissues that were potentially tumour-contaminated during surgery need to be included in the CTV.

The planning target volume (PTV) is defined as the CTV + 1 cm

 Exceptions: chest wall: 2 cm

In patients receiving a boost after 50.4 Gy, the PTV of the boost is the residual tumour at the start of radiotherapy plus a margin of 1-2 cm.

In growing patients, a radiation dose gradient through the epiphyseal growth plates should be avoided because of the risk of asymmetric growth. The growth plates should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields. The same should be observed for vertebral bodies in order to avoid scoliosis.

Summary:
The PTV consists of the initial tumour volume + 2 cm except for limb and chest wall tumours (+3 cm). Areas contaminated during surgery including scars and drainage sites must be included in the PTV. If more than 50.4 Gy need to be applied, the PTV of the boost is the residual tumour at the start of radiotherapy plus a margin of 1-2 cm.

14.5 Target volume definition for lymph nodes

In case of involved lymph nodes:

1. Radiotherapy could be avoided in case of radical lymphadenectomy (surgical removal of all the lymph nodes of the involved site).
2. After biopsy or non-radical resection (surgical removal of the involved nodes but not of all the lymph nodes of the involved site) radiotherapy is required. The dose of **50.4 Gy** is applied to the entire lymph node site (axilla, groin, paraaortic lymph nodes etc.). When that approach results in very large radiation fields, this extent can be reduced to the involved lymph nodes plus a PTV margin of 3 cm at the discretion of the treating radiation oncologist.

3. In case of still enlarged lymph nodes at the time of radiotherapy, lymph nodes receive an additional boost up to a total dose of **59.4 Gy** if feasible from the surrounding critical structures (PTV definition for the boost as for the boost of primary tumour).

If possible the draining lymphatic vessels between the primary tumour and the involved lymph node site should be irradiated. However, in some cases this would result in unacceptable large radiation fields. In these patients, two separate radiation fields have to be used to treat the primary tumour and the lymph node site excluding draining lymphatic vessels.

### 14.6 Timing of radiotherapy

Since the value of chemotherapy is not clear, radiotherapy should not be delayed when radiotherapy and chemotherapy are given.

In patients submitted to initial gross resection, radiotherapy should start at least after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at **week 9**, at the resolution of the toxicity of the third cycle of chemotherapy.

During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone.

In patients with IRS group III (macroscopical residual disease), the option for second surgery must be checked before the onset of radiotherapy.

In patients receiving **no second surgery**, radiotherapy is performed at **week 9**.

When second surgery is planned, there are 3 treatment options:
- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy

When radiotherapy is performed before second surgery (**pre-operative radiotherapy**), irradiation starts at **week 9**. Surgery should be performed **5 weeks after the end of radiotherapy** (and after the last chemotherapy cycle) to avoid surgical complications.

When **postoperative radiotherapy** is given, radiotherapy should be started within 21 days except when there are postoperative complications.
14.7 Indications and doses

? Synovial sarcoma:

IRS group I  ✗ no RXT

IRS group II  
? 5 cm  ✗ 50.4 Gy (1.8 Gy/d)
> 5 cm  ✗ 54 Gy (1.8 Gy/d)

* RXT could be avoided in selected cases (i.e. age < 10 years)

IRS III  
different options in relation to delayed surgery
(and to age and initial tumour size)

 ✗ no RXT
 ✗ pre-op RXT 50.4 Gy
 ✗ post-op RXT 50.4 Gy (“R0”)
 ✗ post-op RXT 54 Gy (“R1”)
 ✗ definitive RXT 59.4 Gy

? Adult type NRSTS:

IRS group I  
? 5 cm  ✗ no RXT
> 5 cm  
 G1  ✗ no RXT
 G2  ✗ RXT 50.4 Gy
 G3  ✗ RXT 50.4 Gy

IRS group II  
 G1  ✗ no RXT
 G2  ✗ 54 Gy
 G3  ✗ 54 Gy

IRS III  
different options in relation to delayed surgery
(and to age and initial tumour size)

 ✗ no RXT
 ✗ pre-op RXT 50.4 Gy
 ✗ post-op RXT 50.4 Gy (“R0”)
 ✗ post-op RXT 54 Gy (“R1”)
 ✗ definitive RXT 59.4 Gy
14.8 Normal tissue tolerance guidelines

<table>
<thead>
<tr>
<th>Tissue Description</th>
<th>Conventional fractionation (F:fraction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>30.6 Gy; 17 F</td>
</tr>
<tr>
<td>whole liver</td>
<td>19.8 Gy; 11 F</td>
</tr>
<tr>
<td>whole kidney</td>
<td>14.4 Gy; 8 F</td>
</tr>
<tr>
<td>spinal cord (part)</td>
<td>41.4 Gy; 23 F</td>
</tr>
<tr>
<td>spinal cord in pts. with residual paraspinal tumour (on MRI)</td>
<td>50 Gy; 28 F</td>
</tr>
<tr>
<td>optic nerve/optic chiasm</td>
<td>45 Gy; 25 F</td>
</tr>
</tbody>
</table>

14.9 Treatment guidelines for special sites

**Parameningeal tumours**

In case of skull base erosion and cranial nerve palsy, the PTV will be that required to treat the primary tumour (initial tumour volume + 2 cm). Radiation fields must adequately cover the initial skull base erosion but there is no routine whole brain irradiation.

**Extremities**

Extremity tumours should be treated according to the general guidelines described above. Tissue contaminated during surgery must be included in the CTV. After surgical procedures, all scars and drainage sites should be irradiated with a safety margin of 1 - 2 cm. Circumferential radiotherapy must be avoided because of the danger of constrictive fibrosis and lymphedema. In growing patients, a radiation dose gradient through the epiphyseal growth plates should be avoided because of the risk of asymmetric growth. The growth plates should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields.

**Urogenital Site**

The doses and target volume definitions follow the general guidelines. Gonads should be positioned out of the treatment volume if possible (in girls oophoropexy must be discussed!). Individual planning and discussion with the respective reference centre is advised.

**Abdomen**

The kidney and liver tolerance doses have to be respected. In growing patients, a radiation dose gradient through vertebral bodies should be avoided because of the risk of scoliosis. Vertebral bodies and pedicles should either be included in or, if feasible from the tumour extension, be excluded from the radiation fields.
Pelvis
Small bowel/iliocecal bowel may be displaced from the pelvis by treating the patient in prone position and by using a belly board. In some cases, bowel can be spared with special surgical techniques using a spacer. Tumours with non-infiltrating extension into the preformed pelvic cavity often show a large intrapelvic mass. Irradiating the pre-treatment volume would mean that large volumes of normal tissue (bowel and bladder) are in the radiation field. In these cases, the target volume in the areas of non-infiltrating tumour encompasses only the residual mass after surgery/chemotherapy at the beginning of radiotherapy and a 2 cm safety margin. For all other parts of the tumour (infiltrated muscle, bone or organs), the general safety margins according to the initial tumour extension are to be applied.

Retroperitoneum
Tolerance doses of organs in this region need to be respected (i.e. kidneys, bowel, spinal cord). Dose volume histograms for these organs are strongly recommended. In order to avoid scoliosis in growing patients the vertebral bodies should either be irradiated symmetrically or shielded.

Chest wall
The doses and target volume definitions follow the general guidelines. Tumours with non-infiltrating extension into the preformed thoracic cavity often show a large intrathoracic mass. Irradiating the pre-treatment volume would mean that large volumes of lung tissue are in the radiation field. In these cases, the target volume in the areas of non-infiltrating tumour encompasses only the residual mass after surgery/chemotherapy at the beginning of radiotherapy and a 3 cm safety margin. For all other parts of the tumour (infiltrated muscle or bone), the general safety margins according to the initial tumour extension are to be applied.

14.10 Quality assurance of radiotherapy
Radiotherapy documentation forms will be completed and submitted via the relevant data office for review by the Radiotherapy Committee. Simulator films, plans and diagnostic films which determined treatment volume will be requested in all cases who fail locally after radiotherapy and in randomly selected cases of those who do not fail as part of a quality assurance assessment. This will be co-ordinated by the Radiotherapy Committee who will contact centres for films from individual patients as requested.

NRSTS Radiotherapy Committee

?? Andreas Schuck (Germany) – coordinator
?? Guido Sotti (Italy)
?? Lorenza Gandola (Italy)
?? Mark Gaze (United Kingdom)
?? David Spooner (United Kingdom)
?? Jean Luis Habrand (France)
References


15 Chemotherapy guidelines

It is well-known that the role of chemotherapy in the treatment of adult and childhood NRSTS continues to be controversial. NRSTS are generally considered tumours with uncertain sensitivity to chemotherapy. Synovial sarcoma represents a partial exception; its chemosensitivity has long been appreciated by paediatricians, who often included synovial sarcoma patients in the same protocols as for RMS. In recent years, adult oncologists have increased their use of chemotherapy in synovial sarcomas; as for chemotherapy responsiveness, this histotype probably comes somewhere between most typical adult soft tissue sarcomas and “paediatric” small round cell sarcomas, generally characterized by high response to chemotherapy.

In paediatric age, few studies reported data on the efficacy of chemotherapy in NRSTS. Paediatric NRSTS were generally treated with the same chemotherapy regimens adopted for RMS (cyclophosphamide/ifosfamide, vincristine, actinomycin-D as standard treatment). In patients with measurable disease, the overall response rate to chemotherapy was in the 30-50% range, but it may be superior when one consider also the minor response (that in some cases could permit however a delayed surgery considered unfeasible at diagnosis) or consider only the chemotherapy regimen including ifosfamide and doxorubicin (in the series from Istituto Nazionale Tumori of Milan the overall response rate was 39% in term of CR+PR, 58% in term of CR+PR+MR, and 80% for CR+PR+MR considering only ifosfamide-doxorubicin treatment) (Ferrari A, J Clin Oncol 2005).

The role of adjuvant chemotherapy was explored by POG trial that compared a regimen with cyclophosphamide, vincristine, doxorubicin and actinomycin-D to observation. The study failed in its aim because 51 out of 81 patients refused randomization (Pratt, 1999).

More data could be collected by adult literature. Several randomized adjuvant chemotherapy trials have been performed over the years in adult soft tissue sarcomas. To date, only a minority of them have shown a significant survival advantage for chemotherapy. Nevertheless, more recent data would seem to suggest some different considerations. In fact, 1,568 adult patients with NRSTS were included in a meta-analysis that demonstrated a reduction in the risk of local and distant failures at 10 years in the group treated with intensified doxorubicin-based chemotherapy, with an advantage of 10% in recurrence-free survival and of 4% in overall survival (Thierny JF. Sarcoma meta-analysis collaboration 1997). Moreover, an Italian randomized trial on adjuvant full-dose doxorubicin + ifosfamide was closed in advance due to an early striking benefit in overall survival in favour of the chemotherapy arm. Long-term results of this trial are still consistent with a benefit (Frustaci S, 2001).

Therefore, though adjuvant chemotherapy is yet not currently standard treatment for adult soft tissue sarcomas, more hints of efficacy have been provided, and chemotherapy is often suggested in high-risk cases (high-grade, large size) or considered for a shared decision-making in conditions of uncertainty (Bramwell VHC, 2001). However, it is of note a recently-published study from the M.D.Anderson and the Memorial Sloan Kettering Cancer Centers, that reported a benefit for adjuvant doxorubicin-based chemotherapy during the first year only: this initial clinical benefit seems not be sustained over time (beyond one year of follow-up) (Cormier, J Clin Oncol 2004).

In conclusion, the role of chemotherapy is yet unclear, but some findings would seem to suggest a more relevant effect when a fair selection of high risk and high-grade cases is provided, and when a high-dose intensity chemotherapy including the most active drugs is delivered.
Various data from adult trials have shown: 1) that ifosfamide may be more effective than cyclophosphamide against these tumours, 2) that increased doses of ifosfamide improves the benefit, 3) that the association ifosfamide-doxorubicin constitutes the regimen with the higher response rate, and 4) that the higher doses of doxorubicin are associated with the improvement of response rate and disease-free survival.

Therefore, the EpSSG NRSTS 2005 protocol will try to intensify the use of ifosfamide and doxorubicin in these tumours. This choice was based on the various data from clinical trials in adult sarcomas that showed the IFO-DOXO regimen as the most effective one, and on the absence of data on the effectiveness of vincristine and actinomycinD. Moreover, results will be then more comparable with those from adult trials.

**15.1 Chemotherapy regimen**

The chemotherapy regimen adopted will be as follows:

*ifosfamide 3 g/m²/day, for 3 days + doxorubicin 37.5 mg/m²/day, for 2 days*

? every 21 days

? for 3, 4 or 5 cycles according to the risk-group

? ± ifosfamide alone at 3 g/m²/day, for 2 days, concomitantly to radiotherapy

ᐖ maximum cumulative dose of doxorubicin = 375 mg/m²

flate maximum cumulative dose of ifosfamide = 57 g/m²

In patients that need to receive both chemotherapy and radiotherapy, it is important to avoid the concomitant administration of doxorubicin and radiotherapy, due to the radio-synergistic effects of doxorubicin that could increase the acute side effects of irradiation. Since radiotherapy will be given in conventional fractionation, it will last 5-6 weeks and overlap with 2 chemotherapy cycles. These 2 cycles will be given with ifosfamide alone, at the dose of 3 g/m²/day, for 2 days.

Synovial sarcoma and high grade adult-type sarcomas, group II > 5 cm, and group III: after the first three courses of ifosfamide-doxorubicin and the tumour re-assessment, radiotherapy should start at week 9th, then the fourth chemotherapy cycle would start at week 10th and should be ifosfamide alone; the fifth cycle would be at week 13th (ifosfamide alone), and the sixth (ifosfamide-doxorubicin) could therefore be planned at least 2 weeks after the completion of radiotherapy. In case of some delay in radiotherapy start, it could be better to give ifosfamide-doxorubicin as fourth cycle, and utilize ifosfamide alone in the subsequent courses, considering that the sixth
Chemotherapy could probably overlap the radiotherapy or be administered few days after the end of irradiation.

Therefore, the protocol requires 4 cycles (for synovial sarcoma) and 5 cycles (for adult-type STS) of IFO-DOXO and 2 cycles of IFO alone.

In comparison to the previous experience of European paediatric NRSTS (usually treated with the same treatment program adopted for RMS, i.e. 9 cycles of IVA/VAIA), patients will receive less cycles of chemotherapy (shortening the overall treatment length), but the dose-intensity of ifosfamide and doxorubicin will be increased.

**15.2 Chemotherapy administration and drugs information**

All the drugs used are licensed in Europe and have passed clinical phase II trials.

The use of central lines is recommended

The administration of chemotherapy courses should not be started unless all these conditions are present:
- 2,000/\( ?_l \) WBC, or 1,000/\( ?_l \) neutrophils
- 80,000/\( ?_l \) platelets are reached.
- absence of any relevant organs dysfunction
  - in particular: adequate cardiac function (ejection fraction EF \( \geq 47\% \))
  - adequate renal function (creatinine \( < 1.3 \text{ mg}\% \))
  - adequate hepatic function
    (bilirubin \( < 1.5 \text{ mg}\% \), transaminases \( < 2 \times \text{ normal value} \))

?? ?? **DOXORUBICIN (ADRIAMYCIN)**

?? Mechanism of action: inhibition of DNA synthesis

?? Side effects: bone marrow depression, acute and late cardiotoxicity, gastrointestinal irritation (nausea, vomiting, ulceration), allergic reactions with skin rash and fever, alopecia. Local ulceration with extravasation.

?? *Dose and Mode of administration in this protocol:*

- Doxorubicin: 37.5 mg/m\(^2\) day 1, and 2 (75 g/m\(^2\) total for cycle)
- 10 mg/hour infusion (longer infusion does not seem cardioprotective and may increase the risk of mucositis)
- The drug can be given by peripheral iv. cannula or central line with appropriate precautions against extravasation.
**IFOSFAMIDE**

- **Mechanism of action:** alkylating agent (IFO has to be activated hepatic hydroxylation)
- **Side effects:** haemorrhagic cystitis (Mesna uroprotection is required), nephrotoxicity (tubulopathy with glucosuria, aminoaciduria, loss of phosphate and Ca, full range of tubulopathies from subclinical changes to a full Fanconi syndrome), bone marrow depression, gastrointestinal irritation (nausea, vomiting, diarrhoea, stomatitis), alopecia, neurotoxicity with transient somnolence and mental disturbance, infertility, immunosuppression

**Dose and Mode of administration in this protocol:**
- Ifosfamide: 3 g/m² day 1, 2 and 3 (9 g/m² total for cycle)
- 3 hours infusion
- Hyperhydration (3 L/m²/day) and Mesna (3 g/m², day 1, 2 and 3) are required until 12 hrs after completion of IFO.

**Dose modifications**

**Age < 3 months** - Anthracyclines should be avoided in the initial(s) cycle(s), but should be administered when the child is >3 months old with doses calculated by weight.

**Age > 6 months and < 12 months (or < 10 kg body weight)** -
Drug dose should be calculated by weight without further reduction.

*Note:* when the drug doses are initially calculated by weight, in absence of important toxicity they have to be gradually increased (by 30%) at each cycle up to dose calculated by body surface area.

**In patients with body surface area (BSA) > 2 m²,** the chemotherapy dose should not exceed the dose calculated for a BSA of 2 m².

The dose given to obese patients should be calculated based on regular body weight.

The chemotherapy doses must be recalculated for each course of chemotherapy according to the actual weight and surface area.

If count recovery is delayed more than 2 weeks after the planned start of the next course of chemotherapy, consider dose reduction of all drugs in the subsequent course to 66% of previous dose.
15.3 Chemotherapy toxicity

HAEMATOLOGICAL TOXICITY
Recovery of neutrophils > 1.0 x 10^9/l and Platelets > 80 x 10^9/l is required before the start of each course of chemotherapy.
If count recovery is delayed more than 2 weeks after the planned start of the next course of chemotherapy, a dose reduction of all drugs in the subsequent course to 66% of previous dose could be considered.

BLADDER TOXICITY
Haemorrhagic cystitis with ifosfamide is rare if hydration and mesna are utilised appropriately. Microhaematuria can usually be tolerated. In case of macrohaematuria it is important to continue (or re-implement) hydration. In case of cystic bleeding under or within 24 hours of completion of IFO-infusion mesna protection should be continued or started again.
Only recurrent macroscopic haematuria is an indication for discontinuing IFO, in which case cyclophosphamide at a dose of 1500 mg/m² per course may be substituted.

RENAL TOXICITY
Serious renal toxicity may occur with exposure to IFO. A prospective monitoring is therefore necessary and is more likely to occur with an increasing cumulative dose.
If nephrotoxicity occurs discontinue IFO and substitute with cyclophosphamide at a dose of 1500 mg/m² per course for the remaining courses of treatment.
Be careful because increased excretions of tubular enzymes, amino acid or proteins may be evident shortly after IFO infusion. This is tubular dysfunction, is usually transient, and does not require dose modification.

CARDIOTOXICITY
In this protocol the maximum cumulative dose of doxorubicin is 375 mg/m², therefore at the limit of the threshold dose for late cardiotoxicity reported in most studies. A very-careful monitoring for possible acute or late cardiotoxicity is recommended. The echocardiogram is required in all patients who have to receive chemotherapy, 1) as baseline assessment, 2) after 3 cycles of IFO-DOXO and 3) at the end of the treatment.
Significant deterioration in cardiac function is indicated by a shortening fraction (SF) <28%. In this event, doxorubicin must be withdrawn.
A fall in shortening fraction by an absolute value of >10 percentile units but with an actual SF value >28% (i.e. from SF 42% to SF 31%) may also represent a significant deterioration in function. Also in this event, doxorubicin must be omitted.

NEUROLOGICAL TOXICITY
Serious neurological toxicity from IFO is rare but more likely to occur in patients with impaired renal excretion of the drug, either from an obstructed urinary tract at initial diagnosis or from renal impairment later in treatment. Evidence of IFO encephalopathy may be mild initially but should be considered in any patient who demonstrates altered level of consciousness during or shortly after the drug infusion.
In case seizures occur, methylene-blue may be given: 30 mgs/m² (max 50 mgs) as a 2% aqueous solution, give by slow i.v. injection. The reversal of encephalopathic features should occur over the next 30-60 minutes.

If grade 3 or 4 central neurotoxicity occurs (somnolence > 30% of the time, disorientation / hallucination / echolalia / perseveration / coma) consider to avoid further ifosfamide and substitute with cyclophosphamide 1500 mg/m² per cycles.

TOXICITY MONITORING

This protocol should be regarded as “therapeutic recommendations” and not at all as an “investigational protocol”. Therefore, the toxicity monitoring must be quite different of an investigational protocol (as the EpSSG RMS 2005), for which all adverse events (AE) must be registered.

Definitions:

Adverse events (AE) are illnesses, signs of illnesses or symptoms which occur or aggravate after the patient has been included in protocol.

The investigator must try to assess the relationship of any adverse event to the use of study drugs, based on available information, using the following guidelines:

1. not connected to the Protocol treatment = Unlikely-no temporal association, or the cause of the event has been identified, or the drugs cannot be implicated
2. possibly connected to Protocol treatment = Possible-temporal association, but other aetiologies are likely to be the cause; however involvement of the drug cannot be excluded
3. definitely or most probably connected to Protocol treatment = Probable-temporal association, other aetiologies are possible, but unlikely to be the cause of the event.

Severity of adverse event must be classified as

- **Mild:** Awareness of any sign, symptom or event, but easily tolerated, and not requiring intervention.
- **Moderate:** Discomfort enough to cause interference with usual activity and may warrant intervention
- **Severe:** Incapacitating with inability to do usual activities or significantly affecting clinical status, and warrants intervention.
- **Life threatening:** Serious adverse event

A serious adverse event (SAE) is any event that:

- Is fatal
- Is life threatening
- Is significantly or permanently disabling
- Is a congenital anomaly or birth defect

Important medical events that may not result in death, be life-threatening, or require hospitalisation may be considered a serious adverse drug experience when, based upon appropriate medical judgement, they may jeopardise the patient and may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in patient hospitalisation, or the development of drug dependency or drug abuse. In addition, laboratory value(s) changes may require reporting unless otherwise specified in the protocol.
Second malignancy

For this protocol, only very severe and/or unexpected adverse events must be reported. The Remote Data Entry System provides a special form denominate “SAE form” that should be completed and will be sent to the national and protocol coordinators.
In case the system is not used the notification must be done by fax to the national coordinator that will be in charge to inform the protocol coordinator.

15.4 Supportive care

The treatment of patients with NRSTS require a multidisciplinary approach with a high degree of medical competence existing only in institutions familiar with the administration of intensive chemotherapy and adequate infrastructure to provide the necessary supportive care.

NAUSEA AND VOMITING

Antiemetic therapy according to the institutional policy should be given with each major block of therapy.

HEMATOLOGICAL TOXICITY

?? Anemia should be treated by transfusion if necessary (Hb 7-8 g/l) according to national or centre guidelines but is not an indication to modify the treatment schedule.

?? Thrombocytopenia: should be treated by transfusion if platelets count >10,000/mmcc or in hemorrhagic patients with thrombocytopenia.

?? Use of G-CSF/GM-CSF: according to centre guidelines

Primary prophylaxis with G-CSF or GM-CSF is not required but is advised for the IFO-DXO regimen. If infection complications (neutropenic fever) or prolonged neutropenia develops, administration of growth factors will be recommended. G-CSF or GM-CSF should be given at a dose of 5 µg/kg (maximum dose 300 µg) and should be continued until WBC > 1000 x 10^9 for 3 days. Chemotherapy must not be resumed until 48 hours after the end of chemotherapy.
INFECTIONS

Neutropenic Fever - Episodes of neutropenic infection are likely to occur after chemotherapy. All participating Institutions must be familiar with managing such problems instituting promptly all necessary investigations (e.g. blood culture) and empiric antibiotic treatment according centre guidelines. Note: neutropenic fever is not a serious adverse event.

Pneumocystis carinii pneumonia - Patients could be treated with cotrimoxazole according to the centre guidelines for prophylaxis. The usual dose is 5 mg trimethoprim/kg/day in two divided doses or 10 mg trimethoprim/kg (in two divided doses per day) given twice weekly.

Varicella or herpes - Patients who develop varicella or herpes should receive Aciclovir and chemotherapy should not be restarted until one week after the resolution of the rash.

References

?? Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 19:1235-1237, 2001 (editorial)


16 Investigation during and at the end of treatment

16.1 Investigation during treatment

Physical Examination
A thorough physical examination should be performed prior to every block of chemotherapy.

Laboratory Investigations
?? Full blood count (including differential white cell count and platelets) before each course of chemotherapy (neutrophils > 1.0 x 10^9/l and platelets > 100 x 10^9/l is required before the start of each course of chemotherapy).
?? Serum creatinine, electrolytes and liver function tests: before each block of chemotherapy
?? Ifosfamide Nephrotoxicity Monitoring: ifosfamide nephrotoxicity needs to be monitored periodically. Monitoring must include:
   ✈ Blood for Na, K, Ca, Mg, PO_4, Cl, Total CO_2/HCO_3 and AP
   ✈ Early morning urine sample for PO_4, Creatinine and Osmolarity
   ✈ GFR
   ✈ Renal Tubular Threshold for Phosphate (Tm_p/GFR)

Echocardiogram
It is required in all patients who receive chemotherapy after 3 cycles of IFO-DOXO and at the end of the treatment.

16.2 Tumour reassessment

If no signs of progression are present, a formal tumour reevaluation is advised at the end of treatment in patients without measurable disease, and at 6th week in IRS group III patients (after 3 cycles of chemotherapy).
A clinical assessment of tumour response should be made at each visit in order to detect tumour progression at any point during treatment. This should be supplemented by radiological examination as appropriate.
The radiological reassessment must use comparable techniques to those used at diagnosis (MRI and/or CT scan).

Note: If the lesion can be completely analysed with ultrasonography (for example, a limb primary), then ultrasound may be used instead of MRI or CT to study the response rate during neoadjuvant chemotherapy.
MR or CT remains necessary prior to surgery.

As at diagnosis, tumour dimensions should be recorded in three diameters and can be compared choosing, as far as possible, the diameters selected at diagnosis.
Tumour volume (V) calculation:

\[ V = \frac{a \times b \times c}{6} = 0.52 \times a \times b \times c \text{ in } cm^3 \]

16.3 Response evaluation criteria

Response in patients with macroscopic residual disease after initial surgery (IRS group III) will be evaluated as follows:

All response must last at least 4 weeks without evidence of tumour progression or relapse.

- **Complete Response (CR)**: Complete disappearance of all visible disease, complete disappearance of tumour with no residual disease.

- **Very Good Partial Response (VGPR)**: 90% reduction of tumour volume (volume response between 90-99%).

- **Partial Response (PR>2/3)**: 66% reduction of tumour volume (volume response between 66-90%).

- **Minor Partial Response (PR<2/3)**: Volume response between 34-65%.

- **Stable Disease (SD)**: < 33% reduction of tumour volume (no criteria for PR or PD).

- **Progressive Disease (PD)**: Any increase of more than 40% in the sum of volumes of all measurable lesions, or appearance of new lesions.

**Residual disease** should be defined as macroscopic measurable residue. Residual ill-defined areas of high density on CT-scan, or residual signal abnormalities on MR such as low intensity on T1WI, high intensity on T2WI and ill-defined margins of enhancement areas are commonly observed after chemotherapy. If no measurable mass, these may be regarded as post-therapeutic residue, and should not exclude the classification as CR.
16.4 Investigations at the end of treatment

Investigations required at this point are:

- Thorough physical and neurological examination (weight, height, pubertal status)
- Blood: Full Blood Count, liver enzymes, K, Na, Ca, PO₄, Cl, Mg, Glucose, AP, H₂CO₃, creatinine.
- Urine: Na, Ca, Glucose, PO₄, Creatinine, pH, Total Protein; 24 h urine: Calculate GFR, 24 h Ca, PO₄ and Glucose loss, max. PO₄ reabsorption/GFR.
- MRI/CT/ultrasound of primary tumour site, CXR, abdominal ultrasound.
- Other investigations if previously abnormal (CSF, hormonal status, ECG, PET) may be indicated but are not generally recommended.

16.5 Investigations during follow-up

Post therapy, all patients should be followed for possible tumour relapse and treatment side effects monitoring.

? TUMOUR RELAPSE SURVEILLANCE

Patients should be evaluated with:

- Clinical examination
- Ultrasound ± CT scan or MNR of the primary tumour site
- Chest X-ray

with these recommended interval periods:

- every 3 months during the 1st year of follow-up
- every 4 months during the 2nd and 3rd year
- every 6 months during the 4th and 5th year
- then every 12 months up to 10 year from diagnosis.

? LATE EFFECTS SURVEILLANCE

Height and weight at 6 months to 1 year intervals. Any child showing a growth deceleration of 20–25 percentile units on standard growth charts from the pretreatment height, should be evaluated for thyroid and pituitary function.

Annual blood pressure measurement.

Annual Tanner Staging for girls and boys till maturity. If there is delayed, the patient warrants evaluation of gonadotrophins values, i.e., at 12-14 years for girls (FSH, LH and estradiol) and boys (FSH, LH and testosterone).
Record annual measurement of testicular size in boys using volume measured by Prader orchidometer if possible. The vast majority of patients on this study will receive alkylating agents and may accrue damage to the germinal epithelium of the testis. Surveillance of testicular growth in boys at annual visits and initial screening of gonadal hormone values at 14 years of age (FSH, LH and testosterone). Adult values for these hormones are expected at 16-17 years of age. High FSH values suggest damage to the germinal epithelium. Semen analysis can be done if requested by the patient or if the patient is receptive to the suggestion by a physician.

Record the onset of menses in girls and regularity of periods. Because of local radiotherapy or alkylating agents therapy, ovarian failure may occur in some patients.

History should include school performance and behavioural disturbances so that early intervention can be made for recognized problems.

Cardiac surveillance. Annual evaluation of cardiac function should be made for at least 5 years. Histories should include reference to exercise tolerance or shortness of breath.

Particular studies for specific primary sites:

- **Head and neck NRSTS:**
  - Annual growth measurements plotted on standard growth curves for all patients
  - Annual ophthalmologic exam by an ophthalmologist if eye was in radiotherapy field
  - Annual dental exam if maxillary/mandibular sites were in radiotherapy field
  - Auditory examination every year if the ears were in the irradiated field
  - If radiotherapy was given to the primary site, get bone X-Rays of the primary site every 1-2 years till maturity. Include opposing normal side for comparison of degree of bone hypoplasia
  - Thyroid function (TSH, T3, T4) must be verified every 2 years in case of irradiation on the neck.

- **Trunk**
  - If radiotherapy was given to primary tumours of the chest or to pulmonary metastases, take history for exercise intolerance or shortness of breath.
  - If part of heart was in radiotherapy field and patient also received doxorubicin, follow for cardiac toxicity (see 2.a.).
  - X-Rays of the bone in the primary site with the opposite normal side for evaluation of bone hypoplasia - facultative
  - Studies appropriate to investigate problems following abdominal/pelvic irradiation which may include bowel obstruction, chronic diarrhea, inadequate absorption, rectal stenosis, and sphincter problems.
  - Kidney function should be followed annually in patients receiving para-aortic node irradiation or other abdominal sites encroaching on the kidneys.
- If radiotherapy port included the upper femurs/hip joints, slipped capital femoral epiphyses may occur several years after therapy. Symptoms are limp or pain.

- **Extremities**

  - If radiotherapy was given, appropriate bilateral limb length measurements should be done annually.
  
  - **X-Rays of primary sites for bone growth-abnormalities** – facultative. Get normal side for comparison.
  
  - History should address **limp, evidence of pain and other dysfunction** of the involved extremity.

? **Pain in the primary site 5-10 years after therapy** warrants investigation for the development of secondary bone tumours. This is applicable to all radiation treated sites.

? The development of **a second malignant neoplasm**, either leukaemia, lymphoma or solid tumour, should be reported immediately.
17. SYNOVIAL SARCOMA

Synovial sarcoma is the most common NRSTS in childhood. It occurs mostly in extremities of adolescents, marked by the presence of both epithelial-like and spindle cells, with a biphasic aspect, or a monophasic, or a poorly differentiated one. The specific translocation t(X;18) has been found in more than 90% of cases. Though it could be graded according to mitotic index, differentiation and percent of necrosis, synovial sarcoma needs to considered as a high-grade tumour.

17.1 Chemotherapy

The optimal treatment approach to synovial sarcoma remains to be determined, and over the years different strategies have been used in paediatric oncology protocol as compared to the adults. Adult patients have been treated within trials including all soft tissue sarcoma histotypes, generally with an adjuvant chemotherapy and a no-therapy arm. Concerning its chemoresponsiveness, only recently has synovial sarcoma been recognized to stand halfway between most typical adult soft tissue sarcomas and paediatric small round cell tumours.

On the contrary, paediatricians have long appreciated that this tumour needs to be considered a “quite” chemoresponsive tumour, borrowing their approach from RMS. Thus, in previous European protocols synovial sarcoma was considered as a “RMS-like” tumour and included in RMS treatment study: all paediatric patients with synovial sarcoma received chemotherapy (with the same regimen in use for RMS), regardless of surgery and size (i.e. also in case of small tumour completely resected). The role of adjuvant chemotherapy is however still uncertain, and up to now a randomized trial has been considered unfeasible due to the low accrual even in national cooperative studies.

Recently-reported studies would seem unable to definitely clarify the need to adjuvant chemotherapy in synovial sarcomas.

On the one hand, the multicenter multivariate analysis coordinated by the M.D.Anderson (with German and Italian cases), suggested that adjuvant chemotherapy did not seem to have an impact on survival in IRS Group I-II patients. In this series, 5-yr OS was 80%, and tumour size appeared to be the most relevant prognostic factor. Event-free survival (EFS) was 84% in the subset of 37 IRS group I-II patients treated without adjuvant chemotherapy and 78% in the subset of 122 group I-II patients who received it. In IRS group III cases, however, the response rate to chemotherapy was quite high (60%) (Okcu F, J Clin Oncol 2003). These results would seem to suggest to avoid adjuvant chemotherapy in resected patients.

On the other hand, various data suggest continuing to treat all synovial sarcomas with chemotherapy.

In a retrospective analysis of 271 patients of all ages treated at the Istituto Nazionale Tumori of Milano (Ferrari A, Cancer 2004), the outcome was clearly better in paediatric than in adult cases. This could be related on the different incidence of adverse prognostic factors (i.e. size) in the different age groups, but also to the different use of chemotherapy.

<table>
<thead>
<tr>
<th>Age-groups</th>
<th>% adjuvant chemotherapy</th>
<th>5yr EFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-16 years</td>
<td>78%</td>
<td>66%</td>
</tr>
<tr>
<td>17-30 years</td>
<td>20%</td>
<td>40%</td>
</tr>
<tr>
<td>&gt; 30 years</td>
<td>14%</td>
<td>31%</td>
</tr>
</tbody>
</table>
Moreover, adjuvant chemotherapy would seem to improve the outcome, with benefit in high risk cases (adults, tumour larger than 5 cm) but even in the low-risk subgroup (completely resected, size less than 5 cm).

<table>
<thead>
<tr>
<th>Adult patients, group I-II, &gt; 5 cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>adjuvant chemotherapy</td>
</tr>
<tr>
<td>NO adjuvant chemotherapy</td>
</tr>
</tbody>
</table>

Far from a demonstration of efficacy of adjuvant chemotherapy in synovial sarcomas, these data would seem suggestive of a role of it.

Thereafter, the issue of the role of adjuvant chemotherapy in synovial sarcomas still remains unclear.

The attractive open question concerns the possibility to avoid chemotherapy in tumours smaller than 5 cm after initial complete resection.

This question could really be answered only by an international multicenter collaborative randomized trial. A possible European-American randomized study has been proposed to North-American colleagues, but it has been considered unfeasible. ESSG accrual could not be sufficient for a randomized trial in this subset of patients (IRS group I-II smaller than 5 cm: about 30% of all paediatric synovial sarcomas – no more than 10 patients/year in ESSG - possible estimated OS around 90%).

Given this consideration, EpSSG NRSTS Committee performed an analysis on grossly-resected synovial sarcoma patients, focusing on the pattern of relapse: 150 IRS group I-II cases from CWS and AIEOP STSC have been collected and included in the analysis (Brecht IB, submitted 2005).

The study shows good overall results, with 5-year EFS and OS of 77% and 89%, respectively. Survival rates did not depend on the surgical margins (IRS group I and II patients have similar outcomes), but on tumour size and local invasiveness. The T2B subset of patients shows 5-year EFS and OS of 41% and 67% respectively.

<table>
<thead>
<tr>
<th>Pattern of relapse:</th>
<th>L</th>
<th>L+M</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>group I, = 5 cm (48 pts)</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>group I, &gt; 5 cm (27 pts)</td>
<td>3</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>group II, = 5 cm (43 pts)</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>group II, &gt; 5 cm (30 pts)</td>
<td>2</td>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>

Analysing thoroughly the data, it is noteworthy that the rate of metastases in patients with tumour = 5 cm (both group I and II) is really small.

In this series, all but very-few patients received adjuvant chemotherapy.
The good outcome of group I patients is confirmed by the SIOP MMT experience. In the SIOP MMT 84-89-95 studies, 66 patients aged 2-17 years (median 12 years) with synovial sarcoma were enrolled; 71% had tumour localized at the extremities. EFS and OS at 5 years were 67% and 81%, respectively, being 5-year EFS 73% in cases with tumour size less than 5 cm, and 62% in those with tumour larger than 5 cm. When we consider only patients submitted to complete resection at diagnosis (16 cases), all were alive at the time of the analysis, 13 in first remission and 3 in second remission (at more than 5 years from relapse, that was local in all cases); no metastatic relapse was observed. Chemotherapy regimen was VA in 9 cases and IVA in 5; 2 patients did not receive chemotherapy.

Given these data, the treatment plan will require:

- the use of the ifosfamide-doxorubicin regimen, at a maximum of 4 cycles (maximum cumulative dose of doxorubicin: 300 mg/m²)
- the omission of chemotherapy in group I, = 5 cm patients (with stopping rules for MFS)
- the reduction of chemotherapy in group II, = 5 cm, administering 3 cycles of ifosfamide-doxorubicin (ICG-CWS data would suggest that the risk of metastases correlate with tumour size and not with surgical margins; nevertheless, the decision to give 3 cycles of chemotherapy was taken, due to the consideration that in previous protocols these patients received a full plan of chemotherapy, i.e. 9 courses of VAIA in CWS and ICG trials, and in relation to the INT Milan data that showed a statistically significant difference in EFS between IRS group I (144 patients, 5-year EFS 45.2%) and group II (71 patients, EFS 31.6%)
- 2 cycles of ifosfamide concomitantly to radiotherapy will be added to the 4 ifosfamide-doxorubicin courses in IRS group II, > 5 cm patients and in IRS group III patients
- for patients considered unresectable at diagnosis, 3 cycles of ifosfamide-doxorubicin neo-adjuvant chemotherapy will be required.

Ifosfamide (concomitantly to radiotherapy) and post-operative chemotherapy will be required in case of response to primary therapy (also “minor partial response” will be considered sufficient), whereas chemotherapy will be avoided in case of stable disease and progression of disease.

In patients whose local treatment will be surgery alone, 2 cycles of ifosfamide alone will be however added to uniform the systemic treatment in the IRS group III patients.
The chemotherapy response will be evaluated according to the radiological response.

Complete Response (CR) Complete disappearance of all visible disease, complete disappearance of tumour with no residual disease

Very Good Partial Response (VGPR) 90% reduction of tumour volume (volume response between 90-99%)

Partial Response (PR>2/3) 66% reduction of tumour volume (volume response between 66-90%)

Minor Partial Response (PR<2/3) Volume response between 34-65%

Stable Disease (SD) < 33% reduction of tumour volume (no criteria for PR or PD)

Progressive Disease (PD) Any increase of more than 40% in the sum of volumes of all measurable lesions, or appearance of new lesions.

17.2 Radiotherapy

Concerning radiotherapy, as for other STS, it will be given as conventional fractionation of 1.8 Gy/day. The total dose will range between 50.4 and 59.4 Gy.

? IRS Group I (initial complete resection, R0):

The INT Milan series seemed to suggest a favourable trend for post-operative radiotherapy in patients previously submitted to complete resection (with no statistically significant difference).

<table>
<thead>
<tr>
<th>5 year LRFS</th>
<th>post-operative radiotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>yes</td>
</tr>
<tr>
<td>complete resection (n.patients 144)</td>
<td>77.8% (n.51)</td>
</tr>
<tr>
<td>complete resection, tumour = 5 cm (n.63)</td>
<td>100% (n.19)</td>
</tr>
<tr>
<td>complete resection, tumour &gt; 5 cm (n.72)</td>
<td>73.1% (n.30)</td>
</tr>
<tr>
<td>marginal resection (n.71)</td>
<td>57.4% (n.56)</td>
</tr>
</tbody>
</table>
In the common ICG-CWS analysis, no benefit of adding radiotherapy in IRS group I patients (complete macroscopic and microscopic resection) was observed, independent on the initial tumour size. So far there is no clear evidence of the role of radiotherapy in these patients. Since large initial tumour size is a recognized risk factor stopping rules for local failures for patients with tumours larger than 5 cm in diameter at diagnoses will be defined.

IRS group II (microscopic residual disease at initial resection or positive lymph nodes):

Important note:
Every effort should be done by the surgeon to avoid IRS group II patients (the use of primary re-excision is recommended, when feasible).

In the CWS-ICG-analysis, the treatment results for patients in IRS group II were comparable to those in IRS group I. These results were obtained with nearly all patients in IRS II receiving radiotherapy.

The multicenter analysis from the M.D. Anderson (Okcu F, J Clin Oncol 2003) showed the benefit of post-operative radiotherapy on LRFS and OS in group I-II patients.

In the analysis of the INT Milan data, a clear benefit was observed for group II patients who received radiotherapy: 5-year LRFS was 7% in the 15 group II patients treated without irradiation.

This series regards patients of all ages, mainly adults (Ferrari A, Cancer 2004). These findings would suggest the use of radiotherapy after marginal resection.

In the cohort of 66 paediatric patients with synovial sarcoma enrolled in the SIOP MMT 84-89-95 studies, 22 patients initially submitted to microscopically incomplete resection were seen. All of them received chemotherapy (IVA), while radiotherapy was given to 5 patients only (17 did not receive radiotherapy).

Local relapses were seen in 1/5 patients treated with radiotherapy (then the child was salvaged with second-line therapy). Among the 17 patients treated without irradiation, 3 patients had local relapse and 2 had metastatic relapse: 1 out of the 3 local relapsing patients and 1 of the patients who developed metastases died of their disease; at the end, 20/22 IRS group II patients were alive in first (16) or second (4) remission at the time of the analysis.

Concerning radiotherapy, 12 patients with initial microscopically incomplete resection were cured without radiotherapy, and therefore without radiotherapy-related side effects. These findings may suggest that radiotherapy could be avoided in some IRS group II patients, at least those with younger age and small tumour size.

The debate on indication for radiotherapy in IRS II patients has its background on the different philosophies adopted over the years by the CWS-ICG groups and the SIOP group. It is important to underline the concept of the “total burden of therapy” experienced by a given patient and the predicted sequelae that treatments may have. In particular, the philosophy behind the SIOP-MMT studies has pointed to a lesser use of radiotherapy in selected subsets of patients, i.e. children submitted to marginal resection at diagnosis, with suspected microscopical residual disease: this strategy generally produced worse local relapse rates than those reported elsewhere, but the overall survival was superimposable, since a significant number of locally relapsing patients were cured by salvage treatments (including aggressive surgery and radiotherapy); on the other hand, a significant proportion of patients could be cured without radiotherapy. In other words, according to this strategy, outcome should be measured on the combination of overall survival and “cost” of survival in terms of sequelae, rather than on disease-free survival alone.
This is yet matter of debate.
The EpSSG NRSTS 2005 protocol will suggest the use of radiotherapy in IRS group II synovial sarcomas (as required by ICG-CWS groups), but an alternative option may be to avoid irradiation, in particular for younger patients (age less than 10 years) and tumour size smaller than 5 cm (SIOP option). The multidisciplinary discussion may determine the decision in individual case.

Radiotherapy will be applied in conventional fractionation. The total radiation dose for patients with tumours ≤ 5 cm in diameter is 50.4 Gy in 1.8 Gy fractions. Because of a higher local failure risk in patients with larger tumours, 54 Gy are given in patients with > 5 cm initial tumour size.
In order to avoid concomitant administration of doxorubicin and radiotherapy (that will last 5-6 weeks, overlapping with 2 chemotherapy cycles), in group II = 5 cm patients (3 cycles of chemotherapy required), radiotherapy will start after the completion of the 3 chemotherapy cycles, avoiding the need of concomitant chemo-radiotherapy.
In group II > 5 cm, radiotherapy cannot be delayed at the end of chemotherapy (18th week). Therefore, radiotherapy will start at 9th week and will be administered concomitantly to 4th and 5th cycles of chemotherapy (ifosfamide alone)

? IRS group III (macroscopic residual disease at initial resection):

After the initial 3 cycles of chemotherapy, tumour-reassessment and then local treatment need to be planned.
Four different options are possible:

a. Patients with the option of secondary complete resection:

Surgery remains the mainstay of treatment for synovial sarcomas.
The use of radiotherapy is a matter of debate in patients with secondary complete resection.
In the CWS group, nearly all patients treated with complete second surgery received radiotherapy.
In INT Milan series, 30 out of 40 IRS group III patients had delayed complete resection: 11 of them received radiotherapy, 19 did not, and no difference was observed on the outcome. Survival rates strongly correlated with the chances to achieving complete surgery (5-year EFS 42% vs 10%), though metastases (and not the local relapse) were the main cause of treatment failure (5-year LRFS 80%, MFS 34%) (Ferrari A, Cancer 2004).
In the EpSSG centers, there is no a consensus on:
1) the necessity to give radiotherapy after delayed complete surgery; it is not clear whether the use of radiotherapy in these patients results in improved survival
2) what is the best option, when the decision to give radiotherapy has been taken, between pre-operative and post-operative radiotherapy
(pre-operative irradiation can improve the chance to perform a complete secondary resection; moreover, pre-operative radiotherapy could be more effective in non-hypoxic tissues, may reduce the risk of intra-operative contamination, and could use smaller radiotherapy fields; post-operative radiotherapy has a small risk of wound complication).

Therefore, there are three treatment options for patients with the option of secondary complete resection:

a1. Preoperative RXT with 50.4 Gy in 1.8 Gy daily fractions
a2. No additional RXT following secondary complete resection

a3. Postoperative RXT with 50.4 Gy in 1.8 Gy daily fraction

The decision may depend also to the physician’s preference. However, possible suggestions are:
- to avoid RXT in younger patients after delayed complete surgery (< 6 years)
- to give RXT in case of initial large tumour size (> 10 cm) and in case on first surgical approach (biopsy) that could have caused tissue contamination.

The results of the different local modality groups will be compared

a.4 Following secondary incomplete resection, 54 Gy have to be given with microscopical residual disease. In case of macroscopic residual disease, radiotherapy has to be given according to patients with no second surgery (see below)

b. Patients without the option of secondary complete resection:

IRS group III patients who cannot have a complete secondary resection have a poor prognosis and need to have radiotherapy. Radiotherapy is then the only local therapy modality and should be given with high doses. The recommended dose is 59.4 Gy.
An additional boost of 5.4 Gy can be given when there is residual disease at the end of radiotherapy. The dose recommendation may need modification depending on the age of the patient and the tumour site.

?? ?? ?? Timing of radiotherapy

IRS group II:
Radiotherapy should start after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at week 9 at the resolution of the toxicity of the third cycle of chemotherapy.
During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone (patients with tumour > 5 cm).

IRS group III:
The option for second surgery must be checked before the onset of radiotherapy.
In patients receiving no second surgery, radiotherapy is performed at week 9.
When second surgery is planned, there are 3 treatment options:
- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy
When radiotherapy is performed before second surgery (pre-operative radiotherapy), irradiation starts at week 9. Surgery should be performed 5 weeks after the end of radiotherapy (and after the last chemotherapy cycle) to avoid surgical complications.
When postoperative radiotherapy is given, radiotherapy should be started within 21 days except when there are postoperative complications.

Radiotherapy in younger children

<table>
<thead>
<tr>
<th>Children &lt; 3 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy is only given when there is residual tumour after primary or secondary resection. For patients in IRS group III without an option of secondary complete resection, the dose is reduced to 50.4 Gy</td>
</tr>
<tr>
<td>- IRS group I: no RXT</td>
</tr>
<tr>
<td>- IRS group II: no RXT</td>
</tr>
<tr>
<td>- IRS group III, secondary complete resection: no RT</td>
</tr>
<tr>
<td>- IRS group III, no secondary surgery: 50.4 Gy</td>
</tr>
</tbody>
</table>
17.3 Risk-adapted treatment program

<table>
<thead>
<tr>
<th>IRS group I, = 5 cm</th>
<th>surgery only</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NO adjuvant chemotherapy, NO radiotherapy</td>
</tr>
<tr>
<td></td>
<td>* stopping rules for MFS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRS group I, &gt; 5 cm</th>
<th>IFO-DOXO x 4 cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(cumulative IFO 36 g/m², cumulative DOXO 300 mg/m²)</td>
</tr>
<tr>
<td></td>
<td>NO radiotherapy</td>
</tr>
<tr>
<td></td>
<td>* stopping rules for LRFS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRS group II, = 5 cm</th>
<th>IFO-DOXO x 3 cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(cumulative IFO 27 g/m², cumulative DOXO 225 mg/m²)</td>
</tr>
<tr>
<td>Radiotherapy 50.4 Gy (1.8 Gy/d)</td>
<td></td>
</tr>
<tr>
<td>starting at 9th week, after the completion of chemotherapy</td>
<td></td>
</tr>
<tr>
<td>* radiotherapy could be avoided in selected cases, i.e. age &lt; 10 yrs</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRS group II, &gt; 5 cm</th>
<th>IFO-DOXO x 3 cycles – IFO x 2 – IFO-DOXO x 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(cumulative IFO 48 g/m², cumulative DOXO 300 mg/m²)</td>
</tr>
<tr>
<td>Radiotherapy 54 Gy (1.8 Gy/d)</td>
<td></td>
</tr>
<tr>
<td>starting at 9th week, concomitantly to 4th and 5th cycles</td>
<td></td>
</tr>
<tr>
<td>* radiotherapy could be avoided in selected cases, i.e. age &lt; 10 yrs</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRS group III</th>
<th>IFO-DOXO x 3 cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>then evaluation of tumour response (week 9th) and local treatment:</td>
<td></td>
</tr>
<tr>
<td>o delayed complete surgery, no RXT</td>
<td></td>
</tr>
<tr>
<td>o pre-op RXT 50.4 Gy, then surgery</td>
<td></td>
</tr>
<tr>
<td>o delayed complete surgery, then post-op RXT 50.4 Gy</td>
<td></td>
</tr>
<tr>
<td>o delayed incomplete surgery, then RXT 54-59.4 Gy</td>
<td></td>
</tr>
<tr>
<td>o RXT 59.4 Gy</td>
<td></td>
</tr>
</tbody>
</table>

in case of major or minor response to chemotherapy:

IFO x 2 during RXT + IFO-DOXO x 1 |
(cumulative IFO 48 g/m², cumulative DOXO 300 mg/m²)
? IRS group I, > 5 cm

<table>
<thead>
<tr>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>10°</th>
<th>weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
</tr>
</tbody>
</table>

? IRS group II, = 5 cm

<table>
<thead>
<tr>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>9°</th>
<th>weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td></td>
</tr>
</tbody>
</table>

? IRS group II, > 5 cm

<table>
<thead>
<tr>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>9°</th>
<th>10°</th>
<th>13°</th>
<th>17°</th>
<th>weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO</td>
<td>IFO</td>
<td>IFO-DOXO</td>
<td></td>
</tr>
</tbody>
</table>

? RADIOTHERAPY 50.4 Gy

? IRS group III

<table>
<thead>
<tr>
<th>biopsy</th>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>9°</th>
<th>tumour re-assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) | 10°  | 13°  | 16°  | 18°  | weeks |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO</td>
<td>IFO</td>
<td>IFO-DOXO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

? pre-op RADIOTHERAPY 50.4 Gy

b) | 10°  | 12°  | 15°  | 18°  | weeks |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO</td>
<td>IFO</td>
<td>IFO-DOXO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

c) | 10°  | 12°  | 15°  | 18°  | weeks |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO-DOXO</td>
<td>IFO</td>
<td>IFO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

? post-op RXT 50.4 Gy (or 54–59.4 Gy)

d) | 10°  | 13°  | 16°  | weeks |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>IFO</td>
<td>IFO</td>
<td>IFO-DOXO</td>
</tr>
</tbody>
</table>

? RADIOTHERAPY 59.4 Gy

* local treatment only in case of no response to primary chemotherapy

S = surgery
IFO-DOXO = ifosfamide 3 g/m²/day, for 3 days + doxorubicin 37.5 mg/m²/day, for 2 days
IFO = ifosfamide 3 g/m²/day for 2 days
17.4 Stopping rules

**Stopping rules for MFS in IRS group I, = 5 cm**

The rate of metastases will be monitored throughout the study, whenever a metastasis occurs. Given our data, a probability of 8% of metastases could be considered acceptable for this study. The enrolment of patients has to be stopped if the probability of a metastatic relapse exceeds 15%.

According to Wald’s Sequential Probability Ratio Test, the data collection has to be terminated if the observed number of patients who develop metastases is higher than 4.08+0.111 x number of recruited patients. The boundary of the test is computed given alpha=0.05 and power=90%.

<table>
<thead>
<tr>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.195</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4.307</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>4.419</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4.531</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>4.642 92.84%</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>4.754 79.23%</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>4.866 69.51%</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>4.978 62.23%</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>5.09 56.56%</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>5.202 52.02%</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>5.313 48.30%</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>5.425 45.21%</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>5.537 42.59%</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>5.649 40.35%</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>5.761 38.41%</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>5.872 36.70%</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>5.984 35.20%</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>6.096 33.87%</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>6.208 32.67%</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>6.32 31.60%</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>6.432 30.63%</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>6.543 29.74%</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>6.655 28.93%</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>6.767 28.20%</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>6.879 27.52%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>6.991 26.89%</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>7.102 26.30%</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>7.214 25.76%</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>7.326 25.26%</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>7.438 24.79%</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>7.55 24.35%</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>7.662 23.94%</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>7.773 23.55%</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>7.885 23.19%</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>7.997 22.85%</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>8.109 22.53%</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>8.221 22.22%</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>8.332 21.93%</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>8.444 21.65%</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>8.556 21.39%</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>8.668 21.14%</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>8.78 20.90%</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>8.901 20.68%</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>9.003 20.46%</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>9.115 20.26%</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>9.227 20.06%</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>9.339 19.87%</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>9.451 19.69%</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>9.562 19.51%</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>9.674 19.35%</td>
<td></td>
</tr>
</tbody>
</table>
Stopping rules for LRFS in IRS group I, > 5 cm

The rate of local relapses will be monitored throughout the study, whenever a relapse occurs. For this study, a probability of 15% of local relapses is considered acceptable. The enrolment of patients has to be stopped if the probability of a local relapse exceeds 25%. According to Wald's Sequential Probability Ratio Test, the data collection has to be terminated if the observed number of patients who develop local relapse is higher than $4.54 + 0.196 \times$ number of recruited patients. The boundary of the test is computed given $\alpha=0.05$ and power=90%.

<table>
<thead>
<tr>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.741</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4.938</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5.135</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>5.331</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>5.528</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>5.725</td>
<td>95.42%</td>
</tr>
<tr>
<td>7</td>
<td>5.922</td>
<td>84.60%</td>
</tr>
<tr>
<td>8</td>
<td>6.119</td>
<td>76.49%</td>
</tr>
<tr>
<td>9</td>
<td>6.315</td>
<td>70.17%</td>
</tr>
<tr>
<td>10</td>
<td>6.512</td>
<td>65.12%</td>
</tr>
<tr>
<td>11</td>
<td>6.709</td>
<td>60.99%</td>
</tr>
<tr>
<td>12</td>
<td>6.906</td>
<td>57.55%</td>
</tr>
<tr>
<td>13</td>
<td>7.103</td>
<td>54.64%</td>
</tr>
<tr>
<td>14</td>
<td>7.299</td>
<td>52.14%</td>
</tr>
<tr>
<td>15</td>
<td>7.496</td>
<td>49.97%</td>
</tr>
<tr>
<td>16</td>
<td>7.693</td>
<td>48.08%</td>
</tr>
<tr>
<td>17</td>
<td>7.89</td>
<td>46.41%</td>
</tr>
<tr>
<td>18</td>
<td>8.087</td>
<td>44.93%</td>
</tr>
<tr>
<td>19</td>
<td>8.283</td>
<td>43.59%</td>
</tr>
<tr>
<td>20</td>
<td>8.48</td>
<td>42.40%</td>
</tr>
<tr>
<td>21</td>
<td>8.677</td>
<td>41.32%</td>
</tr>
<tr>
<td>22</td>
<td>8.874</td>
<td>40.34%</td>
</tr>
<tr>
<td>23</td>
<td>9.071</td>
<td>39.44%</td>
</tr>
<tr>
<td>24</td>
<td>9.267</td>
<td>38.61%</td>
</tr>
<tr>
<td>25</td>
<td>9.464</td>
<td>37.86%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>9.661</td>
<td>37.16%</td>
</tr>
<tr>
<td>27</td>
<td>9.858</td>
<td>36.51%</td>
</tr>
<tr>
<td>28</td>
<td>10.05</td>
<td>35.89%</td>
</tr>
<tr>
<td>29</td>
<td>10.25</td>
<td>35.34%</td>
</tr>
<tr>
<td>30</td>
<td>10.44</td>
<td>34.80%</td>
</tr>
<tr>
<td>31</td>
<td>10.64</td>
<td>34.32%</td>
</tr>
<tr>
<td>32</td>
<td>10.84</td>
<td>33.88%</td>
</tr>
<tr>
<td>33</td>
<td>11.03</td>
<td>33.42%</td>
</tr>
<tr>
<td>34</td>
<td>11.23</td>
<td>33.03%</td>
</tr>
<tr>
<td>35</td>
<td>11.43</td>
<td>32.66%</td>
</tr>
<tr>
<td>36</td>
<td>11.62</td>
<td>32.28%</td>
</tr>
<tr>
<td>37</td>
<td>11.82</td>
<td>31.95%</td>
</tr>
<tr>
<td>38</td>
<td>12.02</td>
<td>31.63%</td>
</tr>
<tr>
<td>39</td>
<td>12.21</td>
<td>31.31%</td>
</tr>
<tr>
<td>40</td>
<td>12.41</td>
<td>31.03%</td>
</tr>
<tr>
<td>41</td>
<td>12.61</td>
<td>30.76%</td>
</tr>
<tr>
<td>42</td>
<td>12.81</td>
<td>30.50%</td>
</tr>
<tr>
<td>43</td>
<td>13.00</td>
<td>30.23%</td>
</tr>
<tr>
<td>44</td>
<td>13.2</td>
<td>30.00%</td>
</tr>
<tr>
<td>45</td>
<td>13.4</td>
<td>29.78%</td>
</tr>
<tr>
<td>46</td>
<td>13.59</td>
<td>29.54%</td>
</tr>
<tr>
<td>47</td>
<td>13.79</td>
<td>29.34%</td>
</tr>
<tr>
<td>48</td>
<td>13.99</td>
<td>29.15%</td>
</tr>
<tr>
<td>49</td>
<td>14.18</td>
<td>28.94%</td>
</tr>
<tr>
<td>50</td>
<td>14.38</td>
<td>28.76%</td>
</tr>
</tbody>
</table>
References


18. ADULT-TYPE SOFT TISSUE SARCOMAS

We have defined as “adult-type” soft tissue sarcomas those NRSTS that are:

- typical of adulthood (excluding infantile fibrosarcoma)
- definitely malignant (excluding borderline tumours, i.e. hemangioendothelioma)
- with morphological features resembling differentiated/mature tissues (excluding small round cell tumours, i.e. extraosseous pPNET/Ewing’s sarcoma and desmoplastic small round cell tumour).

Therefore, the following histotypes are included in this group:

- fibrosarcoma (adult-type)
- malignant peripheral nerve sheath tumour (malignant schwannoma, neurofibrosarcoma)
- epithelioid sarcoma
- epithelioid sarcoma
- leiomyosarcoma
- clear cell sarcoma
- liposarcoma
- alveolar soft part sarcoma
- malignant fibrous histiocytoma
- hemangiopericytoma (adult-type)
- angiosarcoma
- dermatofibrosarcoma protuberans
- mesenchymal chondrosarcoma

The definition of this group tries to respond to the necessity of the identification of a relatively “homogeneous” group of NRSTS. This definition is arbitrary and is based on clinical consideration more than histological ones.

18.1 Chemotherapy

This group includes the large proportion of NRSTS, generally considered as characterized by uncertain response to chemotherapy.

As in adults, conservative surgical resection remains the unquestionable mainstay of therapy, and radiotherapy is considered important in case of incomplete resection or, after wide excision, in case of large tumours.

Surgery (IRS group), tumour size and tumour grade represent the most important prognostic factors, as reported by paediatric and adult published series.

There is a general agreement that patients with small and low-grade tumour, who underwent complete surgical resection, can be cured without adjuvant therapies.

Differently, patients with large tumour and/or high-grade tumour had a high risk of metastatic spread. Therefore, a relevant question concerns the role of adjuvant chemotherapy in these patients.
Though several adult studies did not demonstrate any advantage for chemotherapy (while the only one randomized trial on adjuvant chemotherapy performed in paediatric age failed in its aim because the majority of patients refused randomization), various recent hints would suggest that chemotherapy might have a more significant role in high-risk cases (i.e. large tumour, high-grade) than is generally believed.

A large meta-analysis (including trials on intensified doxorubicin-based chemotherapy) demonstrated a reduction in the risk of local and distant failures in the chemotherapy-group (*The Sarcoma Meta-analysis Collaboration, Lancet 1997*).

Moreover, the Italian randomized trial on high risk patients (high-grade, large, deep, extremities site) was closed in advance due to an early striking benefit in EFS and OS for patients who received intensive ifosfamide-doxorubicin chemotherapy (with G-CSF support) versus those treated with local therapy only (*Frustaci, J Clin Oncol 2001*). This trial has been defined by George Demetri as the first “modern” study on adjuvant chemotherapy in soft tissue sarcoma (*Highlights of sarcoma research, Journal of Clinical Oncology Classic Papers and Current Comments, 7:681-684, 2002*): IFO-DOXO regimen needs to be considered the most effective chemotherapy and several suggestions have prompted that the dose intensification has been associated with the improvement of response rate and disease-free survival.

More recently, the M.D.Anderson and the Memorial Sloan Kettering Cancer Centers published a common retrospective analysis on localized, high-risk (high-grade, deep, size > 5 cm) STS of extremities, with the aim to evaluate the impact of doxorubicin-based chemotherapy on outcomes. This reports showed a time-varying effect associated with chemotherapy: during the first year, chemotherapy seemed to improve the outcome, but thereafter the clinical benefits are not sustained over time (*Cormier, J Clin Oncol, 2004*).

In summary, the role of adjuvant chemotherapy remains controversial in these tumours. Caution should be used in interpreting both the negative results from the previous randomized studies (that in most cases used “old” regimens in unselected groups of patients), and the apparently more satisfactory recent findings (*Frustaci, J Clin Oncol 2001; Brodowicz, Sarcoma 2000; Petrioli, Am J Clin Oncol 2002*).

Henceforward, it is clear that clinical trials should properly: 1) target high-risk patients, with a fair selection of the cases, 2) deliver full-dose intensity chemotherapy including the most active drugs.

Currently, it is clear that we cannot yet define intensive adjuvant IFO-DOXO chemotherapy as “standard of care” in high-risk resected soft tissue sarcomas. Moreover, various data would seem to suggest that about 50% of NRSTS with measurable disease might respond to chemotherapy, in particular when minor response are considered too.

In grossly-resected, large, G3 cases, a quite large percentage of patients might have in principle a benefit from the addition of adjuvant chemotherapy, especially when an intensive ifosfamide-doxorubicin regimen is adopted.

In the single-institution series from the Istituto Nazionale Tumori of Milan, (*Ferrari A, J Clin Oncol 2005*), the authors reported the analysis of patients with adult-type STS (excluding synovial sarcomas) considered at high risk of metastatic failure (i.e. IRS group II, size > 5 cm, G3): in this subset of 15 patients, 5-year MFS was 36%, and it was 53% in patients treated with adjuvant chemotherapy (11 cases) and 0% in those treated without chemotherapy (4 cases).

Focusing on these subset of patients (IRS group II, high risk of metastatic failure due to large size and high-grade), a retrospective analysis has been performed within the ICG-CWS groups (*Ferrari A, Ped Blood Cancer 2005*).
Though grade evaluation was not available for the majority of patients enrolled in previous European protocols, 36 patients (age 3-20 years, median 13) with group I-II, > 5 cm, G3 tumour have been found in the ICG-CWS protocols.

The patients’ characteristics were the following:
Histotypes: 14 MPNST, 4 epithelioid sarcoma, 3 clear cell sarcoma, 3 liposarcoma, 3 leiomyosarcoma, 3 fibrosarcoma, 1 alveolar soft part sarcoma, 1 chondrosarcoma, 1 malignant hemagiopericytoma, 1 malignant fibrous histiocytoma, 2 not-otherwise specified.
Tumour site: 20 extremities, 8 trunk, 5 abdomen, 3 head and neck.
Stage: 9 T1B, 27 T2B; 3 N1; 23 IRS group I, 13 group II.

After primary resection, 11 patients received radiotherapy and 21 had adjuvant chemotherapy (11 VACA, 8 VAIA, 1 CEVAIE regimen).
Median follow-up was 75 months (range 11-240).
The analysis showed poor survival rates and, in particular, a high proportion of metastatic failures. The time from diagnosis to relapse was 2-59 months, median 6 months. The median time to relapse was 13 months for the “chemotherapy group” and 3 months for the “no chemotherapy group” (Ferrari A, Ped Blood Cancer 2005).

<table>
<thead>
<tr>
<th>5yr EFS = 26.2%</th>
<th>5yr LRFS = 46.8%</th>
<th>5yr MFS = 34.0%</th>
<th>5yr OS = 37.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>patients treated with adjuvant chemotherapy (no.21)</td>
<td>5yr EFS = 36.7%, LRFS = 56.9%, MFS = 49.5%, OS = 41.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>patients treated without chemotherapy (no.15)</td>
<td>5yr EFS = 0%, LRFS = 33.3%, MFS = 0%, OS = 23.8%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

It is clear that the very-small number of patients strongly limits the value of this analysis. Nevertheless, the combination of the two variables (G3 and size > 5 cm) seems to bestow a high risk of metastatic spread: large size and high-grade probably define the intrinsic biological aggressiveness of the tumour, that affects the survival despite of the initial surgery. This may suggest in principle the use of systemic therapies. Moreover, adjuvant chemotherapy seems to have an impact on survival rates.

The results of this analysis are not comparable with the other reported in literature. Various paediatric and adult series showed EFS rate in the 50% range for large tumours and for G3 tumours, but analyses of large and G3 (considering the two variables together) are not available. As for paediatric series, the POG study reported a 5-year EFS of 52% for group II, G3 patients, but they did not report the outcome of G3 and tumour > 5 cm (Pratt, J Clin Oncol 1999). The St. Jude series reported by Sheri Spunt noted that, in the group of IRS group I-II children, > 5 cm cases had a 5-year EFS of 55%, while G3 cases had a 5-year EFS of 65% (no data on > 5 cm and G3) (Spunt et al, J Clin Oncol 17:3697-3705, 1999). In an older series reported by Rao et al, T2G3 cases had a 10-year OS of 10% (Rao et al. Semin Surg Oncol 9:524-531, 1993).

Other findings from the ICG and SIOP cases confirm the EFS in the range of 50% for patients with large tumour (and a trend of benefit for patients treated with chemotherapy).
ICG: 23 group I-II, > 5 cm patients

<table>
<thead>
<tr>
<th></th>
<th>chemotherapy</th>
<th>NO chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>5yr EFS</td>
<td>50.2%</td>
<td>57.9%</td>
</tr>
<tr>
<td>5yr OS</td>
<td>50.2%</td>
<td>57.9%</td>
</tr>
</tbody>
</table>

(SIOP: 15 group II, > 5 cm patients

<table>
<thead>
<tr>
<th></th>
<th>(11)</th>
<th>(4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5yr EFS</td>
<td>50.9%</td>
<td>63.6%</td>
</tr>
<tr>
<td>5yr OS</td>
<td>70.5%</td>
<td>72.7%</td>
</tr>
</tbody>
</table>

Similarly, the SIOP MMT95 study analysed the outcome of NRSTS according to tumour grade.

In the last MMT trial, 149 patients with NRSTS were included: 68 of them were graded according to the FNCLCC system: 5-year EFS was 74% for G1-G2 patients (44 cases) and 50% for G3, respectively; MFS figure was superimposable.

As a consequence of these considerations, and without the possibility to have the patients accrual necessary to a randomized study, the role of adjuvant chemotherapy will be explored in high-risk adult-type NRSTS (IRS group I-II, G3, tumour > 5 cm) within the EpSSG protocol.

**Adjuvant chemotherapy** will be required in these patients: 4 cycles of ifosfamide-doxorubicin plus 2 additional cycles of ifosfamide concomitantly to radiotherapy.

Though adjuvant chemotherapy is not “standard” in these histotypes, the poor MFS of this selected group suggest its use: this recommendation could be considered questionable in patients with no evidence of disease (and therefore without a parameter of measuring response, that would implicate the risk of a subset of patients pointlessly receiving full courses of such a toxic treatment). However, overall chemotherapy response rate has been reported to be around 40%, but up to 55-60% when minor responses were considered too (Ferrari, J Clin Oncol 2004). So, a potential benefit for about half of cases might be considered acceptable.

**Important note:**

The chemosensitivity of the different histotypes will be evaluated prospectively in IRS group III patients. Interim analyses will be performed considering chemotherapy response rate of each histotype. These results will be considered and – in case of very poor response rate for some particular histotypes - could lead to change the indication for adjuvant chemotherapy with amendments.

For patients considered **unresectable** at diagnosis, 3 cycles of neo-adjuvant chemotherapy with ifosfamide-doxorubicin will be required.

**Response rate will be assessed after three courses, then patients will receive local treatment.**

Additional chemotherapy (2 cycles of ifosfamide concomitantly to radiotherapy, and 2 additional cycles of ifosfamide-doxorubicin) will be required in case of **radiological response** to the first three cycles (also **“minor partial response will be considered sufficient”**).

Chemotherapy will be avoided in case of stable disease and progression of disease.

Two cycles of ifosfamide alone will be added also to those patients whose local treatment will be surgery alone, to uniform the systemic treatment in the IRS group III patients.
Response evaluation:

**Complete Response (CR)**  Complete disappearance of all visible disease, complete disappearance of tumour with no residual disease

**Very Good Partial Response (VGPR)**  ? 90% reduction of tumour volume  
(volume response between 90-99%)

**Partial Response (PR>2/3)**  ? 66% reduction of tumour volume  
(volume response between 66-90%)

**Minor Partial Response (PR<2/3)**  Volume response between 34-65%

**Stable Disease (SD)**  < 33% reduction of tumour volume  
(no criteria for PR or PD)

**Progressive Disease (PD)**  Any increase of more than 40% in the sum of volumes of all measurable lesions, or appearance of new lesions.

**Important note:**

**Neo-adjuvant (pre-operative) chemotherapy** could be proposed with a cytoreductive aim:
- when a patient is considered unresectable at diagnosis, and may be converted to conservative resectability after tumour shrinkage  
  but also  
- in those cases with large tumour size and a biopsy showing a G3 tumour (for these patients adjuvant chemotherapy will be required), in which the surgeon is not sure to obtain a complete resection (histologically free margins), i.e. he might try a resection, with a risk of infiltrated margins. “IRS group II-resections” should be avoided.
- the multidisciplinary evaluation could be lead to consider, in selected cases, the individually-based decision to use primary chemotherapy also in G3, >5 cm cases considered resectable by surgeons. Surgery remains the mainstay of treatment for NRSTS, but high-risk “adult-type” STS fare poor for metastatic dissemination, independently to surgical margins and local control. Neo-adjuvant chemotherapy could be given as front-line, with a) the aim to treat early the micrometastases, b) the opportunity to evaluate the response to chemotherapy given the measurable disease. In these situations, very careful evaluation of tumour extension and dimensions is necessary at any cycles, in order to avoid local progression that could make the potential delayed resection unfeasible.

? Cumulative dose of doxorubicin will be 300 mg/m² in IRS group I-II patients who receive adjuvant chemotherapy, and 375 mg/m² in IRS III patients who respond well to primary chemotherapy and therefore continue with the full program.
18.2 Radiotherapy

? IRS Group I (initial complete resection, R0):

In adult patients with soft tissue sarcoma, radiotherapy is required after incomplete resection, but often also after wide excision, especially in case of large tumour. In children with a higher risk of severe late effects of radiotherapy, the indication has to be stricter than in adults.

There is little data about the impact of radiotherapy in IRS group I patients in paediatric age. In the analysis of the St. Judes experience of patients with at least grossly resected tumours, univariate analysis of factors associated with improved local control included the use of radiotherapy. It is of note, though, that the majority of irradiated patients belonged to IRS group II. (Spunt S, 2002).

In the INT Milan series, 100 paediatric patients were classified as IRS group I: 22 received post-operative radiotherapy and 78 did not. LRFS at 5 years was 95.2% in the group of patients who had radiotherapy and 84.4% in the second group, without statistically significant difference. When only patients with tumour larger than 5 cm were considered, 5-year LRFS and OS were 91.7% and 90.0% for patients treated with radiotherapy (13 cases) and 69.8% and 53.8%, respectively, for those who were not irradiated (23 cases), and the p value was significant for OS (though the OS results may be influenced by the different use of chemotherapy in this two groups, the percentage of patients who had also chemotherapy being higher in the first group) (Ferrari A, J Clin Oncol 2005).

However:

?? because of the low risk of local failure in patients with small tumours, no radiotherapy is given in patients in IRS group I with < 5 cm tumour diameter at diagnosis.

?? in IRS group I patients with tumours > 5 cm, radiotherapy is given in G2 and G3 tumours (no in G1 tumour). In case of local relapses, these patients are at risk of metastatic relapse and consequently impaired prognosis. The radiation dose of adjuvant radiotherapy is 50.4 Gy in 1.8 Gy fractions.

? IRS group II (microscopic residual disease at initial resection):

Patients with microscopic residual disease following secondary complete resection are at a considerable risk to develop local recurrences. In the INT Milan series, 5-year LRFS was 75.7% in patients who had radiotherapy (n = 27) and 55.6% in those who did not receive it (n = 9) (Ferrari A, J Clin Oncol 2005)

An exception is low-grade tumours. The risk of relapse is lower, and furthermore local recurrences are usually again low-grade, are hardly ever associated with systemic failure, and could be treated with success with re-surgery and eventual radiotherapy. COG (Children’s Oncology group) series included 4 IRS group II G1 patients treated without radiotherapy who did not relapse (unpublished data). In the INT Mila series, 3 patients were classified as group II/G1: two received radiotherapy, and one did not; this patient relapsed locally, but he was salvage with surgery and radiotherapy. Therefore, no radiotherapy is recommended in patients with IRS group II G1 tumours.

An exception is patients in whom surgery of local recurrence would be problematic because of tumour site or because of the extent of primary surgery. In these cases, radiotherapy should be given at primary treatment (54 Gy).

In patients IRS group II G2-3, radiotherapy is given with 54 Gy, 1.8 Gy daily fractions.
IRS group III (macroscopic residual disease at initial resection):

As for synovial sarcoma, after the initial 3 cycles of chemotherapy, tumour-reassessment and then local treatment need to be planned.

a. Patients with the option of secondary complete resection:

Patients with initially unresectable tumour are at high risk of local failure. In the St. Jude’s experience, local failure rate was 44% at 5 years (Spunt S, 2002). The mainstay of treatment is to obtain a secondary complete resection. Initial incomplete resection should be followed by immediate re-resection if expected to be complete and non-mutilating. In all other patients, chemotherapy is administered before second surgery is attempted. The use of radiotherapy is a matter of debate in patients with secondary complete resection. In the paediatric series from the INT Milan, the 5-year OS of the 40 group III patients was 52%, and correlated with the chance to undergo delayed surgery with histologically free margins. No major differences were observed according to the administration of post-operative radiotherapy: 5-year OS was 80% in the 11 patients who had delayed complete surgery alone, and 86% in the 8 patients who had delayed complete surgery followed by radiotherapy (Ferrari A, J Clin Oncol 2005).

Similarly to IRS group III synovial sarcomas, there is no a consensus about a common approach concerning radiotherapy, in particular on:
1) the necessity to give radiotherapy after delayed complete surgery
2) what is the best option, when the decision to give radiotherapy has been taken, between pre-operative and post-operative radiotherapy
(pre-operative irradiation can improve the chance to perform a complete secondary resection; moreover, pre-operative radiotherapy could be more effective in non-hypoxic tissues, may reduce the risk of intra-operative contamination, and could use smaller radiotherapy fields; post-operative radiotherapy has a small risk of wound complication).

Therefore, there are three treatment options for patients with the option of secondary complete resection:

a1. Preoperative RXT with 50.4 Gy in 1.8 Gy daily fractions

a2. No additional RXT following secondary complete resection

a3. Postoperative RXT with 50.4 Gy in 1.8 Gy daily fraction

The decision may depend also to the physician’s preference. However, possible suggestions are:
- to avoid RXT in younger patients after delayed complete surgery (<6 years)
- to give RXT in case of initial large tumour size (>10 cm) and in case on first surgical approach (biopsy) that could have caused tissue contamination.

The results of the different local modality groups will be compared

a.4 Following secondary incomplete resection, 54 Gy have to be given with microscopical residual disease. In case of macroscopic residual disease, radiotherapy has to be given according to patients with no second surgery (see below)
b. Patients without the option of secondary complete resection:

Radiotherapy is then the only local therapy modality and should be given with high doses. The recommended dose is 59.4 Gy. An additional boost of 5.4 Gy can be given when there is residual disease at the end of radiotherapy. The dose recommendation may need modification depending on the age of the patient and the tumour site.

**Timing of radiotherapy**

**IRS group I (> 5 cm) and group II:**
Radiotherapy (when indicated) should start after 3 cycles of chemotherapy. Radiotherapy plans should be performed during the 7th week, with the aim to start the irradiation at week 9 at the resolution of the toxicity of the third cycle of chemotherapy. During the administration of radiotherapy (5-6 weeks, overlapping with 2 chemotherapy cycles) chemotherapy will be given with ifosfamide alone.

**IRS group III:**
The option for second surgery must be checked before the onset of radiotherapy. In patients receiving no second surgery, radiotherapy is performed at week 9. When second surgery is planned, there are 3 treatment options:
- preoperative radiotherapy
- postoperative radiotherapy
- no radiotherapy

When radiotherapy is performed before second surgery (pre-operative radiotherapy), irradiation starts at week 9. Surgery should be performed 5 weeks after the end of radiotherapy to avoid surgical complications. The sixth cycle of chemotherapy should be given after the end of radiotherapy and before surgery, the last cycle after surgery. When postoperative radiotherapy is given, radiotherapy should be started within 21 days except when there are postoperative complications.

**Radiotherapy in younger children**

<table>
<thead>
<tr>
<th>Children ≤ 3 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRS group I independent of size:</td>
</tr>
<tr>
<td>IRS group II G1:</td>
</tr>
<tr>
<td>IRS group II G2 and G3:</td>
</tr>
<tr>
<td>IRS group III and delayed complete resection</td>
</tr>
<tr>
<td>IRS group III, no second surgery possible:</td>
</tr>
</tbody>
</table>
## 18.3 Risk-adapted treatment program

<table>
<thead>
<tr>
<th>IRS Group I</th>
<th>≤ 5cm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>⚫ SURGERY alone</td>
</tr>
<tr>
<td></td>
<td>no chemotherapy, no radiotherapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IRS Group I</th>
<th>&gt; 5cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>? G1</td>
<td>⚫ SURGERY alone</td>
</tr>
<tr>
<td>? G2</td>
<td>⚫ radiotherapy 50.4 Gy</td>
</tr>
<tr>
<td>? G3</td>
<td>⚫ IFO-DOXO x 3 cycles – IFO x 2 – IFO-DOXO x 1 (cumulative IFO 48 g/m², cumulative DOXO 300 mg/m²)</td>
</tr>
</tbody>
</table>

Radiotherapy 50.4 Gy (1.8 Gy/d)  
starting at 9th week, concomitantly to 4th and 5th cycles

<table>
<thead>
<tr>
<th>IRS Group II N0</th>
</tr>
</thead>
<tbody>
<tr>
<td>?? G1</td>
</tr>
<tr>
<td>?? G2-G3, = 5 cm</td>
</tr>
<tr>
<td>?? G2, &gt; 5 cm</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>? G3, &gt; 5 cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>⚫ IFO-DOXO x 3 cycles – IFO x 2 – IFO-DOXO x 1 (cumulative IFO 48 g/m², cumulative DOXO 300 mg/m²)</td>
</tr>
</tbody>
</table>

Radiotherapy 54 Gy (1.8 Gy/d)  
starting at 9th week, concomitantly to 4th and 5th cycles

<table>
<thead>
<tr>
<th>IRS III &amp; N1</th>
</tr>
</thead>
<tbody>
<tr>
<td>⚫ IFO-DOXO x 3 cycles</td>
</tr>
</tbody>
</table>

then evaluation of tumour response (week 9th) and local treatment:

- delayed complete surgery, no RXT
- pre-op RXT 50.4 Gy, then surgery
- delayed complete surgery, then post-op RXT 50.4 Gy
- delayed incomplete surgery, then RXT 54-59.4 Gy
- RXT 59.4 Gy

in case of major or minor response to chemotherapy:
IFO x 2 during RXT, then IFO-DOXO x 2  
(cumulative IFO 57 g/m², cumulative DOXO 375 mg/m²)
**IRS group I - II, G3, > 5 cm**

<table>
<thead>
<tr>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>9°</th>
<th>10°</th>
<th>13°</th>
<th>17°</th>
<th>weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S</strong></td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO</td>
<td>IFO</td>
<td>IFO-DOXO</td>
<td></td>
</tr>
</tbody>
</table>

? **RADIOTHERAPY** 50.4-54 Gy

**IRS group III**

<table>
<thead>
<tr>
<th>biopsy</th>
<th>1°</th>
<th>4°</th>
<th>7°</th>
<th>9°</th>
<th>tumour re-assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td>IFO-DOXO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ε a) 10°  13°  16°  18°  20°  weeks

<table>
<thead>
<tr>
<th></th>
<th>IFO</th>
<th>IFO</th>
<th>IFO-DOXO</th>
<th>S</th>
<th>IFO-DOXO</th>
</tr>
</thead>
</table>

? pre-op **RADIOTHERAPY** 50.4 Gy

ε b) 10°  12°  15°  18°  21°  weeks

<table>
<thead>
<tr>
<th></th>
<th>S</th>
<th>IFO-DOXO</th>
<th>IFO-DOXO</th>
<th>IFO</th>
<th>IFO</th>
</tr>
</thead>
</table>

ε c) 10°  12°  15°  18°  21°  weeks

<table>
<thead>
<tr>
<th></th>
<th>S</th>
<th>IFO-DOXO</th>
<th>IFO</th>
<th>IFO</th>
<th>IFO-DOXO</th>
</tr>
</thead>
</table>

? post-op **RXT** 50.4 Gy (54-59.4 Gy)

ε d) 10°  13°  16°  21°  weeks

<table>
<thead>
<tr>
<th></th>
<th>IFO</th>
<th>IFO</th>
<th>IFO-DOXO</th>
<th>IFO-DOXO</th>
</tr>
</thead>
</table>

? **RADIOTHERAPY** 59.4 Gy

* local treatment only in case of no response to primary chemotherapy

*S = surgery
IFO-DOXO = ifosfamide 3 g/m²/day, for 3 days + doxorubicin 37.5 mg/m²/day, for 2 days
IFO = ifosfamide 3 g/m²/day x 2 days*
References

?? Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 19:1235-1237, 2001 (editorial)


19. OTHER HISTOTYPES

For the so-called “other histotypes”, the EpSSG NRSTS protocol provides general suggestions only.

19.1 Infantile Fibrosarcoma

Infantile fibrosarcoma is the most common soft tissue sarcoma under 1 year of age and is identified by the t(12;15) translocation. The clinical behaviour of this tumour may be peculiar, and the overall prognosis is very good.

The so-called “infantile fibrosarcoma” (in general clinically defined with a cut off of 2 years) shows peculiar clinical characteristics: it could have initial rapid growth, but also indolent evolution; metastatic spread is uncommon (1-13%) but local recurrence after surgery alone is possible (17-43%). Spontaneous regressions in congenital cases have been described.

The overall prognosis is good with survival rates between 80-100%.

Surgery is the mainstay of treatment, and wide resection represents the adequate treatment strategy in most of patients. However, infantile fibrosarcoma is generally regarded as a chemosensitive tumour (complete remission could be achieved with chemotherapy alone). As a consequence, surgery need to be proposed only if it can be done simply without mutilation; immediate re-excision is required in case of initial incomplete surgery (in case if initial wrong diagnosis).

Surgery alone could be considered the appropriate treatment approach not only for patients who underwent complete resection (histological free margins), but also for IRS group II patients (the salvage rate after local relapse has been reported as more than 80%). Given the age of the patients, radiotherapy is not usually recommended.

Chemotherapy is the initial treatment in cases of inoperable tumours (preoperatively) to permit the tumour shrinkage and the subsequent conservative surgery. Adjuvant chemotherapy following gross-resection, instead, is not established.

The most common chemotherapy regimen used in the literature is VAC (or VadC), while IVA is the standard in Europe.

The VA regimen (vincristine plus actinomycinD, avoiding alkylating agents and anthracyclines) have demonstrated its efficacy. Due to the reported good response to chemotherapy, the good overall outcome, and the age of the patients, this regimen is considered the first treatment of choice in this protocol.

Treatment options:

?? IRS group I and group II:
  o Only surgery – no further therapy

?? patients with unresectable disease (IRS group III):
  o VA chemotherapy
VA regimen is the treatment of choice in patients with unresectable disease, although congenital cases could be differentiated from the others:

- in congenital patients (defines as age less than 3 months), a “wait and see” strategy could be considered, in the view to evaluate possible spontaneous regression or the baby’s growth (that can facilitate a subsequent surgery). The patient needs to be carefully monitored. In case of progression, VA chemotherapy needs to be started.

- older patients (> 3 months of age) need to be treated with VA chemotherapy. If the tumour responds to VA, and surgery could become feasible without antracyclines and alkylating agents, VA is to be continued up to the surgery; chemotherapy will be stopped after surgery. If the response if not sufficient to permit a conservative surgery (but an initial tumour shrinkage appears evident), IFO could be add (IVA regimen). In case of no response to VA, IFO-DOXO regimen will be required.

VA regimen (Vincristine + Actinomycin-D)

<table>
<thead>
<tr>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>A</td>
</tr>
</tbody>
</table>

Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Cycle no. 1 2 3 4 5 6 7 8

Vincristine and actinomycin –D doses:

- Age 1-3 months or weight < 5 kg 25 µg/kg than increased to 50 µg/kg if well tolerated
- Age 3-6 months or weight > 5 kg 50 µg/kg
- Age 6-12 months or weight < 10 kg 50 µg/kg
- Age > 12 months or weight > 10 kg 1.5 mg/mq

IVA regimen:

| I V V V A |
| I V V V A |
| I V A |
| I V A |

1 2 3 4 5 6 7 10 weeks
For a total of 9 courses (25 weeks)

? IFOSFAMIDE: no alkylating agent before 1 month, than ifosfamide 66 mg/kg x 2 days in patients aged 1-3 months or with weight < 5 kg, then 100 mg/kg x 2 days in patients > 3 months and > 5 kg, then 3 g/m² x 2 days
? for vincristine and actinomycin-D: see above

IFO-DOXO regimen

? IFOSFAMIDE: no alkylating agent before 1 month, than ifosfamide 66 mg/kg x 3 days in patients aged 1-3 months or with weight < 5 kg, then 100 mg/kg x 3 days in patients > 3 months and > 5 kg, then 3 g/m² x 3 days
? DOXORUBICIN: no anthracyclin before 3 months than 2 mg/kg/course (until 1 year, than full dose of 75 mg/m²/course)

References:


19.2 Extracranial rhabdoid tumours

In recent months several discussions have been made in Europe with the aim to develop a common European protocol for extracranial rhabdoid tumours, and there is now an outline agreement for a joint study including renal and soft part rhabdoid tumours. Therefore, the EpSSG NRSTS Scientific Committee would be involved for those cases of rhabdoid tumour arising in soft tissues.

At the time of the start of the EpSSG NRSTS 2005 protocol, work on the “rhabdoid project” are still ongoing.

Herein, a summary of the “rhabdoid project” is reported, just to provide an overview of the disease and to note the aims and the general treatment guidelines of the future protocol.

At the present, centers participating to the EpSSG NRSTS protocol are invited to register patients with rhabdoid tumour in the NRSTS data-base. The following treatment plans must be considered as suggestions only.

Background

Extracranial rhabdoid tumours, like their CNS counterparts, are rare, highly aggressive and frequently lethal tumours of childhood. They were first recognized, as a separate pathological entity in the 1980s and have now been reported widely at most anatomical sites in the body (Haas, 1981). Although there are many reports describing their lethal outcome (Gururangan, 1993; Hirose, 1996), there are no published series describing their management in a consistent manner on national or international protocols. This is mainly as a result of their rarity, with only 2-3 ERT occurring in children in the UK each year. Recently there have been reports of survivors, even when there has been metastatic disease, with the use of more intensive chemotherapy regimes including doxorubicin (Waldron, 1999; Wagner, 2002).

There has been considerable debate over whether extrarenal rhabdoid tumour represents the same entity as rhabdoid tumour of the kidney. The recent recognition that both rhabdoid tumour of the kidney and CNS atypical teratoid/rhabdoid tumours (AT/RT) have deletions and mutations of the hSNF5/INI1 gene indicates that rhabdoid tumour of the kidney and AT/RT are identical or very closely related entities (Versteege, 1998; Biegel, 1999). It is less clear whether non-CNS extrarenal malignant rhabdoid tumours have the same histogenetic origin as their renal counterparts (Weeks, 1989; Wick, 1995; Parham, 1994). Whereas some of these tumours may be considered to be undifferentiated sarcomas or carcinomas with “rhabdoid features,” others likely represent true malignant rhabdoid tumours because they have documented hSNF5/INI1 mutations (Biegel, 1999). An important component of this study will be central pathology review and molecular genetic analysis to better define the entity of extrarenal rhabdoid tumour.

Treatment of rhabdoid tumour of the kidney

In the United Kingdom (UK) patients with rhabdoid tumour of the kidney have historically been treated on two consecutive national Wilms’ tumour protocols (UKW2 and UKW3) with a combination of vincristine, actinomycin D and doxorubicin. In a recent audit of 21 patients with
renal rhabdoids treated on these protocols the overall survival was 35% (standard error 9%), with all deaths within 13 months of diagnosis. Both Stage I patients survived, all three Stage II patients died, four of the nine Stage III patients survived and only one of the Stage IV patients survived. Two of the four Stage III patients who survived had had local radiotherapy. Anecdotally there is one Stage IV renal rhabdoid patient alive in the UK who was diagnosed in 1996 and, following initial nephrectomy, was treated with an intensive regimen consisting of courses of vincristine 2mg/m², carboplatin 500mg/m², epirubicin 100mg/m², and etoposide 300mg/m², alternating with vincristine 2mg/m², ifosfamide 7.5g/m² and actinomycin D 1.8mg/m², and followed by a continuation regimen of oral etoposide (Brennan, 2004).

In the United States patients with rhabdoid tumour of the kidney have historically been treated on the National Wilms Tumour Study Group (NWTSG) trials with agents such as vincristine, actinomycin, and doxorubicin, with or without cyclophosphamide (Parham, 1994; Brennan, 2004). The outcomes attained with these agents were poor (Table 1) (D'Angio, 1989; Dome, 2002; Weeks, 1989). The International Society of Paediatric Oncology (SIOP) reported similarly unfavorable outcomes (Vujanic, 1996).

To try to improve upon these results, NWTS-5 adopted a different treatment strategy consisting of carboplatin/etoposide alternating with cyclophosphamide (Regimen RTK). Preliminary analysis of patients treated with this regimen revealed a survival percentage of 25.8%, which was unlikely to demonstrate an improvement compared to previous studies, and this treatment arm was closed.

<table>
<thead>
<tr>
<th>Stage</th>
<th>NWTS 1-3 (number of pts.)</th>
<th>NWTS 1-4* (number of pts.)</th>
<th>NWTS-5 Regimen RTK** (number of pts.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>50% (6)</td>
<td>-</td>
<td>50.0% (2)</td>
</tr>
<tr>
<td>II</td>
<td>44% (9)</td>
<td>42.3% (22)</td>
<td>33.3% (3)</td>
</tr>
<tr>
<td>III</td>
<td>22% (37)</td>
<td></td>
<td>33.3% (9)</td>
</tr>
<tr>
<td>IV</td>
<td>0% (18)</td>
<td>17.8% (73)</td>
<td>21.4% (14)</td>
</tr>
<tr>
<td>V</td>
<td>——</td>
<td>——</td>
<td>0% (3)</td>
</tr>
</tbody>
</table>

* Tomlinson et al, submitted.
** Preliminary analysis of NWTS-5, as of April, 2001. Duration of follow-up is short.

Treatment of extrarenal rhabdoid tumour

Like rhabdoid tumour of the kidney, AT/RT of the brain has a very unfavorable prognosis and is characterized by resistance to chemotherapy. A literature review by Hilden and colleagues revealed that only 6/35 (17%) patients with AT/RT survived disease-free with follow-up ranging from 5 to 89 months (Hilden, 1998). The survivors were treated with surgery, XRT, and various chemotherapy regimens, typically including cisplatin, etoposide, vincristine, ifosfamide, doxorubicin, actinomycin, cyclophosphamide, and intrathecal chemotherapy. One survivor was treated with high-dose therapy with autologous stem cell rescue.

A retrospective review of patients with non-CNS extrarenal rhabdoid tumour was reported by the Intergroup Rhabdomyosarcoma Study Group (Kodet, 1991). Twenty-six cases with features similar to rhabdoid tumour of the kidney were identified among 3000 cases treated on the IRS Studies I-III. The tumours originated in the soft tissues of the extremities, trunk, retroperitoneum, abdomen, and
pelvis. Of the 26 patients, only five had survived the disease for 2 to 13 years. Hence, regardless of its tissue of origin, only 20-25% of patients with malignant rhabdoid tumour survive.

During the same time period of UKW2 and UKW3 22 children were notified to the UK National Registry of Childhood Tumours with extracranial, extrarenal rhabdoid tumours. Only one patient is alive at the time of writing. The survivor were treated on SIOP MMT protocols which includes vincristine, actinomycin D, ifosfamide, etoposide, epirubicin and carboplatin.

**Rationale for ICE/VDCy Chemotherapy**

Several case reports have documented the successful treatment of advanced or metastatic rhabdoid tumour of the kidney. Waldron and colleagues used ifosfamide/etoposide (IE) alternating with vincristine/doxorubicin/cyclophosphamide (VDCy) to cure a patient with Stage IV rhabdoid tumour the kidney with metastases to the lung (Waldron, 1999). Wagner and colleagues reported the successful treatment of two patients with distant metastatic rhabdoid tumour of the kidney using ifosfamide/carboplatin/etoposide (ICE) alternating with VDCy (Wagner, 2002). Of note, one of the patients described in this report had recurrent disease following treatment with Regimen RTK; he had a complete response to one cycle of ICE followed by one cycle of VDCy. Gururangan and colleagues reported encouraging, albeit transient, responses to ICE chemotherapy in patients with advanced-stage renal and extrarenal rhabdoid tumour (Gururangan, 1993).

**Genetics of Rhabdoid tumours**

Cyto genetic, fluorescence in situ hybridization (FISH), and loss of heterozygosity (LOH) studies have revealed that malignant rhabdoid tumours frequently contain alterations at chromosome locus 22q11.1 (Biegel, 1990, Schofield, 1996; Biegel, 1996). Through positional cloning efforts, this locus was recently found to contain the hSNF5/INI1 gene, which encodes a member of the human SWI/SNF complex (Versteege, 1998; Biegel, 1999). The SWI/SNF complex acts in an ATP-dependent manner to remodel chromatin, which regulates gene transcription. Because rhabdoid tumours demonstrate biallelic, inactivating mutations of INI1, consistent with the “two-hit” model of tumour formation, it is presumed that this gene functions as a classic tumour suppressor (Versteege, 1998; Biegel, 1999, Rousseau-Merck, 1999). The observation that mice haploinsufficient for INI1 are predisposed to rhabdoid tumour supports this premise (Roberts, 2000).

Inactivation of wild-type INI1 in rhabdoid tumour may result from homozygous deletions, deletion of one locus with mutation of the second locus, or mutation/deletion of one locus with duplication or recombination of the abnormal allele. INI1 mutations have been located in each of the nine coding exons of the gene (Biegel, 1999). The predominant mutations are nonsense mutations or frameshifts, which are predicted to result in premature truncation of the protein. Identical mutations may give rise to a brain or kidney tumour. Germ line mutations of INI1 have been documented for patients with one or more primary tumours of the brain and/or kidney, consistent with a genetic predisposition to the development of rhabdoid tumours (Biegel, 1999; Savla, 2000). In most cases, the mutations are de novo, and not inherited from a parent. Germline mosaicism has been suggested for several families with multiple affected siblings (Sevenet, 1999).

At present, there is insufficient data to suggest an association between specific mutations and clinical outcome. However, it does appear that those patients with germline mutations have the
worst prognosis *(Tomlinson; Biegel, unpublished data)*. An aim of this study whether the presence of somatic or germline *INI1* mutations correlates with the clinical phenotype of the tumour (age at presentation, multi-focality, and clinical outcome).

**Objectives**

1. To determine whether cyclophosphamide/carboplatin/etoposide alternating with vincristine/doxorubicin/cyclophosphamide improves the outcome of patients with extracranial rhabdoid tumour (ERT) as compared to historical controls.

2. To evaluate whether the presence of somatic or germline mutations of the *INI1* gene correlates with clinical outcome in patients with ERT

The study will be a single-arm study to evaluate event-free and overall-survival in comparison to historical controls. Based on case reports of successfully treated patients with metastatic malignant rhabdoid tumour we are proposing a regimen of cyclophosphamide/carboplatin/etoposide alternating with vincristine/cyclophosphamide/doxorubicin. The COG proposal has been adapted to exclude their phase II window study with vincristine and irinotecan. If resectable at diagnosis surgery should be performed after 12 weeks of chemotherapy. In addition, patients will receive local irradiation to all sites of disease either after surgical resection at diagnosis or following delayed surgery. The dose of irradiation will be dependent upon patient age and the site of disease.

The schedule of treatment will be:

**VDCy course weeks 1,10,13,22,28,**

V- Vincristine 0.025mg/kg/day IV x 1 as bolus for infants < 12 months  
0.05mg/kg/day IV x 1 as bolus for children 12 mo.-3 yrs  
1.5 mg/m²/day x1 as bolus for children = 3 years old  
and also at weeks 2,3,11,12,14,15,23,24,29 and 30

D – Doxorubicin 1.25mg/kg/day IV x 2 days over 15 minutes for infants <12 months  
37.5mg/m²/day IV x 2 days over 15 minutes for children = 12 months

Cy – Cyclophosphamide 40 mg/kg/day IV x 1 day over 1 hour for infants < 12 months  
1200mg/m²/day IV x 1 day over 1 hour for children = 12 months  
with MESNA protection and hydration

G-CSF support is suggested dependant on institutional guidelines

**Cy* CE course weeks 4,7,16,19,25**

Cy* - cyclophosphamide 14.7 mg/kg/day IV over 1 hour x 5 days for infants < 12 months  
440 mg/m²/day IV over 1 hour x 5 days for children =12 months  
with hydration
C – Carboplatin IV over 1 hour

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;150 ml/min/1.73m²</td>
<td>560mg/m² (18mg/kg for infants)</td>
</tr>
<tr>
<td>100-150 ml/min/1.73m²</td>
<td>500mg/m² (16.6 mg/kg for infants)</td>
</tr>
<tr>
<td>75-99 ml/min/1.73m²</td>
<td>370 mg/m² (12.3 mg/kg for infants)</td>
</tr>
<tr>
<td>50-74 ml/min/1.73m²</td>
<td>290 mg/m² (9.7 mg/kg for infants)</td>
</tr>
<tr>
<td>= 49 ml/min/1.73m²</td>
<td>Discuss with study coordinators</td>
</tr>
</tbody>
</table>

E – Etoposide 3.3mg/kg/day IV over 1 hour x 5 days for infants < 12 months
100mg/m²/day IV over 1 hour x 5 days for children = 12 months

G-CSF support is suggested dependant on institutional guidelines

<table>
<thead>
<tr>
<th>Week</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>V</td>
<td>V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
<td></td>
<td>Cy*</td>
<td>Cy*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cy</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>Cy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>V</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
<td></td>
<td>Cy*</td>
<td>Cy*</td>
<td>D</td>
<td>Cy*</td>
<td>D</td>
<td>Cy*</td>
<td>D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cy</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>Cy</td>
<td>C</td>
<td>Cy</td>
<td>C</td>
<td>Cy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>E</td>
<td>E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Genetic Study

INI1 Mutation Analysis

Established methods in Dr. Jaclyn Biegel’s laboratory will be utilized for molecular genetic testing of rhabdoid tumours (Biegel, 1999). Tumours will be analyzed for an INI1 deletion by interphase fluorescence in situ hybridization, using an INI1 probe from 22q11.2 and an EWS control probe that maps to 22q12. Tumours that are not deleted by FISH will be analyzed by microsatellite analysis to detect loss of heterozygosity. Tumours with one or two copies of INI1 will be screened by reverse transcriptase-polymerase chain reaction (RT-PCR) to determine expression of the INI1 gene. RT-PCR products will be sequenced to detect mutations. Heteroduplex analysis and direct
sequencing will be employed to detect mutations at the DNA level. If mutations are demonstrated in the tumour tissue, DNA from blood from the patient will be sequenced to identify a germline mutation. Parental blood specimens will be analyzed to detect inherited versus de novo mutations. As newer methods for detecting alterations of the INI1 gene at the DNA, RNA and protein level are developed, they will be incorporated into these studies.

References


19.3 Desmoplastic small round cell tumour

Desmoplastic small round cell tumour (DSRCT) is an aggressive neoplasm that has an extremely poor outcome despite an intensive multimodality treatment approach. Since its first description in 1989 by Gerald and Rosai (Gerald WL, 1989), DSRCT is being increasingly identified, but its histogenesis remains uncertain. The specific translocation t(11;22)(p13;q12), with the chimeric transcript EWS-WT1, characterises this tumour. The tumour predominantly affects young males, usually in their second decade of life (Leuschner I, 1996). DSRCT typically presents as a large abdominal mass already widely disseminated at the
time of diagnosis, with extensive spread to regional lymph nodes, peritoneal seeding, and distant metastases to the lungs, liver and bones. Other, less frequent primary sites are the paratesticular region, the thoracic cavity, sometimes extensive involvement of pleura (Parkash B, 1995). Intracranial origin has also been described (Tyson V, 1996).

Several small series have now been published examining upfront chemotherapy, +/- aggressive local and metastatic control with surgery and radiotherapy (Kushner, 1996; Bisogno G, 2000; La Quaglia; 2000) and specifically high dose chemotherapy with stem cell rescue (Bertuzzi A, 2003).

Several factors seem to be emerging which may be important in achieving CR and hence a chance of cure in the long term. Firstly dose intensive and upfront chemotherapy may be important for cure. The P6 regimen of high dose alkylating base chemotherapy Kushner describes achieves more PR’s with the chemotherapy alone compared to lower dose regimens such as ICG group based on ifosfamide, vincristine and actinomycin. This, however, may be at a cost, certainly in terms of toxic deaths and also in the median term the risk of developing AML on Kushner’s P6 regimen is greater than expected (Kushner, 1998).

Secondly, the role of surgery: the patients in the Kushner series and Bisogno’s series who were in CR after surgery at diagnosis had no events at the time of publication of their papers and therefore appear to be survivors. Furthermore there are no survivors in any chemotherapy series who do not achieve CR following chemo with surgery.

The role of radiation is difficult to assess. Whole abdominal radiotherapy (up to 30 Gy) has been proposed (Goodman, 2002). Certainly in the Kushner series (Kushner, 1996) and the ICG (Bisogno G, 2000) series, some patients with microscopic residual disease prior to radiotherapy survived. No patient, however, with bulky disease was converted to CR after radiotherapy and hence its role maybe with aggressive surgery in the minimal residual disease setting.

Lastly, the Bertuzzi paper does not support the use of high dose therapy and stem cell rescue (Bertuzzi A, 2003). The study does demonstrate, however, the possible role of graft versus tumour effect in apparently clearing the hybrid transcript from peripheral blood in a progressing patient. This should be explored further in any prospective biological study.

Therefore, suggested therapeutic approach:

1. Surgery either upfront, debulking/removal if feasible or early after possibly no more than 4 to 6 courses of induction chemotherapy.

2. Chemotherapy should be aggressive, and probably using Kushner’s P6 regimen of alternating vincristine, doxorubicin, cyclophosphamide with ifosfamide, etoposide to a maximum tolerated dose without stem cell support.

P6 Chemotherapy

HD_CAV – courses 1,2,3,6 as follows

Cyclophosphamide 2100mg/m²/day x 2 days 6-hour infusion
Doxorubicin 25mg/m²/day x 3 days 24-hour infusion
Vincristine 0.67mg/m²/day x 3 days 24-hour infusion (maximum dose 0.67 mg per day)

Ifosfamide – etoposide courses 4,5,7 as follows
Ifosfamide 1.8 mg/m²/day x 5 days 24-hour infusion with mesna uroprotection
Etoposide 100mg/m²/day x 5 days 1-hour infusion

3. Radiotherapy to all sites of disease but only those patients in a minimal residual disease setting.

4. A biological study looking at larger patient numbers for the presence of the hybrid transcript in peripheral blood and perhaps bone marrow, its significance if it is present and what its relationship is to clinical outcome.

References


?? Bertuzzi A, Castagna L, Quagliuolo V, et al. Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumor. Br J Cancer 2003;89: 1159-1161


19.4 Undifferentiated sarcoma of the liver

Undifferentiated (embryonal) sarcoma of the liver (UESL) is an uncommon hepatic tumour of mesenchymal origin, recognized as a unique clinicopathologic entity in 1978 (Stocker, 1978). It accounts for 9-13% of paediatric hepatic tumours, occurring mainly between 5 and 10 years of age, without gender predilection. Clinical presentation is typically an abdominal mass. Malignant mesenchymal elements without any evidence of specific differentiation are observed on histology.

The old reported series described an aggressive neoplasm with poor outcome. More recently, a high rate of long-term survivors after multidisciplinary treatment approach have been described. In particular, the Italian and German groups reported the experience on 17 children, with 70% of long-term survivors (Bisogno, 2002). As expected, in this series surgery continued to play a crucial role in the outcome (all patients with localized, completely resected tumours were cured), but partially unexpected good responses to chemotherapy were observed (tumour shrinkage was evident in 6 out of 9 cases with measurable disease). Others confirmed the same findings, pointed out the efficacy of chemotherapy regimens usually adopted for rhabdomyosarcomas. The role of adjuvant chemotherapy, after initial complete resection, is debatable: however, the overall good outcome reported in patients treated with adjuvant chemotherapy would support its use.

Possible future collaboration with cooperative groups involved in the treated of paediatric liver tumours (SIOPEL) could be welcome and might open the opportunity to design a protocol specifically tailored for UESL.

The current suggestions within the EpSSG protocol are the following:
- Surgery remains the mainstay of treatment and aggressive surgical approach should be suggested
- Patients with tumour considered unresectable at the time of diagnosis may benefit from chemotherapy, according to the regimens used for RMS (i.e. IVA, or VAIA regimen including also anthracyclines)
- Also without strong evidence, adjuvant chemotherapy should be recommended.
- The role of radiotherapy in case of incomplete resection is still unclear.

References:

19.5 Malignant ectomesenchymoma

It is a very rare tumour comprised of ganglion cells or neuroblasts and one of more malignant mesenchymal elements including rhabdomyosarcoma (as indicated by its alternative designation “gangliorhabdomyosarcoma”). Molecular findings suggest that malignant ectomesenchymoma could be another member of the Ewing’s sarcoma/PNET family (EWS/FLI-1 was found in some cases) and may also overlap with alveolar rhabdomyosarcoma (t(2;13)-encoded PAX3/FKHR), as a polyphenotypic small round cell tumour capable of multidirectional differentiation. This tumour is usually diagnosed in the first 3 years of life, and may arise anywhere in the body. Complete surgical resection is theainstay of treatment, but chemotherapy probably need to be used. Overall survival is around 60%, and correlates with resectability.

The EpSSG committee suggests to treat malignant ectomesenchymoma as high-risk rhabdomyosarcoma, but patients will not be included in the RMS protocol (i.e. not randomized).

References:


19.6 Epithelioid hemangioendothelioma

The term hemangioendothelioma (HE) included different soft part neoplasms of vascular origin:
- malignant HE should probably considered as angiosarcomas
- kaposiform HE, spindle cells HE and retiform HE are low-grade tumours, that need to be treated with surgery alone
- epithelioid HE represents a more difficult entity with peculiar clinical features, and needs a particular treatment approach. It is a intermediate or borderline tumour, and could include two distinct subtypes:
  o epithelioid HE of soft part: usually presents as a unique lesion localized at extremities or cervical district; and rarely metastasizes or causes patient’s death. Surgery is the only treatment for these patients.
  o epithelioid HE of bone, lung and liver

Epithelioid hemangioendothelioma of bone, lung and liver is often metastatic or multifocal, could have indolent course, but the death rate is around 35-65% (Bollinger et al. Cancer 1994;73:610-615). The optimal treatment approach is not clear: different data (including ICG-CWS cases), however, underlined a significant role for alpha-interferon (a-IFN),
probably due to an anti-angiogenic effect (Ferrari et al. Ital J Pediatr 2001;27:774-778). On the contrary, the absence of response to chemotherapy (regimen in use for soft tissue sarcomas) has been reported.

These cases are not so infrequent. Thereafter, ESSG NRSTS Committee could gather all cases and standardize the treatment, with the opportunity to define the role of interferon. The use of α-IFN is generally suggested (in Italy, both in adult and paediatric cases), but not filed. We can propose, in all cases with multifocal or unresectable hemangioendothelioma:

- α-IFN at the starting dose of $3 \times 10^6$ U x 3/week SC
- if well tolerated, the dose may be increased to 6 and then to $9 \times 10^6$ U x 3/week
- in case of response (or stable disease?), the treatment should be continued for 9-12 months

References:


19.7 Myofibroblastic lesions and aggressive fibromatosis/desmoid tumours.

Infantile myofibroma (solitary) and myofibromatosis (multicentric) are benign neoplasms originating from contractile myoid cells around thin walled blood vessels. Myofibroma probably forms a morphological continuum with myopericytoma and infantile hemangiopericytoma. Three entities could be described: 1) solitary myofibroma (most common: >50%), 2) multicentric myofibromatosis (less common), and 3) multicentric myofibromatosis with visceral involvement (<15%). No specific translocations or genetic aberration are known for this entity. Solitary or multicentric myofibroma are most commonly found in subcutaneous tissue or bone of the head and neck, less frequently in extremities and trunk. Visceral lesions can involve central nervous system, lungs, heart, gastro-intestinal tract, liver, or kidney (Behar PM, 1998; Fletcher CDM, 2002). The natural course often involves rapid initial growth, then a stable phase, often followed by spontaneous regression.

Complete excision is often curative, with a low local recurrence rate (<10%). In the absence of visceral involvement, the prognosis is excellent and spontaneous regression is common. Visceral involvement is prognostically unfavorable, with reported survival of 0-25% (Davies RS, 1994). The use of chemotherapy is generally recommended for patients with visceral involvement or multicentric lesions that compromise normal function and involve mutilating surgery. However,
recommendations for chemotherapy based on systematic testing are absent and it is not known if chemotherapy does improve outcome (Palumbo JS, 1999; Williams W, 2002).

**Inflammatory myofibroblastic neoplasms** (IMT) (inflammatory pseudotumour and inflammatory fibrosarcoma are considered to be synonymous) generally follow a benign course. Predominantly, they most commonly occur in lungs and abdomen, but can arise in many other areas of the body. Associated symptoms include mass, fever, pain, weight loss, malaise or growth failure, anemia, thrombocytosis, polyclonal hyperglobulinaemia and/or elevated erythrocyte sedimentation rate. Although generally benign, IMT can be locally invasive and the local recurrence rate is reported between 15-35%, especially for abdominal localization.

Wide resection is the mainstay of treatment.

However, some IMT tumours have a more aggressive behaviour, including multiple recurrences and/or metastases. Little is described about the management of these aggressive IMTs. Radiation therapy has been reported to be of use, but others have reported little effect (Dishop MK, 2003). Immunosuppressive treatment with corticosteroids has also met with variable results. Chemotherapy has been utilized (cyclophosphamide, actinomycin-D, adriamycin, 5-fluorouracil, cisplatin, ifosfamide, etoposide, and carboplatin), but its role is unclear. Overall, the benefit of chemotherapy, radiotherapy or other therapies not been established yet. Use of these additional treatments in addition to the surgical resection however is advised in locally recurrent histologically malignant tumours not amenable to complete resection (Janinis J, 2003).

**Aggressive fibromatosis (AF) or desmoid tumours** are fibrous tissue proliferations of intermediate malignancy that display local aggressiveness but no propensity to metastasize.

AF usually involves deep fibromatosis, intra-abdominal or extra-abdominal. Intra-abdominal fibromatosis has a distinct behaviour, being primarily associated with familial adenomatous polyposis, and mutations of the APC gene on chromosome 5q21 (Gardner’s syndrome). Extra-abdominal fibromatosis arise in musculo-aponeurotic structures, mainly in extremities and girdles, chest and abdominal wall, and neck. The propensity of AF to grow diffusely along muscle bundles and fascial planes, and the lacks of a pseudocapule contributes to the difficulty to define the border of the tumour at resection.

Although surgery is generally considered the mainstay of treatment, a high local recurrence rate is reported, ranging from 24-77% at 10 years, while overall survival is generally over 90% at 10 years (Mendez-Fernandez MA, 1991; Catton CN, 1995; Gronchi A, 2003). The best predictors of local recurrence are microscopically positive margins, negative margins that fall close to the tumour and large tumours located at the extremities or girdles, regardless of positive or negative margins (Gronchi A, 2003).

The role of radiation therapy in AF has not fully been established yet, but is generally considered useful in local control, especially in case of microscopically positive margins (Ballo MT, 1998; Plukker JT, et al. 1995). The pharmacological treatment of AF can involve non-cytotoxic and cytotoxic agents. Non-cytotoxic agents include hormonal treatment, NSAIDs/anti-inflammatory agents, and IFN-alfa (Janinis J, et al. 2003).

Most commonly used cytotoxic drug regimens are doxorubicin-based, in combination with dacarbazine or cyclophosphamide and vincristine, actinomycinD-based treatment (vincristine, actinomycinD and cyclophosphamide), or a combination of weekly low-dose methotrexate with vinca alkaloid (vinblastine or vinorelbine). The effectiveness of the different regimens is comparable to that in adult STS, with a chemo-responsiveness around 50%. However, since AF is a slow growing tumour with a slow response to chemotherapy, prolonged exposure of at least 6 months or even 12-18 month is generally recommended. Considering this, the **low-dose methotrexate with vinblastine/vinorelbine** is an effective and least toxic regimen, especially in
the paediatric patient for whom toxicities from doxorubicin (cardiotoxicity) or cyclophosphamide (infertility, secondary tumours) are a potential threat (Azzarelli A, 2001; Janinis J, et al. 2003).

In summary:

? No adjuvant treatments after gross resection (negative or positive margins)

? In case of unresectable disease:
different drugs could be utilized
as first option, the EpSSG NRSTS protocol suggest
Methotrexate 30 mg/m\(^2\)/week iv + Vinorelbine 20 mg/m\(^2\)/week iv
for 6-12 months
other options:
Methotrexate 30 mg/m\(^2\)/week iv + Vinblastine 6 mg/m\(^2\)/week iv
IVA regimen
Tamoxifene 5 mg x 2/day if age < 10 years, 10 mg x 2/day if > 10 years for 3 months, then assessment.

References


20. SECOND-LINE THERAPIES

As for the “other histotypes”, the following chapter must be considered as **general considerations and suggestions**, and not as therapeutic guidelines.

It is important to underline that in patients who relapse surgery must be considered as the first choice. For local relapse, mutilating surgery must be considered. Surgery is regarded as the mainstay of treatment also in case of distant relapse when the lung is the only site and in particular when the number of metastases is low. Nevertheless, the prognosis of relapsing patients is generally poor, and consequently with the exception of selected cases, chemotherapy could be required.

In adult or adult-type soft tissue sarcomas, few drugs have demonstrated to be effective. The ifosfamide-doxorubicin regimen is the most effective combination, and must be the chemotherapy of choice in patients previously treated with surgery (± radiotherapy) alone. In patients previously treated with ifosfamide-doxorubicin as first therapy, standardized second-line chemotherapy is not available.

Possible cooperation with adult oncology groups would be welcome: in particular, this cooperation could allow relapsing EpSSG patients to be included in phase I and phase II studies. **Future phase I-II studies developed within the EpSSG will be welcome.**

The EpSSG NRSTS protocol indicates some possible suggestions for relapsing patients: vinorelbine (alone or in association with cyclophosphamide) has been already used in some EpSSG centers and its role could be better evaluated. For high-dose ifosfamide, gemcitabine in leiomyosarcoma, and paclitaxel in angiosarcoma, open studies are under evaluation within the adult Italian Sarcoma Group (ISG), and ESSG patients could be treated with the same programs.

### 20.1 Vinorelbine

Vinorelbine is a semi-synthetic vinca-alkaloid that has recently explored in various EpSSG centers, in order to evaluate its role in the treatment of paediatric soft tissue sarcomas. Preliminary data of vinorelbine as a single agent showed a response rate in already heavily-treated patients with recurrent RMS better than the one obtained with other drugs known to be active in RMS. Moreover, due to some data that suggested a possible anti-angiogenic effect of vinorelbine, this drug has subsequently been evaluated in combination with oral cyclophosphamide. This EpSSG pilot study has confirmed the efficacy of vinorelbine in RMS; as a consequence, the future EpSSG RMS protocol for high-risk patients included a maintenance therapy with vinorelbine and low-dose oral cyclophosphamide as randomization.

Regarding NRSTS, few data are available on the efficacy of vinorelbine, and are not satisfactory.
To summarize:

?? Data on vinorelbine alone:

- 4 patients with NRSTS evaluable for tumour response (2 synovial sarcoma, 1 liposarcoma, 1 fibrosarcoma):
  
  - 3 stable disease
  - 1 disease progression.

?? Data on vinorelbine-cyclophosphamide regimen:

- 6 patients with NRSTS evaluable for tumour response (2 synovial sarcoma, 2 MPNST, 2 DSRCT):
  
  - 2 PR (1 synovial sarcoma, 1 DSRCT)
  - 1 stable disease (1 synovial sarcoma)
  - 3 disease progression (1 DSRCT, 2 MPNST).

According to these results, a possible efficacy in synovial sarcoma and DSRCT could be supposed and further evaluation might be useful to define it.

Patients could be treated with:

**vinorelbine 30 mg/m²/ev** (or alternatively, **80 mg/m² oral**)

day 1, 8, 21, 28

or

**vinorelbine 25 mg/m²/ev** (or alternatively, **60 mg/m² oral**) **day 1, 8, 15**

+ oral cyclophosphamide **25 mg/m²/day** (every day)

References:


20.2 High-dose ifosfamide

As already underlined, adult experiences showed that the association ifosfamide-doxorubicin represented the most active regimen against adult soft tissue sarcomas. Ifosfamide has been described as more effective than cyclophosphamide, and the increase of the doses of ifosfamide has been associated with an improvement in response rate. Moreover, high dose ifosfamide (defined as doses \( \geq 12\text{ g/m}^2 \)) has shown satisfactory response rate in patients that did not respond to conventional-dose ifosfamide \( \geq 9 \text{ g/m}^2 \), or relapsed after
Ifosfamide-doxorubicin regimen. Therefore, these patients might be successfully treated with high-dose ifosfamide, especially when they relapsed more than 1 year after the end of the first treatment. High-dose ifosfamide can be administered in 4-5 day infusion; this administration is generally associated with important neutropenia, and this side effect must be considered in relapsing patients when the quality of life represents an important goal.

Recently, ifosfamide has been proposed at the dose of 14 g/m², given in 14-day infusion by external pump. This administration has been proven to be safe and well-tolerated, with the same activity of 4 or 5-day infusion. The drug has been demonstrated to be stable in solution for 7 days, so the pump must be renewed after one week of therapy.

A prospective phase II trial is open in the adult Italian Sarcoma Group (ISG), for patients with pre-treated locally advanced or metastatic soft tissue sarcomas.

This study schedules the administration of continuous infusion ifosfamide as follow:

**Ifosfamide 14 g/m² day 1-14**

corresponding to 1 g/m²/day for 14 consecutive days, given by external pump in 7-day infusion, with Uromitexan at the same dose (oral hydration of 1.5 l/day)

Alternatively, **ifosfamide at 14-15 g/m²** may be given in 4-5-day infusion (2.8-3 g/m²/day).

References:


20.3 Gemcitabine in leiomyosarcoma

Adult leiomyosarcoma is regarded to have poor responsiveness to the most adopted chemotherapy regimens, including ifosfamide and doxorubicin. However, in paediatric age, the German-Italian retrospective analysis reported a response rate of 43%, with a OS of 85% (Kunz D, et al. SIOP Meeting, Brisbane, 2001).

Recently, a possible role of gemcitabine in treatment of leiomyosarcoma has been reported:

☞ non-gastrointestinal leiomyosarcoma: 40% RP with gemcitabine
☞ objective response: 53% to gemcitabine + taxotere

Due to these results, a prospective phase II trial has been proposed within the adult Italian Sarcoma Group (ISG), for patients with pre-treated locally advanced or metastatic leiomyosarcoma.

Chemotherapy schedula:

Gemcitabine 1000 mg/mq, day 1-8-15 – second cycle at 28th day.

References:


20.4 Paclitaxel in angiosarcoma

Though angiosarcoma is extremely rare in childhood, the few available experiences confirmed the high aggressiveness and the poor outcome reported by adults series (Ferrari A, 2002). New drugs are absolutely necessary for this tumour.
The experience reported by the Memorial Sloan-Kettering Cancer Center (Fata, 1999) has opened the question on the role of paclitaxel in the treatment of malignant vascular tumours, with results superior to any other drugs never used in angiosarcoma: paclitaxel as a single agent achieved 8 objective responses (4 CR, 4 PR) in 9 adult patients with cutaneous angiosarcoma of the scalp and face. Further investigations are soon needed to confirm these results.

A prospective phase II trial has been proposed within the adult Italian Sarcoma Group (ISG), for patients with pre-treated locally advanced or metastatic angiosarcoma.

Chemotherapy schedula:

**Paclitaxel 80 mg/m² 1-hour infusion, day 1,8,15.**

References:


20.5 Isolated limb perfusion (chemo-hyperthermic perfusion)

Isolated limb perfusion is not included in the EpSSG NRSTS therapy plan, as routine treatment procedure. Nevertheless, centers that have the experience on this technique could decide to utilize this procedure as part of the treatment in selected cases.

Possible indications for isolated limb perfusion could be multifocal recurrence, or recurrence in irradiated areas (patients who probably require amputation), although in some cases this procedure is utilized also as front-line treatment, in patients who are still not eligible for conservative surgery after pre-operative chemo-radiotherapy.

Technique: Isolated limb perfusion (ILP) surgically isolates the main limb vessels in order to deliver high concentrations of anti-tumour drugs to a limb-threatening tumour. ILP can achieve regional concentrations in the tumour-bearing limb 5-25 times higher than achieved after systemic administration and without systemic side-effects. Isolation of the limb circulation is achieved by clamping and cannulation of the main artery and vein followed by connection to an extracorporeal circuit, ligation of collateral vessels, and application of a tourniquet. After isolation, drugs can be injected into the isolated perfusion circuit, together with radiolabelled albumin and erythrocytes for monitoring of systemic leakage by using a precordial scintillation probe. After 60-90 minutes of perfusion, the limb is rinsed with an electrolyte solution, the cannulae are removed and the vessels repaired. Delayed surgery of the tumour is usually feasible 6-8 weeks after ILP.

Specific Side effects:
1. Acute tissue reactions must be monitored and classified (I: No reaction, II: Erythema and/or oedema, III: Substantial oedema and/or erythema, with some blistering, slightly disturbed motility, IV: Extensive epidermolysis and/or obvious damage to the deep tissue with functional disturbances;
threatening or manifest compartmental syndrome, V: Reactions that may necessitate amputation). Grade IV and V acute tissue reactions occur in a small minority of ILP.
2. Toxicity to the growth plates should be considered and joints/growth plates are preferentially kept out of the perfused area.
3. Postoperative morbidity described in ~2% of cases is arterial thrombosis at the arteriotomy site, which can be resolved by prompt thrombectomy.
4. Hematologic toxicity in case systemic leakage of anti-cancer drugs occurs. TNF-a can induce septic shock syndrome and the use of high concentrations of TNF-a also necessitates the monitoring for systemic leakage during the procedure.

Hyperthermia and drugs:
*Hyperthermia* is applied to prevent vasoconstriction and increase perfusion in (sub)cutis for superficial tumours. Secondly, tumour cells are sensitive to heat and uptake of drugs is increased at higher temperatures. True hyperthermia (>41°C) yields high CR rates, but is also associated with unacceptable regional toxicity. Mild hyperthermia (39-40°C) is probably no more effective than normothermia (37-38°C), and borderline true hyperthermia (40-41°C) seems to increase the tumour response rate, but possibly also increases regional toxicity. Most current studies in adults with soft tissue sarcomas (STS) use borderline true hyperthermia.

*Melphalan:* Melphalan has proven to be an effective drug for local perfusion with low regional toxicity, most commonly used at a dose of 10 mg/L perfused tissue for the leg and 13 mg/L for the arm.

*Doxorubicin:* Doxo is the most effective single agent in STS. However, it may induce more local toxicity than melphalan. MTD of Doxo was established at 0.7 and 1.4 mg/kg for upper and lower limb, respectively.

*TNF-a:* The use of TNF-a has strongly increased the effectiveness of ILP. It seems to increase the tissue delivery of chemotherapy, it has a direct cytotoxic effect and it has a damaging effect on the tumour vascularity. Dose-limiting toxicity in ILP is achieved at concentrations 10-50 times higher as systemic doses. Most studies use 3-4 mg in adult patients.

**Indications for use of ILP:**
ILP should be considered in patients with limb-threatening primary or recurrent STS, when an adequate tissue reconstruction is considered feasible after ILP and tumour excision. Usually it concerns bulky, unresectable tumours and/or tumours close to important structures (nerve, vessels, interosseous membrane). Encouraging results have also been achieved in non-STS tumours, such as advanced osteosarcoma, desmoid tumours, kaposi sarcoma. In adults, ILP alone, or in combination with surgery (usually after 6-8 weeks) improves local control, by induction of tumour shrinkage, and induction of tumour necrosis. ILP has also been used for the management of local tumour recurrence of previously irradiated limbs. Multiple treatments with ILP can be applied to improve local control if the desired effect has not been achieved after one treatment, or in the management of local recurrences that had responded previously to ILP. The use of irradiation as adjuvant treatment after ILP and marginal tumour excision is controversial. The addition of radiotherapy will increase local control, but there have been contradictory reports concerning the additional toxicity.

**Treatment results:**
In adults, ILP is a treatment of choice in *in-transit* metastases of melanoma. Response rates are significantly improved in studies with melphalan with TNF-a (CR 64%) versus melphalan alone (CR 17%) in bulky (sarcoma-like) melanomas. ILP improves local control and is limb-sparing in 74-87% of adult melanoma patients who would normally have been managed by amputation. Similarly, in adult STS, limb amputation could be avoided in 73-86%. Local control was reported as high as 57%. However, ILP did not improve outcome in adult patients with melanoma or STS. The
use of ILP in paediatric STS patients is anecdotal, but seems to be no different from the adult patient groups.

References:

??  Rossi et al. Cancer 1999; 86:1742
21 Statistical considerations

The EpSSG NRSTS includes a prospective trial for synovial sarcomas and adult-type sarcomas, and general considerations and suggestions only for the so-called “other histotypes”

BIOSTATISTIC AND DATA-MANAGEMENT PANEL

Gian Luca De Salvo (Italy) – coordinator
Sue Ablett (UK)
Annie Ray (France)
Cristoph Int-Veen (Germany)
Paola Del Bianco (Italy)

SYNOVIAL SARCOMA AND “ADULT TYPE” SOFT TISSUE SARCOMAS

Design of the trial

This study is a prospective, non randomised, international, multi-institutional and historically controlled clinical trial.

First objective of the study is to make uniform the treatment of NRSTS patients in Europe.

Main objectives:

?? evaluate the survival rates and the pattern of treatment failure in patients with synovial sarcoma and adult-type sarcomas

?? improve the response rate in patients with unresectable synovial sarcoma and adult-type sarcomas by a full-dose ifosfamide-doxorubicin regimen

Secondary objectives:

?? the prospective evaluation of clinical/pathological prognostic factors, in particular: a) the radiological and pathological response to neo-adjuvant treatment, b) the tumour grade, assessed according to the POG and the FNCLCC, and to the new prospective EpSSG grading system

?? to verify the impact of the omission of adjuvant chemotherapy in patients with low-risk synovial sarcoma (IRS group I, tumour smaller than 5 cm)

?? the role of adjuvant chemotherapy in IRS group I-II, G3, size > 5 cm adult-type STS patients in improving the MRS and the OS

Moreover, the study aims to improve the biological studies and samples collection of these malignancies.

The study patients with the same subtype of sarcoma, enrolled into the previous European studies RMS96, CWS-96 and SIOP-MMT95 trials, are defined as the historical control group.

Like as for the EpSSG RMS trial, the accrual period of this study will be **5 years**, followed by a minimum follow up period of 3 years.

It is expected that 250 patients will be enrolled during 5 years.
Expected patient per year in the different European group according to the number of cases enrolled in last studies (RMS96, CWS-96 and SIOP-MMT95 trials)

<table>
<thead>
<tr>
<th></th>
<th>ICG</th>
<th>SIOP</th>
<th>CWS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synovial sarcomas (localized)</td>
<td>6/year</td>
<td>4-5/year</td>
<td>11/year</td>
</tr>
<tr>
<td>Adult-type STS (localized)</td>
<td>16/year</td>
<td>12/year</td>
<td>17/year</td>
</tr>
</tbody>
</table>

End points

The objectives of the study are:

?? Event free survival (EFS), measured as time from histological diagnosis (first surgical approach – biopsy or resection – that leads to histological diagnosis) up to an event. Event is defined as: death for all reasons, progression of a residual tumour, relapse following previous complete remission, appearance of a new tumour. Patients without an event at the end of the study or lost to follow up will be censored at the date of last observation.

?? Local relapse free survival (LRFS), measured as time from histological diagnosis up to local progression or local relapse. Patients without local failure at the end of the study or lost to follow up will be censored at the date of last observation.

?? Metastases free survival (MFS), measured as time from histological diagnosis up to appearance of metastasis. Patients without metastasis at the end of the study or lost to follow up will be censored at the date of last observation.

?? Overall survival (OS), measured as time from histological diagnosis up to death for all reasons. Patients still alive at the end of the study or lost to follow up will be censored at the date of last observation.

?? Response rate in according to classification criteria reported in chapter 16. Complete response, very good partial response, partial response, minor partial response and stable disease will be considered responses in this study.

Analysis Population

All efficacy analysis will be carried out according to the intention to treat principle. It foresees that all subjects, whether or not they received any study medication, will be analysed.

Patients will be also analysed according to the treatment they actually received. This per-protocol population is defined as all subjects who fulfil all inclusion and exclusion criteria and who receive the planned doses of chemotherapy and radiotherapy according to protocol indications for dose delivery and modifications (i.e., patients who were eligible and who received treatment as planned).

Note: for patients who require adjuvant chemotherapy according to the protocol guidelines, the eligibility criteria to the trial include “no more than 8 week-interval between the diagnostic surgical approach and the start of chemotherapy”. Patients with a longer delay will be excluded from the analysis.

Analysis of toxicity will be based on the safety population that consists of all the subjects who received at least one dose of chemotherapy analysed according to the actual treatment received.

All analyses will be performed exploratively. Therefore the p-values are regarded as descriptive.
Description of patient population
The number and percentage of patients included, completed, withdrawn and lost to follow-up will be summarised using descriptive statistics.

The patient population will be described by descriptive statistics as follows:
1. Demography Variables
   ?? Co-operative group and Country of provenience
   ?? Age (<10 years, ? 10 years)
   ?? Gender
2. Prognostic Factors
   ?? Tumour size
   ?? Tumour grade
   ?? Site of disease
   ?? Extent of the tumour (TNM classification and IRS post-surgical grouping system)

Description of treatment exposure
?? Surgical resection
?? Radiotherapy
?? Chemotherapy
The number of treatment cycles administered will be summarised using descriptive statistics. Treatment delays will be summarised using counts and percentages. The cumulative dose and actual dose intensity (mg/m²/wk) and the relative dose intensity (actual dose/planned dose) of Doxorubicin and Ifosfamide regimen will be summarised using descriptive statistics (median, range).

Survival and prognostic analyses
EFS, LRFS, MFS and OS will be plotted as a function of time using Kaplan-Meier product limit method. The two-sided log rank test will be used to compare the treatment arms with the historical control population. Summary statistics (3-yr and 5-yr, EFS, LRFS, MFS and OS) will be reported together with their 95% confidence interval.
In addition, the Cox regression model, whenever all assumptions will be satisfied, will be used to check the influence on EFS, LRFS, MFS and OS of the prognostic variables as defined above.

Response rate analysis
The frequencies of responses will be reported with 95% confidence intervals. Comparisons will be analysed by a two-side chi-squared test.

Safety evaluation and analysis
The safety evaluation will be based on the NCI-CTC Version 3 and will be displayed in summary tables according to NCI CTC Version 3 category and grade (all grades, grade 3 and grade 4) for the worst grade documented.
Stopping rules for synovial sarcoma trial

The rate of metastases will be monitored throughout the study, whenever a metastasis occurs. Given our data, a probability of 8% of metastases could be considered acceptable for this study. The enrolment of patients has to be stopped if the probability of a metastatic relapse exceeds 15%.

According to Wald's Sequential Probability Ratio Test, the data collection has to be terminated if the observed number of patients who develop metastases is higher than 4.08 + 0.111 x number of recruited patients. The boundary of the test is computed given alpha=0.05 and power=90%.

<table>
<thead>
<tr>
<th>Number of Study patients</th>
<th>Number of events</th>
<th>Event rate</th>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.195</td>
<td></td>
<td>26</td>
<td>6.991</td>
<td>26.89%</td>
</tr>
<tr>
<td>2</td>
<td>4.307</td>
<td></td>
<td>27</td>
<td>7.102</td>
<td>26.30%</td>
</tr>
<tr>
<td>3</td>
<td>4.419</td>
<td></td>
<td>28</td>
<td>7.214</td>
<td>25.76%</td>
</tr>
<tr>
<td>4</td>
<td>4.531</td>
<td></td>
<td>29</td>
<td>7.326</td>
<td>25.26%</td>
</tr>
<tr>
<td>5</td>
<td>4.642</td>
<td>92.84%</td>
<td>30</td>
<td>7.438</td>
<td>24.79%</td>
</tr>
<tr>
<td>6</td>
<td>4.754</td>
<td>79.23%</td>
<td>31</td>
<td>7.55</td>
<td>24.35%</td>
</tr>
<tr>
<td>7</td>
<td>4.866</td>
<td>69.51%</td>
<td>32</td>
<td>7.662</td>
<td>23.94%</td>
</tr>
<tr>
<td>8</td>
<td>4.978</td>
<td>62.23%</td>
<td>33</td>
<td>7.773</td>
<td>23.55%</td>
</tr>
<tr>
<td>9</td>
<td>5.09</td>
<td>56.56%</td>
<td>34</td>
<td>7.885</td>
<td>23.19%</td>
</tr>
<tr>
<td>10</td>
<td>5.202</td>
<td>52.02%</td>
<td>35</td>
<td>7.997</td>
<td>22.85%</td>
</tr>
<tr>
<td>11</td>
<td>5.313</td>
<td>48.30%</td>
<td>36</td>
<td>8.109</td>
<td>22.53%</td>
</tr>
<tr>
<td>12</td>
<td>5.425</td>
<td>45.21%</td>
<td>37</td>
<td>8.221</td>
<td>22.22%</td>
</tr>
<tr>
<td>13</td>
<td>5.537</td>
<td>42.59%</td>
<td>38</td>
<td>8.332</td>
<td>21.93%</td>
</tr>
<tr>
<td>14</td>
<td>5.649</td>
<td>40.35%</td>
<td>39</td>
<td>8.444</td>
<td>21.65%</td>
</tr>
<tr>
<td>15</td>
<td>5.761</td>
<td>38.41%</td>
<td>40</td>
<td>8.556</td>
<td>21.39%</td>
</tr>
<tr>
<td>16</td>
<td>5.872</td>
<td>36.70%</td>
<td>41</td>
<td>8.668</td>
<td>21.14%</td>
</tr>
<tr>
<td>17</td>
<td>5.984</td>
<td>35.20%</td>
<td>42</td>
<td>8.78</td>
<td>20.90%</td>
</tr>
<tr>
<td>18</td>
<td>6.096</td>
<td>33.87%</td>
<td>43</td>
<td>8.891</td>
<td>20.68%</td>
</tr>
<tr>
<td>19</td>
<td>6.208</td>
<td>32.67%</td>
<td>44</td>
<td>9.003</td>
<td>20.46%</td>
</tr>
<tr>
<td>20</td>
<td>6.32</td>
<td>31.60%</td>
<td>45</td>
<td>9.115</td>
<td>20.26%</td>
</tr>
<tr>
<td>21</td>
<td>6.432</td>
<td>30.63%</td>
<td>46</td>
<td>9.227</td>
<td>20.06%</td>
</tr>
<tr>
<td>22</td>
<td>6.543</td>
<td>29.74%</td>
<td>47</td>
<td>9.339</td>
<td>19.87%</td>
</tr>
<tr>
<td>23</td>
<td>6.655</td>
<td>28.93%</td>
<td>48</td>
<td>9.451</td>
<td>19.69%</td>
</tr>
<tr>
<td>24</td>
<td>6.767</td>
<td>28.20%</td>
<td>49</td>
<td>9.562</td>
<td>19.51%</td>
</tr>
<tr>
<td>25</td>
<td>6.879</td>
<td>27.52%</td>
<td>50</td>
<td>9.674</td>
<td>19.35%</td>
</tr>
</tbody>
</table>

Rejection boundary

Reject H0
**Stopping rules for LRFS in IRS group I, > 5 cm**

The rate of local relapses will be monitored throughout the study, whenever a relapse occurs. For this study, a probability of 15% of local relapses is considered acceptable. The enrolment of patients has to be stopped if the probability of a local relapse exceeds 25%. According to Wald’s Sequential Probability Ratio Test, the data collection has to be terminated if the observed number of patients who develop local relapse is higher than \(4.54 + 0.196 \times \text{number of recruited patients}\). The boundary of the test is computed given \(\alpha=0.05\) and power=90%.

<table>
<thead>
<tr>
<th>Number of study patients</th>
<th>Number of events</th>
<th>Event rate</th>
<th>Number of study patients</th>
<th>Number of events</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.741</td>
<td></td>
<td>26</td>
<td>9.661</td>
</tr>
<tr>
<td>2</td>
<td>4.938</td>
<td></td>
<td>27</td>
<td>9.858</td>
</tr>
<tr>
<td>3</td>
<td>5.135</td>
<td></td>
<td>28</td>
<td>10.05</td>
</tr>
<tr>
<td>4</td>
<td>5.331</td>
<td></td>
<td>29</td>
<td>10.25</td>
</tr>
<tr>
<td>5</td>
<td>5.528</td>
<td></td>
<td>30</td>
<td>10.44</td>
</tr>
<tr>
<td>6</td>
<td>5.725</td>
<td>95.42%</td>
<td>31</td>
<td>10.64</td>
</tr>
<tr>
<td>7</td>
<td>5.922</td>
<td>84.60%</td>
<td>32</td>
<td>10.84</td>
</tr>
<tr>
<td>8</td>
<td>6.119</td>
<td>76.49%</td>
<td>33</td>
<td>11.03</td>
</tr>
<tr>
<td>9</td>
<td>6.315</td>
<td>70.17%</td>
<td>34</td>
<td>11.23</td>
</tr>
<tr>
<td>10</td>
<td>6.512</td>
<td>65.12%</td>
<td>35</td>
<td>11.43</td>
</tr>
<tr>
<td>11</td>
<td>6.709</td>
<td>60.99%</td>
<td>36</td>
<td>11.62</td>
</tr>
<tr>
<td>12</td>
<td>6.906</td>
<td>57.95%</td>
<td>37</td>
<td>11.82</td>
</tr>
<tr>
<td>13</td>
<td>7.103</td>
<td>54.64%</td>
<td>38</td>
<td>12.02</td>
</tr>
<tr>
<td>14</td>
<td>7.299</td>
<td>52.14%</td>
<td>39</td>
<td>12.21</td>
</tr>
<tr>
<td>15</td>
<td>7.496</td>
<td>49.97%</td>
<td>40</td>
<td>12.41</td>
</tr>
<tr>
<td>16</td>
<td>7.693</td>
<td>48.08%</td>
<td>41</td>
<td>12.61</td>
</tr>
<tr>
<td>17</td>
<td>7.89</td>
<td>46.41%</td>
<td>42</td>
<td>12.81</td>
</tr>
<tr>
<td>18</td>
<td>8.087</td>
<td>44.93%</td>
<td>43</td>
<td>13</td>
</tr>
<tr>
<td>19</td>
<td>8.283</td>
<td>43.59%</td>
<td>44</td>
<td>13.2</td>
</tr>
<tr>
<td>20</td>
<td>8.48</td>
<td>42.40%</td>
<td>45</td>
<td>13.4</td>
</tr>
<tr>
<td>21</td>
<td>8.677</td>
<td>41.32%</td>
<td>46</td>
<td>13.59</td>
</tr>
<tr>
<td>22</td>
<td>8.874</td>
<td>40.34%</td>
<td>47</td>
<td>13.79</td>
</tr>
<tr>
<td>23</td>
<td>9.071</td>
<td>39.44%</td>
<td>48</td>
<td>13.99</td>
</tr>
<tr>
<td>24</td>
<td>9.267</td>
<td>38.61%</td>
<td>49</td>
<td>14.18</td>
</tr>
<tr>
<td>25</td>
<td>9.464</td>
<td>37.86%</td>
<td>50</td>
<td>14.38</td>
</tr>
</tbody>
</table>
22 Organisational and administrative issues

The EpSSG is an inter-group structure which represents an evolution of a well established situation in Europe. It is based on the already existing national and international organisations built with the efforts of the participants to CWS, ICG and SIOP MMT studies over many years. The EpSSG takes into account the differences in the study management and regulations that may exist in the different European countries and co-operative Groups and try to harmonise them.

PARTICIPATING CENTRES

All clinical centres previously part of the SIOP, CWS or ICG Co-operative Group are expected to participate in the EpSSG study.

New clinical centres, whose national group does not take part as a whole, who wish to participate must demonstrate their ability to participate in the study and must link to one of the existing co-operative Groups.

All participating centres are expected to:
- confirm in writing the intention to participate before starting to recruit patients
- name a clinician who will be responsible for communication with the data office.
- obtain patient’s/parents’ written consent to data processing and sending diagnostic material to reference institution
- register all patients with non-metastatic NRSTS
- timely and accurate submit clinical data on paper to their reference Co-ordinating Centres or directly via a Remote Data Entry System
- provide diagnostic material for central pathology review, and for related biological studies

According to the European rules, this trial (considered as therapeutic guidelines) does not need a formal approval from the Research Ethical Committees.

CO-OPERATIVE GROUP AND CO-ORDINATING CENTRES

Each Co-operative Group will keep its existent Co-ordinating Centre.

All existing Co-ordinating Centres are expected to:

- promote the study within their group and obtain specific study commitment by the clinical centres
- distribute the protocol, the forms and all pertinent material to the participating centres within their Group
- manage the data collection and implement procedures for data quality control within their group
- be a referring Centre for the Clinicians from participating centres to address clinical questions
- collaborate with the EpSSG Co-ordinating Centre to update regularly the data

Other National Co-ordinating Centres may be added or created on purpose to support the work of EpSSG if reputed necessary.
CO-ORDINATING CENTRE

The EpSSG Co-ordinating Centre is the trial unit in charge of harmonisation and co-ordination of the study related activity of each Group.

In detail it is expected to:

- co-ordinate the development of the common data base in co-operation with CINECA (Bologna, Italy) and the Co-ordinating Centres
- guarantee the functionality of the data base during the whole study period
- supervise the data collection and data quality to ensure the validity of interim and final analyses on the common data
- be a referring Centre for the Co-ordinating Centres to address technical and operative questions regarding the data management of the study
- be responsible for the statistical analysis within the trial at given time periods in collaboration with the panel of statisticians from individual groups
- update regularly the protocol committees on the ongoing trial

The EpSSG Co-ordinating Centre is located at the:

<table>
<thead>
<tr>
<th>Clinical Epidemiology Unit</th>
<th>Tel: 0039-0498215704</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regional Cancer Centre</td>
<td>Fax: 0039-0498215706</td>
</tr>
<tr>
<td>Via Gattamelata 64</td>
<td>Email: <a href="mailto:cor.epiclin@unipd.it">cor.epiclin@unipd.it</a></td>
</tr>
<tr>
<td>35128 Padova</td>
<td>Website: <a href="http://www.corpadova.it">www.corpadova.it</a></td>
</tr>
<tr>
<td>ITALY</td>
<td></td>
</tr>
</tbody>
</table>

PROTOCOL AND FORMS

One common protocol will be used by the three Groups and all participating Centres. The master protocol will be in English. Translations of the master protocol will be prepared if required by each Co-ordinating Centre.

Any amendments to the protocol must be agreed by all the participants Groups and notified in writing. Addenda may be added independently by any of the national groups to address local needs, provided they have no bearing on the essential aims of the international protocol and they have been previously discussed and approved by the protocol Committee.

Each Co-ordinating Centre will be responsible for distribution of protocols to the Institutions within their Group.

The protocol with all the amendments will be accessible online via the EpSSG website to all the participating Investigators.

Identical data forms will be used by all co-operative groups. The master version will be in English and each Co-ordinating Centre is responsible for translating the document for the national Centres. Additional forms may be produced within each Co-operative group for data collection that are specific for that group and exceed the international data set.
DATA MANAGEMENT

Data flow
The EpSSG NRSTS trial will be managed via a web based system. It is expected that each Co-ordinating centre will utilise the Remote Data Entry system hosted at CINECA to perform the data management of the study. At the moment it has not yet established if the Co-ordinating centres will allow their local sites to enter directly the data into the electronic data base via Internet or if they will choose the traditional paper based flow of data within their group.

If paper based flow is chosen, forms returned from the treating Institutions will be stored at the respective Co-ordinating Centres for time periods conforming to national law.

On receipt of forms at each Co-ordinating centre, common range and logical checks will be carried out on the data prior to entering into the web-based national database.

Errors noted in the national and/or master data base will be reported back to the Co-ordinating centre or to the institution of origin.

Standard Operative Procedures for the electronic data management will be agreed on and followed by the Co-ordinating Centres. These SOPS will be described in a specific document.

Patient Registration procedure
Patients with a diagnosis of localised NRSTS must be registered only after he/she and/or his/her legal guardian has consented to registration and data handling. Patients must be registered before treatment is started by the participating Institutions using the Remote Data Entry (RDE) system.

If the access to the RDE system is not possible for whatever reason a fax must be sent to the corresponding Co-ordinating Centre. The Co-ordinating Centre will register the patient using the RDE system.

Access to data from EpSSG Central Database
The collected data will be available to all the research staff involved in the trial with different access profiles, in real time and with the possibility of multiple concurrent accesses, despite geographical location.

The Co-ordinating Centre of each group, for example, could have access to all data from its Clinical Centres; instead the principle investigator of each participating Centre may have access only to his centre’s data.

Data relating to the present study must not be reported or published without prior consultation of the Protocol Committee.

Data analysis and monitoring
Reports on the study progress will be prepared twice yearly, describing accrual of the patients, group allocations, local therapy modalities and toxicity of the treatments given. This report will be circulated to the Principal Investigators. Data will be published as abstracts at each SIOP meeting if considered appropriate.

The international study committee shall meet as appropriate to consider patient accrual, eligibility, treatment allocation and outcome and ensure a smooth conduct of the study.

According to the European rules, this trial does not need an International Data Monitoring Committee (IDMC) as scheduled for investigational randomised studies (i.e. RMS protocol).

Stopping rules had been developed for synovial sarcomas, for MFS in IRS group I, < 5 cm patients, and for LRFS in IRS group I, > 5 cm patients.
**Protocol modification**

Any modification which may have an impact on the conduct of the study, or may affect patient safety, including changes of study objectives, study design, patient population, sample size, study procedures, or significant administrative aspects will require a formal amendment to the protocol. Such amendment will be agreed upon by the Protocol Committee and reviewed prior to implementation.

A formal approval by the Ethics Committees for minor administrative changes of the protocol which have no impact on the conduction of the study will not be required.

**INSURANCE**

The decision whether the study needs to be covered by a specific insurance against damage ensuing from the organisation of the study depends on the indication of each national group.

**FINANCING**

Each Co-operative Group and Co-ordinating Centre will provide its own financing. EpSSG will not pay for the expenses sustained by the clinicians involved in the study. The EpSSG Co-ordinating Data Centre and the Remote Data Entry system (provided by CINECA) will be supported by a Research Grant from the Fondazione Città della Speranza ONLUS, via Pasubio 17 - 36034 Malo (Vicenza), www.cittadellasperanza.org.

**PUBLICATION POLICY**

Participating centres or national Groups may publish details of their own cases but will agree to allow the committee the exclusive right to publish the results of the EpSSG NRSTS 2005 Protocol, in part or in total.

Similarly each Cooperative Group forming the EpSSG agrees that the results of the Protocol should not be published separately.

All publications using data from the EpSSG central data bank are considered to be official EpSSG papers and these should be agreed by the main author of the project with the EpSSG NRSTS 2005 Protocol Committee before starting the work, so that authorship can be discussed within this group prior to preparation of any publication.

All such publications will be presented on behalf of the EpSSG and will acknowledge the contribution of the participating clinicians.

All persons designated as authors should qualify for authorship. Every other author should have participated sufficiently in the work to take public responsibility for the content.

All manuscripts and abstracts (including abstracts for presentation at meetings) and other documents that contain data from the central EpSSG data bank must be submitted to the EpSSG NRSTS committee at least 21 days prior to the deadline for conference submission.

All abstracts must have written approval from the executive committee prior to final submission.

**ETHICAL ISSUES**

The EpSSG NRSTS 2005 protocol follows the EU Clinical Directive 2001/20/EC for non-commercial clinical trials, in according to the Good Clinical Practice guidelines. National implementation of the directives is a matter of current debate, and possibly divergent views between
Member States could be present. As a consequence, different national groups may need deal
differently with the protocol in order to address relevant ethical and insurance requirements.
The protocol is not an investigational trial: therefore, the decision to submit it, before patients’
enrolment, to the Ethics Committee of each centre for review and approval according to in force
law depends to the each national group.
The patient’s and/or parent’s written consent is required for data management and for collecting
samples for biological studies (sending diagnostic material to reference institutions, which in all
participating countries has to conform to the national data protection legislation). The need for a
written consent for participating in the study depends on the indication of each national group.

INFORMED CONSENT
The patient’s and/or parent’s written consent is needed for data management and biology material
handling. The need for a written consent for participation in the study depends on the indication of
each national group. If the patient is a minor, consent should be received from his/her guardian.
Adequate explanation on treatment options must be given, also to the child according to his/her
means of understanding. Enough time and the opportunity to discuss participation before the
decision for and start of treatment have to be given. The right of a patient to refuse to participate
without giving reasons must be respected.
The patient must remain free to withdraw at any time from the study or to withdraw his/her data
from the study, without giving reasons and without prejudicing further treatment. Administrative documents, consent forms and copies of the study documentation have to be kept
according to set archival terms.
Examples of Consent Forms are provided in Appendix.

DECLARATION OF HELSINKI
The investigator agrees, by signing the protocol, to adhere to the principles of Good Clinical
Practice. A copy of the Declaration of Helsinki in its latest form is provided in Appendix.

CONFIDENTIALITY/SECURITY
A high standard level of data confidentiality and security should be guaranteed throughout the
study.
In detail:
?? The International common data base will not contain individual personal information
?? Patients will be identified by a code, not by full name
?? All traffic with the server will be encrypted.
?? Each user at each site will have a personal User ID and Password.
The system will ensure:
?? appropriate and regular backup on electronic media of all data, to permit restoration in case of
loss or damage of the data base,
?? operation tracking log (for each user: registration of any operation),
?? electronic data audit trails (creation of a data base of original entries/modifications with
identification of date, time, source and user identity),
?? disaster recovery procedures.
Appendix
TNM CLASSIFICATION AND GROUPING

Pre treatment TNM

Tumour:
T0: No evidence of tumour
T1: Tumour confined to organ or tissue of origin
    T1a: Tumour = 5 cm in greatest dimension
    T1b: Tumour > 5 cm in greatest dimension
T2: Tumour not confined to organ or tissue of origin
    T2a: Tumour = 5 cm in greatest dimension
    T2b: Tumour > 5 cm in greatest dimension
TX: No information on size and tumour invasiveness

Lymph nodes:
N0: No evidence of lymph node involvement
N1: Evidence of regional lymph node involvement
NX: No information on lymph node involvement

Metastasis:
M0: No evidence of metastases or non-regional lymphnodes
M1: Evidence of distant metastasis or involvement of non-regional lymphnodes
MX: No information on metastasis
**pTNM: Post surgical TNM classification**

**pT**
- **pT0**: No evidence of tumour found on histological examination of specimen.
- **pT1**: Tumour limited to organ or tissue of origin. Excision complete and margins histologically free.
- **pT2**: Tumour with invasion beyond the organ or tissue of origin. Excision complete and margins histologically free.
- **pT3**: Tumour with or without invasion beyond the organ or tissue of origin. Excision incomplete.
  - **pT3a**: Evidence of microscopic residual tumour.
  - **pT3b**: Evidence of macroscopic residual tumour.
  - **pT3c**: Adjacent malignant effusion regardless of size.
- **pTX**: Tumour status may not be assessed.

**pN**
- **pN0**: No evidence of tumour found on histological examination of regional lymph nodes.
- **pN1**: Evidence of invasion of regional lymph nodes.
  - **pN1a**: Evidence of invasion of regional lymph nodes. Involved nodes considered to be completely resected.
  - **pN1b**: Evidence of invasion of regional lymph nodes. Involved nodes considered not to be completely resected.
- **pNX**: N status may not be assessed due to lack of pathological examination or inadequate information on pathological findings.

**pM**
- **pM0**: No evidence of metastasis found on histological examination of regional lymph nodes.
- **pM1**: Evidence of metastasis on histological examination.
- **pMX**: M status may not be assessed due to lack of pathological examination or inadequate information on pathological findings.

For evaluations NX and pNX will be regarded as N0 and pNX, MX and pMX will be regarded as M0 and pM0.
IRS CLINICAL GROUPING CLASSIFICATION

**Group I:** Localized disease, completely resected

(Regional nodes not involved – lymph node biopsy or dissection is required except for head and neck lesions)

(a) Confined to muscle or organ of origin

(b) Contiguous involvement – infiltration outside the muscle or organ of origin, as through facial planes.

**Notation:** This includes both gross inspection and microscopic confirmation of complete resection. Any nodes that may be inadvertently taken with the specimen must be negative. If the latter should be involved microscopically, then the patient is placed in Group IIb or IIc (See Below).

**Group II:** Total gross resection with evidence of regional spread

a) Grossly resected tumour with microscopic residual disease.

(Surgeon believes that he has removed all of the tumour, but the pathologist finds tumour at the margin of resection and additional resection to achieve clean margin is not feasible.) No evidence of gross residual tumour. No evidence of regional node involvement. Once radiotherapy and/or chemotherapy have been started, re-exploration and removal of the area microscopic residual does not change the patient’s group.

b) Regional disease with involved nodes, completely resected with no microscopic residual.

**Notation:** Complete resection with microscopic confirmation of no residual disease makes this different from Groups IIa and IIc.

Additionally, in contrast to Group IIa, regional nodes (which are completely resected, however) are involved, but the most distal node is histologically negative.

c) Regional disease with involved nodes, grossly resected, but with evidence of microscopic residual and/or histologic involvement of the most distal regional node (from the primary site) in the dissection.

**Notation:** The presence of microscopic residual disease makes this group different from Group IIb, and nodal involvement makes this group different from Group IIa.

**Group III:** Incomplete resection with gross residual disease

a) After biopsy only

b) After gross or major resection of the primary (>50%)

**Group IV:** Distant metastatic disease present at one site

(Lung, liver, bones, bone marrow, brain, and distant muscle and nodes)

**Notation:** The above excludes regional nodes and adjacent organ infiltration which places the patient in a more favorable grouping (as noted above under Group II).

The presence of positive cytology in CSF, pleural or abdominal fluids as well as implants on pleural or peritoneal surfaces are regarded as indications for placing the patient in Group IV.
**pTNM and Grouping System**

<table>
<thead>
<tr>
<th>Group</th>
<th>Definition</th>
<th>pTNM</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumour macroscopically and microscopically removed</td>
<td></td>
</tr>
<tr>
<td>(IA)</td>
<td>Tumour confined to organ or tissue of origin</td>
<td>pT1</td>
</tr>
<tr>
<td>(IB)</td>
<td>Tumour not confined to organ or tissue of origin</td>
<td>pT2</td>
</tr>
<tr>
<td>II</td>
<td>Macroscopic complete resection but microscopic residuals</td>
<td>pT3a</td>
</tr>
<tr>
<td>IIA</td>
<td>Lymphnodes not affected</td>
<td></td>
</tr>
<tr>
<td>IIB</td>
<td>Lymphnodes affected but removed</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Macroscopic complete resection but microscopic residuals and lymphnodes affected and not removed</td>
<td>pT3a</td>
</tr>
<tr>
<td></td>
<td>Macroscopic residuals after resection or biopsy</td>
<td>pT3b</td>
</tr>
<tr>
<td></td>
<td>With malignant effusion</td>
<td>pT3c</td>
</tr>
<tr>
<td>IV</td>
<td>Metastasis present or non-regional lymphnodes involved</td>
<td>pT4</td>
</tr>
</tbody>
</table>
DEFINITION OF SITES

To define the site of origin may be difficult in some cases of NRSTS. A correct site assignment is of importance in the choice of treatment. The following definitions are given to facilitate the clinician in the appropriate site classification. We acknowledge the permission given by the IRSG to modify and use their original document on site definitions.

ORBIT

1. Eyelid
This site is sometimes erroneously designated as “eye”. Although there may occasionally be a case arising from the conjunctiva of the eye, the globe itself is not a primary site. The eyelid is much less frequent than the orbit itself.

2. Orbit
This refers to the bony cavity, which contains the globe, nerve and vessels and the extra-ocular muscles. Tumour in this site will only rarely invade the bony walls and extend into the adjacent sinuses. This is why this tumour which is clearly adjacent to the skull base and its meninges is not by its natural history appropriate to include in the parameningeal sites unless there is invasion of bone at the base of the skull.

PARAMENINGEAAL

1. Middle ear
This refers to a primary that begins medial to the tympanic membrane. This tumour is often advanced at presentation and because of extension laterally may present with a mass in front of or under the ear suggesting a parotid origin. It may also extend through the tympanic membrane and appear to be arising in the ear canal. When there is doubt about the site of origin, the “middle ear” designation should be picked as it implies the more aggressive therapy required of parameningeal sites.

2. Nasal Cavity and Paranasal Sinuses
The three paranasal sinuses are the maxillary sinuses, the ethmoid sinuses, and the sphenoid sinus. These surround the nasal cavity, and a primary in one will frequently extend to another. It can be difficult to determine the exact site of origin, but the choice is academic as the treatment is not affected. The site designation will have a bearing on the design of radiotherapy portals. Tumour arising in the maxillary or the ethmoid sinuses may invade the orbit. This is much more likely than a primary in the orbit invading one of the sinuses. When the distinction between orbit and paranasal sinus is unclear, the site selected should be paranasal sinus as it is the more likely primary site and requires appropriately more aggressive therapy. A primary arising in the sphenoid sinus (rare) may extend inferiorly to involve the nasopharynx.

3. Nasopharynx
This refers to the superior portion of the pharynx which is bounded anteriorly by the back of the nasal septum, superiorly by the sphenoid sinus, inferiorly by a level corresponding to the soft palate, and laterally and posteriorly by the pharyngeal walls.

4. Infratemporal Fossa/Pterygopalative and Parapharyngeal Area
This refers to the tissues bounded laterally by the medial lobe of the parotid gland and medially by the pharynx. Large tumours in this region may extend through the parotid gland and present as a mass of the lateral face, sometimes extending even to the cheek. Where there is doubt as to the primary, the parameningeal designation should be chosen as it confers appropriately more aggressive treatment. The superior boundary of this tissue volume is the base of skull just under the temporal lobe, hence the term “infratemporal”. The distinction between this and the “parapharyngeal” area is academic.

5. **Orbital tumours with bone erosion**
Tumours arising in the orbit but with intracranial extension or important bone erosion are included in the parameningeal group.

*In addition the following are classified as parameningeal tumours:*
- Tumours involving vessels or nerves with direct intracranial connection (Arteria carotis interna, vertebralis, N. opticus, trigeminus, facialis etc).
- All intracranial and intraspinal tumours (but tumours arising from the paraspinal muscles with intraspinal extension should be designated as paraspinal, see “Other site” definition)
- All tumours with cranial nerve paresis
- CSF tumour cell positive patients

**HEAD AND NECK**

1. **Scalp**
This site includes primaries arising apparently in, or just below, the skin of all the tissues of the face and head that are not otherwise specified below. This usually means the scalp, external ear and pinna, the nose and the forehead, but not the eyelids or cheek.

2. **Parotid**
The parotid gland lies just in front of, and under, the ear and may surround both sides of the posterior aspect of the ascending ramus of the mandible. As noted above, large primaries in the infratemporal fossa may erode through the parotid. A true parotid primary should not, on radiographic studies, reveal a mass in the infratemporal fossa.

3. **Oral Cavity**
This includes the floor of the mouth, the buccal mucosa, the upper and lower gum, the hard palate, the oral tongue (that portion of the tongue anterior to the circumvallate papillae). A primary arising in the buccal mucosa can be impossible to distinguish from one arising in the cheek, but the distinction is academic. This would also include those lesions arising in or near the lips.

4. **Larynx**
This refers to primaries arising in the subglottic, glottic, or supraglottic tissues. Tumours of the aryepiglottic folds can be impossible to distinguish from the hypopharynx, but the distinction is academic.

5. **Oropharynx**
This includes tumours arising from the anterior tonsillar pillars, the soft palate, the base of the tongue, the tonsillar fossa, and oropharyngeal walls. Tumours arising in the parapharyngeal space may indent the oropharyngeal wall. In this circumstance, the primary should be considered parameningeal. If the mucosa of the oropharynx actually contains visible tumour as opposed to being bulged by it, the primary would be oropharynx. Primaries arising in the tongue base, soft palate, or tonsillar region may extend into the oral cavity. The oropharynx designation is preferred.
6. **Cheek**
This refers to the soft tissues of the face that surround the oral cavity. Tumours arising in the parotid may invade the cheek. As noted above, the distinction between this and the buccal mucosa is academic.

7. **Hypopharynx**
This refers to the pyriform sinus and may be difficult to distinguish from larynx although the designation is academic.

8. **Thyroid and Parathyroid**
Primaries arising in these two sites are exceedingly rare, if they exist at all, and should those structures be involved, it would more likely be from a primary arising in an adjacent structure such as the neck or, rarely, the trachea.

9. **Neck**
This refers to the soft tissues of the lateral neck between the mastoid tip and the clavicle. It does not include those medial structures such as hypopharynx and larynx noted above. Unfortunately this site overlaps with the designation “paraspinal” included under the site group “trunk”. Primaries arising in the neck can and frequently do behave as a paraspinal primary with direct invasion into the spinal extradural space, especially if posteriorly placed.

---

**GENITO-URINARY BLADDER AND PROSTATE**

1. **Bladder**
Our criteria for identifying the bladder as a primary site has included the appearance of tumour within the bladder cavity, which can be biopsied under cystoscopy or occasionally at laparotomy. We do not recognize as primary bladder tumours those that simply displace the bladder or distort its shape. The latter are ordinarily primary pelvic tumours, unless otherwise specified.

2. **Prostate**
It is important to differentiate true prostatic tumours from pelvic tumours.

3. **Bladder/Prostate**
In approximately 20% of males with bladder or prostatic tumours, the precise site cannot be determined even at autopsy. The histologic features are similar. Although it is desirable to have an indication of the “most probable” site from the institution, and one should to get this, it may not be possible.

---

**GENITO-URINARY NON BLADDER AND PROSTATE**

1. **Paratesticular**
The tumours arises from mesenchymal elements of the spermatic cord, epididymis, and testicular envelopes, producing a painless scrotal mass.

2. **Testis**
This designation is usually wrong because the tumours arise from paratesticular structures.

3. **Uterus**
A tumour in this primary site may be difficult to differentiate from a primary vaginal site, because a tumour originating in the uterus may fill the vagina. After a therapeutic response, the distinction is usually clear. In
general there is a wide separation of age range between these two groups, with the vaginal cases occurring in infancy or early childhood and uterine primaries in adolescents or young adults.

4. Vagina
A patient with a primary vaginal lesion must have evidence of a visible tumour on the vaginal surfaces which can be biopsied through the vagina. Displacement or distortion of the vagina is not sufficient.

5. Vulva
Primary lesions in this site arise in the labia minora or majora.

EXTREMITIES

1. Hand
   Refers to the area from the top of the fingers to the wrist

2. Forearm
   Refers to the area from the wrist to the elbow joint

3. Arm
   Refers to the area from the elbow joint to the shoulder joint. Tumours arising in the axilla are considered as extremity lesions.

4. Shoulder
   The posterior aspect of the shoulder, i.e., the scapular area, is an extremity site.

5. Foot
   Refers to the area from the top of the toes to the ankle

6. Leg
   Refers to the area from the ankle to the knee

7. Thigh
   Refers from the area from the knee to the hip joint

8. Buttocks
   These are extremity lesions.

OTHER SITES

This term conventionally groups tumours originating from the sites not mentioned above. Prognosis is similar and usually not satisfying.

The following specific sites have been defined:

Thorax
Includes tumours arising in the following sites:
   a) Thoracic wall:
      includes tumours arising from the thoracic muscles and the parietal pleura
   b) Mediastinum
      Occasionally a primary rhabdomyosarcoma may arise from thrachea, heart or nearby areas.
c) Lung:
   includes tumours arising form the lung parenchyma, brochus and visceral pleura

Diaphragm

Abdominal Wall (including Lumbar or lumbo-sacral wall)
This refers to the anterior abdominal wall from the inferior costal margins superiorly to the inguinal ligaments and symphysis pubis, inferiorly, and extends laterally between the costal margin and posterior iliac crests to the paraspinal region.

Paraspinal
When tumours are described as adjacent to the vertebral column, arising from the paraspinal muscles. This designation is preferable to “abdominal wall” or “trunk” or “neck”. They often show an intraspinal component and this should be specified.

Abdomen - Intraperitoneal
a) Liver
   True liver rhabdomyosarcoma are less frequent than bile ducts tumours.
   b) Bile duct
   Bile Duct is a specific site and can be recognised as such at surgery. This might also be called “choledochus” or “biliary tract”. There is probably no way one can distinguish an intrahepatic bile duct site from a primary liver site except by examining the excised specimen.
   c) Pancreas
d) Bowel
e) Abdomen
   The term abdominal refers to tumours arising in the intraperitoneal cavity, when a specific organ of origin such as liver, bile duct, pancreas or intestine cannot be determined.

Abdomen - Retroperitoneal
The term retroperitoneal is reserved for those posteriorly situated abdominal tumours in which there does not seem to be a more specific site. Tumours in a retroperitoneal site are in the posterior aspect of the abdominal and/or pelvis. The term “psosas” as a site is not very specific, as the muscle extends through the posterior lower abdomen, pelvis and into the leg.

Pelvis
It is difficult to define the site of origin when there is a large tumour in the abdomen. The pelvis designation is reserved for lesions involving the lower part of the abdomen when no more specific site is appropriate.

Perianal
These sites are ordinarily “perirectal” or “perianal”. They are distinguished with difficulty from perineal and vulval sites; but the latter distinction is important.

Perineum
This should include the site which appear the anus posterior to the scrotum in males and posterior to the labia in females. It extends anteriorly to the base of the scrotum in males and to the introitus in females. It must be distinguished from labial and sites.
REGIONAL LYMPH NODES DEFINITION

Regional lymph node involvement is defined N1 according to TNM system. Regional lymph nodes are defined as those appropriate to the site of the primary tumour, for example:

**Head & Neck:** ipsilateral cervical and supraclavicular lymph nodes; bilateral adenopathy may be present with centrally situated tumours

**Orbit:** ipsilateral jugular, pre-auricular, cervical

**Intrathoracic:** internal mammary, mediastinal nodes

**Thoracic wall:** axillary, internal mammary, infraclavicular nodes

**Intraabdominal & Pelvic:** Sub diaphragmatic, intra abdominal and iliac lymph nodes according to site.

**Abdominal wall:** inguinal, femoral nodes

**Genito-urinary:**
- **Bladder Prostate:** iliac nodes at renal artery or below (lumboaortic nodes are second level nodes).
- **Cervix and Uterus:** iliac nodes at renal artery or below
- **Paratesticular:** external iliac and para-aortic lymph nodes at renal artery or below
- **Vagina:** retroperitoneal, pelvic nodes at or below common iliacs inguinal nodes
- **Vulva:** inguinal nodes

**Perineum:** inguinal and iliac (may be bilateral)

**Upper Limbs:** axillary lymph nodes (epitrochlear rarely involved)

**Lower Limbs:** inguinal lymph nodes (popliteal rarely involved)

Evidence of nodal involvement different than those listed above must be interpreted as distant metastasis and the patient must be treated according to the protocol for patients with metastasis at diagnosis.

Examples:
- perineal tumour with nodes above the pelvis
- thigh tumour with iliac or periaortic nodes
- intrathoracic tumour with subdiaphragmatic nodes
- paratesticular tumour with inguinal nodes regional
- Unilateral tumour with contralateral involved lymph nodes (except in the head and neck).
# TOXICITY GRADING

This is a short version of the NCI CTC only containing the most common side effects. The full text version can be downloaded from: [http://ctep.cancer.gov/reporting/ctc.html](http://ctep.cancer.gov/reporting/ctc.html).

## Grade

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
</table>

### ALLERGY/IMMUNOLOGY

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic reaction/ hypersensitivity (including drug fever)</td>
<td>transient rash, drug fever $&lt;$ 38°C ($&lt;$100.4°F)</td>
</tr>
</tbody>
</table>

Note: Isolated urticaria, in the absence of other manifestations of an allergic or hypersensitivity reaction, is graded in the DERMATOLOGY/SKIN category.

### BLOOD/BONE MARROW

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (Hgb)</td>
<td>WNL</td>
</tr>
<tr>
<td>Hemolysis (e.g., immune hemolytic anemia, drug-related hemolysis, other)</td>
<td>$&lt;$ LLN - 10.0 g/dl</td>
</tr>
<tr>
<td>Leukocytes (total WBC)</td>
<td>WNL</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>WNL</td>
</tr>
<tr>
<td>Neutrophils/granulocytes (ANC/AGC)</td>
<td>WNL</td>
</tr>
<tr>
<td>Platelets</td>
<td>WNL</td>
</tr>
<tr>
<td>Transfusion: Platelets</td>
<td>none</td>
</tr>
<tr>
<td>Transfusion: pRBCs</td>
<td>none</td>
</tr>
</tbody>
</table>

### CONSTITUTIONAL SYMPTOMS

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue (lethargy, malaise, asthenia)</td>
<td>increased fatigue over baseline, but not altering normal activities</td>
</tr>
</tbody>
</table>

Note: See Appendix III for performance status scales.

### FEVER

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (in the absence of neutropenia, where neutropenia is defined as AGC $&lt;$ 1.0 x 10$^9$)</td>
<td>$38.0 - 39.0°C$ ($100.4 - 102.2°F$)</td>
</tr>
</tbody>
</table>

Also consider Allergic reaction/hypersensitivity.

Note: The following criteria using age, race, and sex normal values may be used for pediatric studies if the protocol so specifies.

### BLOOD/BONE MARROW

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (Hgb)</td>
<td>WNL</td>
</tr>
<tr>
<td>Lymphocytes (total WBC)</td>
<td>WNL</td>
</tr>
<tr>
<td>Neutrophils/granulocytes (ANC/AGC)</td>
<td>WNL</td>
</tr>
<tr>
<td>Platelets</td>
<td>WNL</td>
</tr>
</tbody>
</table>

### TRANSFUSIONS

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfusion: Platelets</td>
<td>none</td>
</tr>
<tr>
<td>Transfusion: pRBCs</td>
<td>none</td>
</tr>
</tbody>
</table>

### CONSTITUTIONAL SYMPTOMS

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue (lethargy, malaise, asthenia)</td>
<td>increased fatigue over baseline, but not altering normal activities</td>
</tr>
</tbody>
</table>

Note: See Appendix III for performance status scales.

### FEVER

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (in the absence of neutropenia, where neutropenia is defined as AGC $&lt;$ 1.0 x 10$^9$)</td>
<td>$38.0 - 39.0°C$ ($100.4 - 102.2°F$)</td>
</tr>
</tbody>
</table>

Also consider Allergic reaction/hypersensitivity.

Note: The temperature measurements listed above are oral or tympanic.

### SWEATING

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rigors, chills</td>
<td>mild, requiring symptomatic treatment (e.g., blanket) or non-narcotic medication</td>
</tr>
<tr>
<td>Sweating (diaphoresis)</td>
<td>normal</td>
</tr>
<tr>
<td>Weight gain</td>
<td>$&lt;$ 5%</td>
</tr>
</tbody>
</table>

This is a short version of the NCI CTC only containing the most common side effects. The full text version can be downloaded from: [http://ctep.cancer.gov/reporting/ctc.html](http://ctep.cancer.gov/reporting/ctc.html).
### EpSSG NRSTS 2005 protocol

**Grade**

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight gain - veno-occlusive disease (VOD)</td>
<td>&lt;2%</td>
<td>?2 - &lt;5%</td>
<td>?5 - &lt;10%</td>
<td>10% or as ascites</td>
</tr>
<tr>
<td>Weight loss</td>
<td>&lt; 5%</td>
<td>5 - &lt;10%</td>
<td>10% or fluid retention</td>
<td></td>
</tr>
<tr>
<td>Constitutional Symptoms (Specify, ________)</td>
<td>none</td>
<td>mild</td>
<td>moderate</td>
<td>severe</td>
</tr>
</tbody>
</table>

**DESMATOLOGY/SKIN**

<table>
<thead>
<tr>
<th>Alopecia</th>
<th>normal</th>
<th>mild hair loss</th>
<th>pronounced hair loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry skin</td>
<td>normal</td>
<td>controlled with emollients</td>
<td>not controlled with emollients</td>
</tr>
<tr>
<td>Injection site reaction</td>
<td>none</td>
<td>pain or itching or erythema</td>
<td>pain or swelling, with inflammation or phlebitis</td>
</tr>
<tr>
<td>Pruritus</td>
<td>none</td>
<td>mild or localized, relieved spontaneously or by local measures</td>
<td>intense or widespread, relieved spontaneously or by systemic measures</td>
</tr>
<tr>
<td>Rash/desquamation</td>
<td>none</td>
<td>macular or papular eruption or erythema without associated symptoms</td>
<td>macular or papular eruption or erythema with pruritus or other associated symptoms covering &lt;50% of body surface or localized desquamation or other lesions covering &lt;50% of body surface area</td>
</tr>
<tr>
<td>Urticaria (hives, welts, wheals)</td>
<td>none</td>
<td>requiring no medication</td>
<td>requiring PO or topical treatment or IV medication or steroids for &lt;24 hours</td>
</tr>
<tr>
<td>Flush (absent)</td>
<td>present</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection (absent)</td>
<td>present</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ENDOCRINE**

<table>
<thead>
<tr>
<th>Hot flashes/flashes</th>
<th>none</th>
<th>mild or no more than 1 per day</th>
<th>moderate and greater than 1 per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIADH (syndrome of inappropriate antidiuretic hormone)</td>
<td>absent</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GASTROINTESTINAL**

<table>
<thead>
<tr>
<th>Anorexia</th>
<th>none</th>
<th>loss of appetite</th>
<th>oral intake significantly decreased</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascites (non-malignant)</td>
<td>none</td>
<td>asymptomatic</td>
<td>symptomatic, requiring diuretics</td>
</tr>
<tr>
<td>Colitis</td>
<td>none</td>
<td>-</td>
<td>abdominal pain with mucus and/or blood in stool</td>
</tr>
<tr>
<td>Constipation</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>none</td>
<td>dry mucous membranes and/or diminished skin turgor</td>
<td></td>
</tr>
<tr>
<td>Diarrhea (Patients without colostomy)</td>
<td>none</td>
<td>increase of &lt; 4 stools/day over pre-treatment</td>
<td>increase of 4-6 stools/day, or nocturnal stools</td>
</tr>
<tr>
<td>Gastritis</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouth dryness</td>
<td>normal</td>
<td>mild</td>
<td>moderate</td>
</tr>
</tbody>
</table>

**Note:** Erythema multiforme (Stevens-Johnson syndrome) is graded separately as Erythema multiforme.

- Also consider Allergic reaction/hypersensitivity.
- Note: Urticaria (hives, welts, wheals) is graded separately as Urticaria.

129
<table>
<thead>
<tr>
<th>Grade</th>
<th>Toxicity</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>none</td>
<td>none</td>
<td>able to eat</td>
<td>oral intake significantly decreased</td>
<td>no significant intake, requiring IV fluids</td>
<td>-</td>
</tr>
<tr>
<td>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</td>
<td>none</td>
<td>none</td>
<td>painless ulcers, erythema, or mild soreness in the absence of lesions</td>
<td>painful erythema, edema, or ulcers, but can eat or swallow</td>
<td>painful erythema, edema, or ulcers requiring IV hydration</td>
<td>severe ulceration or requires parenteral or enteral nutritional support or prophylactic intubation</td>
</tr>
<tr>
<td>Note: Radiation-related mucositis is graded as Mucositis due to radiation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>none</td>
<td>none</td>
<td>1 episode in 24 hours over pretreatment</td>
<td>2-5 episodes in 24 hours over pretreatment</td>
<td>76 episodes in 24 hours over pretreatment, or need for IV fluids</td>
<td>Requiring parenteral nutrition, or physiologic consequences requiring intensive care, hemodynamic collapse</td>
</tr>
<tr>
<td>Note: Also consider Dehydration.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEPATIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>WNL</td>
<td>&gt; ULN - 2.5 x ULN</td>
<td>&gt; 2.5 - 5.0 x ULN</td>
<td>&gt; 5.0 - 20.0 x ULN</td>
<td>&gt; 20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>Bilirubin</td>
<td>WNL</td>
<td>&gt; ULN - 1.5 x ULN</td>
<td>&gt; 1.5 - 3.0 x ULN</td>
<td>&gt; 3.0 - 10.0 x ULN</td>
<td>&gt; 10.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>GGT (? - Glutamyl transpeptidase)</td>
<td>WNL</td>
<td>&gt; ULN - 2.5 x ULN</td>
<td>&gt; 2.5 - 5.0 x ULN</td>
<td>&gt; 5.0 - 20.0 x ULN</td>
<td>&gt; 20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>Hepatic enlargement</td>
<td>absent</td>
<td>-</td>
<td>-</td>
<td>present</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Note: Grade Hepatic enlargement only for changes related to VOD or other treatment related toxicity.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoalbuminemia</td>
<td>WNL</td>
<td>&lt; LLN - 3 g/dl</td>
<td>3 - &lt;3 g/dl</td>
<td>&lt;2 g/dl</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Liver dysfunction/failure (clinical)</td>
<td>normal</td>
<td>-</td>
<td>-</td>
<td>asterixis</td>
<td>encephalopathy or coma</td>
<td></td>
</tr>
<tr>
<td>Note: Documented viral hepatitis is graded in the INFECTION category.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portal vein flow</td>
<td>normal</td>
<td>-</td>
<td>decreased portal vein flow</td>
<td>reversal/retrograde portal vein flow</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>SGOT (AST) (serum glutamic oxaloacetic transaminase)</td>
<td>WNL</td>
<td>&gt; ULN - 2.5 x ULN</td>
<td>&gt; 2.5 - 5.0 x ULN</td>
<td>&gt; 5.0 - 20.0 x ULN</td>
<td>&gt; 20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>SGPT (ALT) (serum glutamic pyruvic transaminase)</td>
<td>WNL</td>
<td>&gt; ULN - 2.5 x ULN</td>
<td>&gt; 2.5 - 5.0 x ULN</td>
<td>&gt; 5.0 - 20.0 x ULN</td>
<td>&gt; 20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>Hepatic-Other (Specify, ___)</td>
<td>none</td>
<td>mild</td>
<td>moderate</td>
<td>severe</td>
<td>life-threatening or disabling</td>
<td></td>
</tr>
<tr>
<td>INFECTION/FEBRILE NEUTROPENIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celluler-related infection</td>
<td>none</td>
<td>mild, no active treatment</td>
<td>moderate, infection, requiring local or oral treatment</td>
<td>localized infection, requiring IV antibiotic or antifungal treatment or hospitalization</td>
<td>severe, systemic infection, requiring IV antibiotic or antifungal treatment or hospitalization</td>
<td>life-threatening sepsis (e.g., septic shock)</td>
</tr>
<tr>
<td>Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt; 1.0 x 10^9/L, fever ≥ 38.5°C)</td>
<td>none</td>
<td>-</td>
<td>-</td>
<td>Present</td>
<td>Life-threatening sepsis (e.g., septic shock)</td>
<td></td>
</tr>
<tr>
<td>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC &lt; 1.0 x 10^9/L)</td>
<td>none</td>
<td>mild, no active treatment</td>
<td>moderate, localized infection, requiring local or oral treatment</td>
<td>severe, systemic infection, requiring IV antibiotic or antifungal treatment or hospitalization</td>
<td>life-threatening sepsis (e.g., septic shock)</td>
<td></td>
</tr>
<tr>
<td>Infection with unknown ANC</td>
<td>none</td>
<td>mild, no active treatment</td>
<td>moderate, localized infection, requiring local or oral treatment</td>
<td>severe, systemic infection, requiring IV antibiotic or antifungal treatment or hospitalization</td>
<td>life-threatening sepsis (e.g., septic shock)</td>
<td></td>
</tr>
<tr>
<td>Infection/Febrile Neutropenia-Other (Specify, ___)</td>
<td>none</td>
<td>mild</td>
<td>moderate</td>
<td>severe</td>
<td>life-threatening or disabling</td>
<td></td>
</tr>
<tr>
<td>METABOLIC/LABORATORY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td>Toxicity</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Acidosis (metabolic or respiratory)</td>
<td>normal pH &lt; normal, but &gt; 7.3</td>
<td>-</td>
<td>pH &lt; 7.3</td>
<td>pH &gt; 7.3 with life-threatening physiologic consequences</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alkalosis (metabolic or respiratory)</td>
<td>normal pH &gt; normal, but &gt; 7.5</td>
<td>-</td>
<td>pH &gt; 7.5</td>
<td>pH &gt; 7.5 with life-threatening physiologic consequences</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypokalemia WNL</td>
<td>&lt; ULN - &lt; 5 mmol/L</td>
<td>&gt; 5.5 - 6.0 mmol/L</td>
<td>&gt; 6.0 - 7.0 mmol/L</td>
<td>&gt; 7.0 mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypoglycemia WNL</td>
<td>&lt; LLN - 55 mg/dl</td>
<td>50 - &lt; 55 mg/dl</td>
<td>30 - &lt; 40 mg/dl</td>
<td>&lt; 30 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypokalemia WNL</td>
<td>&lt; ULN - &lt; 3.0 mmol/L</td>
<td>&gt; 2.2 - &lt; 3.0 mmol/L</td>
<td>&gt; 1.7 - &lt; 2.2 mmol/L</td>
<td>&gt; 1.7 mmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypomagnesemia WNL</td>
<td>&lt; ULN - &lt; 1.2 mg/dl</td>
<td>&gt; 0.9 - &lt; 1.2 mg/dl</td>
<td>&gt; 0.7 - &lt; 0.9 mg/dl</td>
<td>&gt; 0.7 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypophosphatemia WNL</td>
<td>&lt; LLN - &lt; 0.8 mmol/L</td>
<td>&gt; 0.6 - &lt; 0.8 mmol/dl</td>
<td>&gt; 0.3 - &lt; 0.6 mmol/dl</td>
<td>&gt; 0.3 mmol/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypernatremia WNL</td>
<td>&lt; ULN - &lt; 130 mmol/L</td>
<td>&gt; 120 - &lt;130 mmol/L</td>
<td>&gt; 120 mmol/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyponatremia WNL</td>
<td>&lt; LLN - &lt; 130 mmol/L</td>
<td>&gt; 120 - &lt;130 mmol/L</td>
<td>&gt; 120 mmol/L</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**OCULAR/VISUAL**

<table>
<thead>
<tr>
<th>Dry eye</th>
<th>Tearing (watery eyes) none</th>
<th>Blurred vision normal</th>
<th>Ocular/Visual-Other (Specify, ____ )</th>
<th>Abdominal pain or cramping none</th>
<th>Headache none</th>
<th>Hepatic pain none</th>
<th>Rectal or perirectal pain (proctalgia) none</th>
<th>Bladder spasms absent</th>
<th>Creatinine WNL</th>
</tr>
</thead>
<tbody>
<tr>
<td>normal</td>
<td>mild, not requiring treatment</td>
<td>moderate or requiring artificial tears</td>
<td>severe</td>
<td>mild pain not interfering with function</td>
<td>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe</td>
</tr>
<tr>
<td>mild</td>
<td>moderate or requiring artificial tears</td>
<td>symptomatic and interfering with activities of daily living</td>
<td>disabled</td>
<td>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</td>
<td>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</td>
<td>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</td>
<td>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</td>
<td>moderate</td>
<td>&gt; 1.5 - 3.0 x ULN</td>
</tr>
<tr>
<td>moderate</td>
<td>-</td>
<td>symptomatic and interfering with activities of daily living</td>
<td>disabled</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe</td>
<td>&gt; 3.0 - 6.0 x ULN</td>
</tr>
<tr>
<td>severe</td>
<td>-</td>
<td>severe</td>
<td>disabled</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe pain: pain or analgesics severely interfering with activities of daily living</td>
<td>severe</td>
<td>&gt; 6.0 x ULN</td>
</tr>
</tbody>
</table>

*Note: Adjust to age-appropriate levels for pediatric patients.*
# NEPHROTOXICITY GRADING

Table 1: Nephrotoxicity Grading: Values

<table>
<thead>
<tr>
<th>Toxicity Grade</th>
<th>GFR</th>
<th>Tm&lt;sub&gt;p&lt;/sub&gt;/GFR</th>
<th>HCO&lt;sub&gt;3&lt;/sub&gt;</th>
<th>EMUO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age &lt; 1 yr</td>
<td>Age = 1 yr</td>
<td>Age &lt; 1 yr</td>
<td>Age = 1 yr</td>
</tr>
<tr>
<td>0</td>
<td>= 90</td>
<td>= 1.10</td>
<td>= 1.00</td>
<td>= 18</td>
</tr>
<tr>
<td>1</td>
<td>60-89</td>
<td>0.90 – 1.09</td>
<td>0.80 – 0.99</td>
<td>15.0 – 17.9</td>
</tr>
<tr>
<td>2</td>
<td>40-59</td>
<td>0.70 – 0.89</td>
<td>0.60 – 0.79</td>
<td>12.0 – 14.9</td>
</tr>
<tr>
<td>3</td>
<td>20-39</td>
<td>No symptoms but</td>
<td>0.60 – 0.69</td>
<td>0.50 – 0.59</td>
</tr>
<tr>
<td>4</td>
<td>= 19</td>
<td>HR or Myopathy or</td>
<td>&lt; 0.60</td>
<td>&lt; 0.50</td>
</tr>
</tbody>
</table>

Tm<sub>p</sub>/GFR = Renal threshold for Phosphate (mmol/l) which is calculated as:

\[
\text{Tm}_p/GFR = \frac{\text{PO}_{4,\text{Plasma}}}{\text{Creatinine}_{\text{Plasma}}} - \frac{\text{PO}_{4,\text{Urine}}}{\text{Creatinine}_{\text{Urine}}}.
\]

EMOU: Early Morning Urine Osmolarity (mOsm/kg)

HR: Hypophosphatemic Rickets: Defined by biochemistry (moderate or severely hypophosphatemia: < 0.90 mmol/l at < 1 year of age, < 0.80 at = 1 year) with either clinical signs (genu valgus, bow legs, rickets rosary, cranial tabes, swollen wrists and ankles, abnormal gait, painful limb) or radiological features (wide epiphysal plate, expanded metaphysis, reduced bone density, secondary hyperparathyreoidism with subperiostal erosion) or with both.

HCMA: Hyperchloremic Metabolic Acidosis: Defined by biochemistry (moderate or severe metabolac acidosis: HCO<sub>3</sub> < 15.0 at < 1 year of age, < 17.0 at = 1 year; usually with moderate or severe hyperchloremia = 112 mmol/l) with or without clinical symptoms (e.g. Kussmaul respiration)

NDI: Nephrogenic Diabetes Insipidus: Defined by clinical symptoms/sings (polyuria, polydipsia, dehydration) with or without biochemistry (moderate or severe hypernatremia < 150 mmol/l) with lack of response to DDAVP (a normal response is defined as a urine osmolality = 800 mOsm/kg).

Table 2: Nephrotoxicity Grading: Total Score

<table>
<thead>
<tr>
<th>Sum scores</th>
<th>Total Score</th>
<th>Extent of nephrotoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFR + Tm&lt;sub&gt;p&lt;/sub&gt;/GFR + HCO&lt;sub&gt;3&lt;/sub&gt; + EMUO</td>
<td>0</td>
<td>No nephrotoxicity</td>
</tr>
<tr>
<td>1-3</td>
<td>Mild nephrotoxicity</td>
<td></td>
</tr>
<tr>
<td>4-7</td>
<td>Moderate nephrotoxicity</td>
<td></td>
</tr>
<tr>
<td>= 8</td>
<td>Severe nephrotoxicity</td>
<td></td>
</tr>
</tbody>
</table>
EpSSG European paediatric Soft Tissue Sarcoma Study Group

RMS & NRSTS 2005
Radiological guidelines

Radiological panel:
- Hervé Brisse (Institut Curie, Paris, France) herve.brisse@curie.net
- Kieran McHugh (Great Ormond Street Hospital, London, UK) kmchugh@gosh.nhs.uk
- Davide Scaramuzza (Instituto Tumouri, Milan, Italy) davide.scaramuzza@istitutotumouri.mi.it

1. Objectives of imaging
- Assessment of tumour extent and possible dissemination
- Biopsy guidance: to define biopsy tract and to choose viable, vascularised tumour, avoiding necrotic areas.
- Defining or excluding residual tumour after surgical excision biopsy: imaging permits depiction of macroscopic residue (imaging cannot accurately depict microspic residue [1]).
- Assessment of initial volume: prognostic value, baseline for further evaluations during chemotherapy.
- Assessment of residual disease after neoadjuvant chemotherapy.
- Assessment for radiotherapy planning.

2. Pre-treatment Evaluation
2.1 Imaging-guided biopsy
- Surgical open biopsy is recommended, but, according to local procedures, US or CT scan-guided core needle biopsies may be appropriate, especially in difficult or inaccessible sites, whereas endoscopic biopsies are appropriate for bladder, prostate or vaginal tumours.
- 18 or 16 Gauge (1.2 – 1.6 mm) needles may be used depending of local procedures. Fine needle aspiration (22 Gauge-0.7 mm) only is not recommended, but additional FNA may provide additional cellular material which can be used for genetical examinations (i.e. DNA ploidy and chromosomal analysis) [2].
- For limb primaries in particular the biopsy tract must contaminate only the anatomical compartment in which the tumour is situated, avoiding major neurovascular structures. Useful anatomical landmarks may be found in the following reference [3].
- For limb or superficial primaries it is recommended the biopsy tract is marked e.g. with ink (tattooing), at the time of biopsy to allow later surgical excision of the tract.
- Local arrangements with the histopathology department should be in place regarding fast transport of fresh tumour biopsy specimens.
Direct fixation must be avoided since no cytogenetic studies are possible when a specimen is placed in formaldehyde, but RPMI medium (Roswel Park Memorial Institute 1640) may be used for specimen transport without jeopardizing genetic studies.

2.2 Imaging techniques and indications
- First locoregional evaluation should be made with MRI. The choice between CT and MR depends also on local availability.
- MRI is preferable for most locations [4, 5], other than the chest [6], including head and neck tumours with possible skull base invasion [7].
- MRI is mandatory for genito-urinary primaries.
- CT is occasionally useful for assessing subtle bone destruction but MRI is sufficient for most head and neck lesions.
- Pre-treatment re-evaluation must be performed after excision biopsy since this can significantly modify initial tumour volume.
- All imaging data should be stored in DICOM format for further review (on CDROM if PACS is not locally available)
- Data transfer on the website (www.essg.cineca.org) is not yet available but is planned to be implemented.

<table>
<thead>
<tr>
<th>TECHNIQUES</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI (or CT) of primary tumour site + initial US if follow-up with US is possible</td>
<td>Will need to be performed (again) after surgical excision biopsy if significant volume resected</td>
</tr>
<tr>
<td>Chest CT</td>
<td>Mandatory in all patients at diagnosis. Intravenous-contrast enhancement is mandatory for limb or abdominal primaries (and ideally for other primaries)</td>
</tr>
<tr>
<td>Abdomen-pelvic CT (during same acquisition as chest CT)</td>
<td>For abdominal, pelvic, paratesticular or lower limb primaries Intravenous-contrast enhancement is mandatory</td>
</tr>
<tr>
<td>Abdomen US</td>
<td>If abdominal CT is equivocal regarding lymphadenopathy or liver metastases</td>
</tr>
<tr>
<td>Radionuclide bone scan</td>
<td>Mandatory in all patients at diagnosis.</td>
</tr>
<tr>
<td>Bone plain films (+/- CT or MRI)</td>
<td>For differential diagnosis if isolated bone uptake on bone scan</td>
</tr>
<tr>
<td>Craniospinal MR</td>
<td>If intraspinal extension or suspected meningeal involvement</td>
</tr>
<tr>
<td>PET-CT</td>
<td>According to local availability and local protocols</td>
</tr>
</tbody>
</table>
2.3 MRI protocol

- Intravenous gadolinium administration (0.2 ml/kg - 0.1 mmol/kg) is mandatory for all MRI examinations (post-contrast T1-weighted sequences should ideally be performed with fat saturation).
- Tumour measurements should be performed on post-gadolinium T1 or T2-weighted sequences (but not on STIR or non-enhanced T1-weighted sequences).
- Fast dynamic sequences (e.g. spoiler 3D T1 : FLASH 3D, VIBE, FSPGR, 3D-FFE, volume RF-FAST) to assess early tumour vascularity are recommended at diagnosis (can help differentiation between vascularized and necrotic areas), after biopsy (helps differentiation between residual disease and fibrosis), and also after chemotherapy (depiction of residual disease) and for suspected relapse (helps differentiation between residual disease and fibrosis) [8].
- Sedation or general anaesthesia for children 6 months-5 years according to local procedures.
- A cutaneous localiser for small superficial lesions or in front of scars on limbs is good practice.

- Additional recommendations according to primary location:

<table>
<thead>
<tr>
<th>Location</th>
<th>Additional Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbit</td>
<td>Bilateral study</td>
</tr>
<tr>
<td></td>
<td>Thin slice width 2-4 mm</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>No sedation if airway obstruction</td>
</tr>
<tr>
<td>Limbs</td>
<td>Surface coil</td>
</tr>
<tr>
<td></td>
<td>Cutaneous localiser</td>
</tr>
<tr>
<td>Cranio-spinal MR</td>
<td>from C0 to S3</td>
</tr>
<tr>
<td></td>
<td>Anterior presaturation</td>
</tr>
</tbody>
</table>

2.4 Technical recommendations for CT scanning

- Apnea if possible for chest and abdominal CT
- 3 to 5 mm reconstruction slice width
- 100 - 120 kV
- mAs adjusted according to patient size, pitch and rotation time
- Recommended CTDI vol : 5 to 15 mGy according to age, location and local technical options
- Reconstruction filters for soft tissue, bone and lung
- Oral contrast opacification is recommended for all abdominal and pelvic studies.
- Intravenous contrast injection: 1.5-2ml/Kg of iodinated agent (300 or 350 mg Iodine/l); rate : 0.7 to 2 cc/sec, scan delay: 35 - 40 sec.
2.5 Evaluate according to primary location

2.5.1 Initial primary tumour volume

3D tumoural measurements are mandatory (sagittal, coronal and axial)

| Tumour volume is calculated as follows : a x b x c x 0.52 |

2.5.2 Locoregional analysis

- **Head and neck primaries: parameningeal extent** should be specified. Parameningeal tumours are those invading one or more of the following structures: skull base, orbital roof, paranasal sinuses, nasal cavity, nasopharynx, infratemporal fossa, pterygopalatine fossa, parapharyngeal space, middle ear or mastoid. In addition the following are also classified as parameningeal tumours:
  - Tumours involving vessels or nerves with direct intracranial connection (internal carotid or vertebral artery, optic, trigeminal or facial nerve etc).
  - All intracranial and intraspinal tumours (but tumours arising from the paraspinal muscles with intraspinal extension should be designated as paraspinal)
  - All tumours with cranial nerve paresis
  - CSF tumour cell positive patients

- **Genito-urinary primaries**: assess bladder wall extension, prostatic, vaginal, uterine, ischio-rectal fossa spread [9]

- **Paraspinal locations**: Intraspinal evaluation mandatory: perform craniospinal MR.

2.5.3 Lymph nodes.

**Comment**: Defining lymph nodal spread of tumour is critical to staging [10], although accurately evaluating pathological lymph node (LN) extension of tumour can be problematic.

- Oval shaped nodes (with a preserved hilum at sonography) and a short axis diameter of less than 1cm are considered normal nodes.
- Locoregional nodes which show only peripheral enhancement on CT or MRI (probable necrotic centres) are likely to be involved by tumour also, even if less than 1 cm axis.
- Mildly enlarged locoregional nodes pose a diagnostic challenge but when round in shape, over 1.5-2 cm in short axis with a heterogenous appearance are likely invaded by tumour.
- All suspicious lymph nodes merit biopsy or another form of nodal sampling.
- Sampling of loco-regional nodes is mandatory for all limb primaries (regardless of imaging findings).
Regional lymph nodes are defined as those appropriate to the site of the primary tumour:

<table>
<thead>
<tr>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head &amp; Neck</td>
<td>Ipsilateral cervical and supraclavicular lymph nodes</td>
</tr>
<tr>
<td></td>
<td>Bilateral adenopathy may be present with centrally situated tumours</td>
</tr>
<tr>
<td>Orbit</td>
<td>Ipsilateral jugular, pre-auricular, cervical</td>
</tr>
<tr>
<td>Intrathoracic</td>
<td>Internal mammary, mediastinal nodes</td>
</tr>
<tr>
<td>Thoracic wall</td>
<td>Axillary, internal mammary, infraclavicular nodes</td>
</tr>
<tr>
<td>Intraabdominal &amp; Pelvic</td>
<td>Sub diaphragmatic, intra abdominal and iliac lymph nodes according to site.</td>
</tr>
<tr>
<td>Abdominal wall</td>
<td>Iliac nodes (external, internal and common chains; note that paraaortic nodes are second level nodes).</td>
</tr>
<tr>
<td>Bladder Prostate</td>
<td>Iliac nodes (external, internal and common chains; note that paraaortic nodes are second level nodes).</td>
</tr>
<tr>
<td>Cervix and Uterus</td>
<td>Iliac nodes (external, internal and common chains)</td>
</tr>
<tr>
<td>Paratesticular</td>
<td>External iliac and para-aortic (retroperitoneal) lymph nodes at renal artery or below (inguinal if the scrotum is involved)</td>
</tr>
<tr>
<td>Vagina</td>
<td>Iliac nodes (external, internal and common chains; note that paraaortic nodes are second level nodes).</td>
</tr>
<tr>
<td>Vulva</td>
<td>Iliac nodes (external, internal and common chains)</td>
</tr>
<tr>
<td>Perineum</td>
<td>Iliac nodes (may be bilateral)</td>
</tr>
<tr>
<td>Upper Limbs</td>
<td>Axillary lymph nodes (epitrochlear rarely involved)</td>
</tr>
<tr>
<td>Lower Limbs</td>
<td>Iliac lymph nodes (popliteal rarely involved)</td>
</tr>
</tbody>
</table>

Locoregional LN extension should be differentiated from distant LN which are considered as true metastases. (Regional lymph node involvement is defined N1 according to TNM system).

Evidence of nodal involvement different than those listed above must be interpreted as distant metastasis and the patient must be treated according to the protocol for patients with metastases at diagnosis.

Examples:
- Perineal tumour with nodes above the pelvis
- Thigh tumour with iliac or periaortic nodes
- Intrathoracic tumour with subdiaphragmatic nodes
- Unilateral tumour with contralateral involved lymph nodes (except in the head and neck).

2.5.4 Pulmonary metastases

Comment: Defining pulmonary spread of tumour is critical to staging, although differentiation between metastatic or benign nodules (i.e. granulomatous disease, hamartoma, intrapulmonary lymph nodes, bronchiolitis…) can be impossible [11-17]. Several criteria are commonly used to diagnose metastatic lesions: number, size, morphology (non-calcified, round and well-defined) and location (inferior lobes, subpleural spaces, vessels-branching). Actually, no radiological criterion has a 100% specificity.

For EpSSG studies, the following patterns will be considered as metastatic pulmonary disease (assuming there is no other clear medical explanation for these lesions):
- One or more pulmonary nodules of 10 mm or more diameter
- Or: two or more well-defined nodules of 5 to 10 mm diameter
- Or: 5 or more well-defined nodules of less than 5 mm

Hence, 4 or less small nodules (< 5mm) at diagnosis will not be considered as pulmonary metastatic disease and should be classified only as “non-specific pulmonary lesions”.

The same lung window settings should be used when pulmonary nodules are being measured at diagnosis and follow-up.

3. Recommendation for imaging dedicated to radiotherapy treatment planning

Pre-radiotherapy scanning with quality assurance assessment will be performed under local arrangements.

4. Imaging during chemotherapy

- Evaluation during treatment should be performed when possible with the same techniques as initially used.
- If the lesion can be completely analysed with sonography (for example, a limb primary), then ultrasound may be used instead of MRI or CT to study the response rate during neoadjuvant chemotherapy.
- MR or CT remains necessary prior to surgery [18-20].

5. Radiological response criteria

- A choice has been made for this study to rely on volume measurements for tumour response assessment. Tumours do not necessarily grow or shrink in a rounded fashion and 3D evaluation may be more accurate than uni or bidimensional criteria [21].
- It is planned to also measure the maximum unidimensional measurement as suggested by the RECIST guidelines and later compare the volume with unidimensional measurements in terms of tumour response [22, 23]. The maximum lesion diameter in any plane should be recorded as the longest tumour diameter, and measurements may be taken from CT or MRI (contrary to the formal RECIST guidance) but the maximum tumour measurement must always be in the same plane (axial, coronal or sagittal).
- The presence or absence of a post-therapeutic residue should be stated in the radiology report [24-26].
- Very good partial response and minor partial response criteria are not recognised international criteria but have been added for this protocol.

Response levels have been adapted to 3D measurements according to published criteria [22].
**Criteria**

<table>
<thead>
<tr>
<th>Complete response</th>
<th>CR</th>
<th>Complete disappearance of tumour with no residual disease (*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>VGPR</td>
<td>Volume response between 90-99%</td>
</tr>
<tr>
<td>Partial response</td>
<td>PR</td>
<td>Volume response of 65-90%</td>
</tr>
<tr>
<td>Minor partial response</td>
<td>Minor PR</td>
<td>Volume response between 34% and 65%</td>
</tr>
<tr>
<td>Stable disease</td>
<td>SD</td>
<td>No criteria for PR or PD</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>PD</td>
<td>Volume increase of more than 40% and/or new lesions</td>
</tr>
</tbody>
</table>

**Note:**

*Residual disease* should be defined as macroscopic measurable residue. Residual ill-defined areas of high density on CT-scan, or residual signal abnormalities on MR such as low intensity on T1WI, high intensity on T2WI and ill-defined margins of enhancement areas are commonly observed after chemotherapy. If no measurable mass, these may be regarded as post-therapeutic residue, and should not exclude the classification as CR.

---

**Note:** Relationship between change in diameter, product and volume (from [22])

<table>
<thead>
<tr>
<th>Response</th>
<th>Diameter (r)</th>
<th>Product (2r^2)</th>
<th>Volume (4/3πr^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease</td>
<td>30%</td>
<td>50%</td>
<td>65%</td>
</tr>
<tr>
<td>50%</td>
<td>75%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>Increase</td>
<td>12%</td>
<td>25%</td>
<td>40%</td>
</tr>
<tr>
<td>20%</td>
<td>44%</td>
<td>73%</td>
<td></td>
</tr>
<tr>
<td>25%</td>
<td>56%</td>
<td>95%</td>
<td></td>
</tr>
<tr>
<td>30%</td>
<td>69%</td>
<td>120%</td>
<td></td>
</tr>
</tbody>
</table>

---

6. Investigations at the end of treatment

   Chest X-ray
   initial location: CT or MR (and US for abdominal primaries)

7. Follow-up after the end of treatment

**First year:**

- Every 3 months: Chest X-ray, initial location CT or MR

**Note:** using MR, T2-weighted and post-contrast T1-weighted sequences are of important predictive values for local relapse depiction [27]
2nd and 3rd year:
Every 4 months: Chest X-ray, initial location CT or MR

4th and 5th years:
Every 6 months: Chest X-ray, initial location CT or MR or US

References:


EpSSG NRSTS 2005 Protocol: Pathology guidelines

**EpSSG Pathology Panel:**

- Professor Vito Ninfo (Italy)
- Dr Anna Kelsey (UK) Co-Chairpersons
- Dr Rita Alaggio (Italy)
- Dr Ivo Leuschner (Germany)
- Dr Dominique Ranchere – Vince (France)
- Dr Núria Torán (Spain)
- Dr J. Bras (The Netherlands)

**National Co-ordinators:**

Dr A Kelsey  
Royal Manchester Children’s Hospital  
U.K.  
Dept. of Pathology, Hospital Road,  
Pendlebury, Manchester, M27 4HA.  
e-mail: anna.kelsey@cmmc.nhs.uk

Dr R Alaggio/Professor V Ninfo  
Azienda Ospedaliera – Università di Padova  
Italy  
Via A. Gabelli, 61  
35128 Padova.  
e-mail: ral@unipd.it  
vito.ninfo@unipd.it

Dr I Leuschner  
Institut für Paidopathologie  
Germany  
Klinikum der Christian-Albrechts, Universität zu Kiel  
Michaelstrasse 11, D-24105 Kiel  
e-mail: ileuschner@path.uni-kiel.de

Dr N Torán Fuentes  
Hospital Universitàri Vall d’Hebron  
Spain  
Passeig Vall d’Hebron 119-129, 08035 Barcelona.  
e-mail: ntoran@cs.vhebron.es

Dr D Ranchere-Vince  
Département de pathologie, Centre Léon Bérard,  
France  
28 rue Laënnec, 69373 Lyon, cedex 08.  
e-mail: rancherd@lyon.fnclcc.fr

Dr J Bras  
Academic Medical Centre Amsterdam  
Netherlands  
Dept. of Pathology, Room M2-259, Postbus 22660,  
1100 DD Amsterdam.  
e-mail: j bras@amc.uva.nl
1. GENERAL REMARKS

Role of the pathologist in a participating centre:

The local pathologist has an essential role in both the clinical trial and the prospective study. The correct histopathological classification is crucial for the appropriate treatment of patients.

1. The diagnosis of Soft Tissue Sarcoma (STS) and subtyping is made by the local pathologist.

2. The local pathologist needs to consider the appropriate handling and triage for diagnosis, assessment of prognosis, determination of pathologic stage, and the assessment of therapeutic response.
3. The pathologist needs to liaise with the molecular biology laboratories so that appropriate molecular diagnostics are carried out.

4. The local pathologist has a key role in coordinating tissue banking.

5. Material needs to be sent to the national coordinator as soon as possible following biopsy or resection.

The national coordinators and the EpSSG panel of pathologists are willing to offer real time review for all STS. In cases where there is a discrepancy between the local pathology diagnosis and the molecular diagnostic result, rapid central review is mandatory.

2. CLASSIFICATION AND DIAGNOSIS OF SOFT TISSUE SARCOMAS

This is not meant to be a comprehensive review.
For full description refer to the following texts:
2. Diagnostic Soft Tissue Pathology, Markku Miettinen
3. Pathology and Genetics. Tumours of Soft Tissue and Bone. WHO Classification of Tumours.

Soft Tissue Tumours are a diverse group of benign, malignant and borderline malignant (intermediate malignant) tumours. Most of them arise from, or show differentiation towards, mesenchymal cells, but some are of neuroectodermal, epithelial or haematolymphatic origin. The accepted basis for soft tissue tumour classification is the World Health Organisation.

2.1. WHO Classification of Soft Tissue Tumours

(from the Working Group of the Editorial and Consensus Conference, Lyon, France, April 24-28, 2002)

ADIPOCYTIC TUMOURS

Benign
Lipoma
Lipomatosis
Lipomatosis of nerve
Lipoblastoma / Lipoblastomatosis
Angiolipoma
Myolipoma
Chondroid lipoma
Extra-renal angiomyolipoma
Extra-adrenal myelolipoma
Spindle cell / Pleomorphic lipoma
Hibernoma

Intermediate
Atypical lipomatous tumour / Well differentiated liposarcoma

Malignant
Dedifferentiated liposarcoma
Myxoid liposarcoma
Round cell liposarcoma
Pleomorphic liposarcoma
Mixed-type liposarcoma
Liposarcoma, not otherwise specified

FIBROBLASTIC / MYOFIBROBLASTIC TUMOURS

Benign
Nodular fasciitis
Proliferative fasciitis
Proliferative myositis
Myositis ossificans
Fibro-osseous pseudotumour of digits
Ischaemic fasciitis
Elastofibroma
Fibrous hamartoma of infancy
Myofibroma / Myofibromatosis
Fibromatosis colli
Juvenile hyaline fibromatosis
Inclusion body fibromatosis
Fibroma of tendon sheath
Desmoplastic fibroblastoma
Mammary-type myofibromatoma
Calciﬁying aponeurotic ﬁbroma
Angiomyoﬁbroblastoma
Cellular angioﬁbroma
Nuchal-type ﬁbroma
Gardner ﬁbroma
Calciﬁying ﬁbrous tumour
Giant cell angioﬁbroma

Intermediate (locally aggressive)
Superﬁcial ﬁbromatoses (palmar / plantar)
Desmoid-type ﬁbromatoses
Lipofibromatosis

Intermediate (rarely metastasizing)
Solitary ﬁbrous tumour and haemangiopericytoma (incl. lipomatous haemangiopericytoma)
Inﬂammatory myofibroblastic tumour
Low grade myofibroblastic sarcoma
Myxoinﬂammatory ﬁbroblastic sarcoma
Infantile ﬁbrosarcoma
Malignant
Adult fibrosarcoma
Myxofibrosarcoma
Low grade fibromyxoid sarcoma / hyalinizing spindle cell tumour
Sclerosing epithelioid fibrosarcoma

SO-CALLED FIBROHISTIOCYTIC TUMOURS

Benign
Giant cell tumour of tendon sheath
Diffuse-type giant cell tumour
Deep benign fibrous histiocytoma

Intermediate (rarely metastasizing)
Plexiform fibrohistiocytic tumour
Giant cell tumour of soft tissues

Malignant
Pleomorphic ‘MFH’ / Undifferentiated pleomorphic sarcoma
Giant cell ‘MFH’ / Undifferentiated pleomorphic sarcoma with giant cell
Inflammatory ‘MFH’ / Undifferentiated pleomorphic sarcoma with prominent inflammation

SMOOTH MUSCLE TUMOURS

Benign
Angioleiomyoma
Deep leiomyoma
Genital leiomyoma

Malignant
Leiomyosarcoma

PERICYTIC (PERIVASCULAR) TUMOURS

Benign
Glomus tumour (and variants)

Intermediate
Myopericytoma

Malignant
Malignant glomus tumour

SKELETAL MUSCLE TUMOURS

Benign
Rhabdomyoma (adult type, fetal type, genital type)

Malignant
Embryonal rhabdomyosarcoma (incl. spindle cell, botryoid, anaplastic)
Alveolar rhabdomyosarcoma (incl. solid, anaplastic)
Pleomorphic rhabdomyosarcoma
VASCULAR TUMOURS

Benign
Haemangiomas (of subcut/deep soft tissue, capillary, cavernous, arteriovenous, venous, intramuscular, synovial)
Epithelioid haemangioma
Angiomatosis
Lymphangioma

Intermediate (locally aggressive)
Kaposiform haemangioendothelioma

Intermediate (rarely metastasizing)
Retiform haemangioendothelioma
Papillary intralymphatic angioendothelioma
Composite haemangioendothelioma
Kaposi sarcoma

Malignant
Epithelioid haemangioendothelioma
Angiosarcoma of soft tissue

CHONDRO-OSSEUS TUMOURS

Benign
Soft tissue chondroma

Malignant
Mesenchymal chondrosarcoma
Extraskeletal osteosarcoma

TUMOURS OF UNCERTAIN DIFFERENTIATION

Benign
Intramuscular myxoma (incl. cellular variant)
Juxta-articular myxoma
Deep (‘aggressive’) angiomyxoma
Pleomorphic hyalinizing angiectatic tumour
Ectopic hamartomatous thymoma

Intermediate (rarely metastasizing)
Angiomatoid fibrous histiocytoma
Ossifying fibromyxoid tumour (incl. atypical / malignant)
Mixed tumour / Myoepithelioma / Parachordoma

Malignant
Synovial sarcoma
Epithelioid sarcoma
Alveolar soft part sarcoma
Clear cell sarcoma of soft tissue
Extraskeletal myxoid chondrosarcoma (“chordoid” type)
Extraskeletal Ewing tumour / pPNET
Desmoplastic small round cell tumour
Extra-renal rhabdoid tumour
Malignant mesenchymoma
Neoplasms with perivascular epithelioid cell differentiation (PEComa) / clear cell myomelanocytic tumour
Intimal sarcoma.

2.2. HISTOTYPES

The following is a brief review of the most common and sometimes challenging soft tissue sarcomas.

Synovial sarcoma
These tumours account for 5-10% of soft tissue sarcomas and 42% of paediatric non-rhabdomyosarcoma soft tissue sarcomas. 85-95% of all synovial sarcomas arise in the extremities with the second most common site being the head and neck region. Synovial sarcomas also arise in the trunk including the chest wall and abdominal wall. However, synovial sarcomas have been described at virtually every anatomic site including the skin, heart, kidney and lung. The peak incidence is in the second decade.

In its classical form synovial sarcoma is biphasic and consists of clearly distinguishable spindle cell and epithelial or glandular areas. Monophasic either spindle or epithelial patterns are recognised. Poorly differentiated synovial sarcomas may have a spindle cell appearance or a round/oval cell pattern that mimics other ‘small blue cell neoplasms’.

The diagnosis of biphasic synovial sarcoma does not pose a problem, but the diagnostic challenges increase when dealing with the monophasic spectrum and poorly differentiated subtypes and in limited biopsy material. The immunohistochemistry profile does overlap with malignant peripheral nerve sheath tumour and primitive neuroectodermal tumour.

The spindle cell component of synovial sarcoma can be immunoreactive for CD57, CD56, S100, Cytokeratin and Epithelial Membrane Antigen (EMA). The epithelial or glandular areas are immunoreactive for high and low weight Cytokeratin and EMA. As some synovial sarcomas stain for EMA but not Cytokeratin and vice versa, both markers should be used. In some monophasic synovial sarcomas it may be necessary to stain multiple sections for those markers. CD99 can be detected in the cytoplasm or membrane of cells in 60-70% of synovial sarcomas and bcl-2 protein has been reported in 75-100% of cases.

Synovial sarcoma is characterised by a translocation t(X;18)(p11.2; q11.2) which is found in more than 90% of cases. There are three possible transcripts, SYT-SSX1, SYT-SSX2 and SYT-SSX4. The SYT-SSX2 has been recently associated with better survival.

Malignant peripheral nerve sheath tumour (MPNST)
This diagnosis has always been regarded as ‘difficult’ due to the lack of standardised diagnostic criteria. However, it is now considered essential that one of the following criteria is met:
a. the tumour arises from a peripheral nerve
b. arises in a pre-existing benign nerve sheath tumour, usually a neurofibroma, or in connection with NF1.
c. the tumour shows histologic features that are seen in the above tumours and reflects schwann cell differentiation.

The tumour occurs in all ages from early childhood but is most common in middle age. Grossly the tumour has an oval or fusiform mass arising from a nerve and usually measures more than 10 cm. Histologically, MPNSTs are high-grade tumours with high mitotic rate and necrosis. A number of patterns are recognised, the most common being a high-grade fibro-sarcomatous pattern. Many tumours have large irregular areas of necrosis and vascular proliferation, the tumour cells forming perivascular collars. Few cases of MPNST show extensive S100 positivity, many show focal positivity. The presence of desmin or actin usually reflects the presence of heterologous rhabdomyoblastic differentiation (Triton tumour). Focal Keratin K8 and K18 positivity is quite common, but K7 and K19 are absent. Considering that synovial sarcoma can also be S100 protein positive, immunohistochemical results need to be interpreted with caution and molecular diagnostics are useful in the differential diagnosis.

**Alveolar soft part sarcoma**

This sarcoma has a female preponderance occurring in the first two decades of life but also in children. When the tumour occurs in infants and children it is often located in the region of the head and neck, especially the orbit and tongue.

The histologic features are distinctive. The immunohistochemical profile is non-specific with variable reactivity for Vimentin, Desmin and S100 protein. A non-balanced translocation, t(x;17), has been described. The differential diagnosis includes alveolar RMS, epithelioid, paraganglioma and adenocarcinoma.

**Malignant rhabdoid tumour of soft tissues**

This tumour, first described in the kidney, has also been reported in the central nervous system, soft tissues, skin and other sites. This diagnosis should only be made in tumours in which there is a predominant rhabdoid morphology and in which no other morphologic evidence of differentiation is seen. These tumours are more common in children. Congenital disseminated malignant rhabdoid tumour with cutaneous involvement and abnormalities of chromosome 22q11 has been reported in infants. The immunohistochemical profile is polyphenotypic with both mesenchymal and epithelial features characterised by reactivity for Vimentin, Cytokeratin, EMA, NSE, S100, CD99, CD34 and Synaptophysin. The hSNF5/INI 1 gene has been reported to be mutated in rhabdoid tumours.

**Desmoplastic small round cell tumour (DSRCT)**

This tumour primarily affects children and young adults, usually presenting with widespread abdominal involvement, frequently located in the retroperitoneum, pelvis, omentum and mesentery. It does occur in thoracic cavity and paratesticular sites.

The microscopic appearance is characteristic with nests of undifferentiated tumour cells surrounded by abundant fibrous stroma. The following features have been observed in some tumours:

- Central necrosis of large tumour nests.
- Cords of cells surrounded by dense fibrous stroma.
- Rhabdoid-like foci.
- Cells with signet ring-like appearance.
Other unusual features include Homer-Wright-like rosettes, papillary areas, transitional carcinoma-like areas and spindle cell areas. Virtually all tumours stain for EMA and Cytokeratin (CK20, CK5 & 6 are negative) and Vimentin. Up to 90% of cases are positive for Desmin with a perinuclear dot-like pattern. Myogenin and MyoD1 are negative. CD99 and NB84a may be positive. WT1 is often expressed as strong nuclear positivity. SCDT is defined by a reciprocal translocation t(11;22)(p13;q12). Occasional cases that clinically and phenotypically appear to be SCDT show the Ewing’s sarcoma phenotype Fli-1/EWS.

**Congenital Infantile Fibrosarcoma (CIFS)**

These tumours usually occur in the distal extremities and the head and neck, mostly diagnosed in the first year of life, some are congenital. The histologic appearance simulates adult-type fibrosarcoma, but the natural history is more like the fibromatosis, with a five-year survival of more than 90% and a recurrence rate of approximately 30%. Metastases are very rare.

These are spindle cell tumours, mitotically very active with interlacing cords, fascicles and even a herring-bone pattern. Collagen formation is common but some cases with a round cell component may have minimal collagen. Focal necrosis, haemangiopericytomatosus pattern, focal extramedullary haematopoiesis and a patchy mononuclear inflammatory cell infiltrate have all been described. A chromosomal translocation t(12;15)(p13;q26) have been identified in these cases. Trisomies for chromosomes 8, 11, 17 and 20 are nearly as characteristic as the translocation. This genetic profile is similar to that described in congenital mesoblastic nephroma.

**Fibroblastic-Myofibroblastic Proliferations of Childhood and Adolescence**

These are an important group of lesions in childhood and adolescence. Diagnostically they can be challenging because of their histologic similarities.

**Inflammatory Myofibroblastic Tumour (IMT)**

This is a pseudosarcomatous lesion that occurs in the viscera and soft tissue of children and young adults. These lesions are lobular or multinodular with a hard cut surface. The tumours range from 2 to 20 cm. Histologically they are composed of spindle or stellate shaped cells in a myxoid or hyaline stroma with scattered inflammatory cells. Some are composed of spindle cells arranged in a more storiform or fascicular growth pattern. Mitotic figures are present but are not atypical. A prominent lymphoplasmacytic infiltrate is usually present. In some lesions there is a pronounced cytologic atypia with spindle cells having large nuclei and distinct nucleoli.

Immunophenotypes of these lesions include diffuse staining for vimentin, muscle actin, and focally for desmin and smooth muscle actin. There is focal cytokeratin positivity in about one third of cases. CD68 is seen in 25% of cases. The lesions are always negative for myoglobin and S-100 protein. A number of intra-abdominal inflammatory tumours show immunohistochemical expression of ALK.

The differential diagnoses include nodular fasciitis, rhabdomyosarcoma and myxoid sarcoma. The more cellular variants of IMT simulate fibrohistiocytic neoplasms, fibromatosis and gastrointestinal stromal tumour.
Desmoid-Type Fibromatosis (Aggressive Fibromatosis)

Desmoid is subclassified by location into abdominal wall, extra-abdominal and mesenteric forms. These lesions vary greatly in size from a small nodule to bulky tumours. They can measure between 3 to 20 cm.

Microscopically they show longitudinally orientated fascicles of spindle fibroblasts and myofibroblasts in a collagenous stroma. This stroma may contain thick keloid-like collagen fibres. The nuclei are oval with delicate nucleoli. Mitotic activity is typically low. The lesions have a prominent, evenly spaced, vascular pattern with ectatic vessels. These tumours may be focally positive for smooth muscle actin and desmin.

The differential diagnoses include nodular fasciitis; this is usually an issue when assessing small biopsies. The lack of lymphohistiocytic infiltrate and the presence of gaping vessels support the diagnosis of desmoid.

The highly cellular lesions, especially those with mitotic activity, have to be separated from fibrosarcoma.

Leiomyosarcoma

These tumours very rarely occur in children; commonly in immuno-suppressed patients. Most of these tumours in immuno-competent children tend to be of low grade with good prognoses. They are spindle cell lesions with longitudinally orientated tumour cells, ‘cigar-shaped’ nuclei and eosinophilic cytoplasm. Some tumours have a myxoid stroma. Although focal pleomorphism is common, some cases show extensive pleomorphism. In some leiomyosarcomas there are foci of osteoclast giant cells and some tumours have cells with granular cytoplasm.

Immunohistochemically, they are positive for smooth muscle actin. Desmin positivity varies. Heavy caldesmon is smooth muscle specific. Some keratins (especially 8 & 18) and EMA are sometimes expressed in these tumours.

Ewing Sarcoma/PNET

These tumours are not being treated in these protocols. However, the differential diagnosis of these tumours includes numerous small round cell tumours. Within the context of soft tissue tumours, rhabdomyosarcoma, especially the alveolar subtype, desmoplastic small cell tumour, myxoid or mesenchymal chondrosarcoma, small cell variant (undifferentiated) synovial sarcoma and malignant rhabdoid tumour need to be considered.
3. IMMUNOHISTOCHEMISTRY

The following list of antibodies is useful when used in ‘Panels’ in the differential diagnosis of soft tissue sarcomas.

**MARKERS**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD31</td>
<td>Angiosarcoma, Kaposi Sarcoma</td>
</tr>
<tr>
<td>CD34</td>
<td>Kaposi Sarcoma, fibroblastic and other tumours</td>
</tr>
<tr>
<td>Fli-1</td>
<td>Ewing’s Sarcoma, Angiosarcoma</td>
</tr>
<tr>
<td>CD99</td>
<td>Ewing’s Sarcoma, Synovial Sarcoma, Lymphoma</td>
</tr>
<tr>
<td>Smooth Muscle Actin</td>
<td>Smooth muscle and myofibroblastic tumours.</td>
</tr>
<tr>
<td>Common Muscle Actin</td>
<td>Smooth and skeletal muscle tumours and myofibroblastic tumours.</td>
</tr>
<tr>
<td>HHF35</td>
<td></td>
</tr>
<tr>
<td>Sarcomerin</td>
<td>Skeletal muscle and RMS.</td>
</tr>
<tr>
<td>Desmin</td>
<td>Smooth and skeletal muscle tumours and some others.</td>
</tr>
<tr>
<td>Calponin</td>
<td>Smooth muscle, myofibroblasts, myoepithelial., Synovial sarcoma (often).</td>
</tr>
<tr>
<td>MyoD1</td>
<td>Rhabdomyosarcoma.</td>
</tr>
<tr>
<td>Myf 4</td>
<td>Rhabdomyosarcoma.</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Neuroblastoma, Paragangioma. Neuroendocrine carcinoma.</td>
</tr>
<tr>
<td>Chromogranin</td>
<td>Paragangioma, Neuroendocrine carcinoma.</td>
</tr>
<tr>
<td>NF protein</td>
<td>Neuroblastoma, Paragangioma, Merkel Cell Ca.</td>
</tr>
<tr>
<td>S100 protein</td>
<td>Melanocytic, Schwannomas, Chondroid, Langerhans cell.</td>
</tr>
<tr>
<td>CD56 (NCAM)</td>
<td>Neuroendocrine Ca., RMS, many other sarcomas.</td>
</tr>
<tr>
<td>HMB45</td>
<td>Melanoma, Clear Cell Sarcoma, Angiomyolipoma.</td>
</tr>
<tr>
<td>Melan A</td>
<td>Naevi, Melanoma, Angiomyolipoma</td>
</tr>
<tr>
<td>CD63</td>
<td>Melanoma, Alveolar Soft Part Sarcoma.</td>
</tr>
<tr>
<td>Lysozyme</td>
<td>Histiocytes, Myelomonocytic cells.</td>
</tr>
<tr>
<td>Antibody</td>
<td>Tissue Types</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>AAT</td>
<td>Histiocytes, many tumours of any lineage.</td>
</tr>
<tr>
<td>AACT</td>
<td>Histiocytes, many tumours of any lineage.</td>
</tr>
<tr>
<td>CD68</td>
<td>Histiocytes, Melanoma, Paraganglioma, Schwannoma, Granular cell tumour.</td>
</tr>
<tr>
<td>Keratins</td>
<td>Synovial and Epithelioid Sarcomas, Carcinomas, Chordoma, Metastatic Melanoma.</td>
</tr>
<tr>
<td>EMA</td>
<td>Synovial Sarcoma, Epithelial Sarcomas, Perineural tumours, and epithelial tumours in general.</td>
</tr>
<tr>
<td>WT protein</td>
<td>DSRCT, Mesothelioma, Ovarian Serous Carcinoma And other tumours.</td>
</tr>
<tr>
<td>ALK 1</td>
<td>Anaplastic lymphomas, Inflammatory myofibroblastic tumours.</td>
</tr>
<tr>
<td>CD10</td>
<td>Endometrial stromal sarcoma.</td>
</tr>
<tr>
<td>CD117 (C-Kit)</td>
<td>GI stromal tumours, Mast cell neoplasms, Ewing’s Sarcoma, Neuroblastoma, Seminoma/Dysgerminoma, Clear Cell Sarcoma, Adenoid Cystic Carcinoma and some other carcinomas.</td>
</tr>
<tr>
<td>GFAP</td>
<td>Glial tumours, Schwannomas, Myoepithelial tumours.</td>
</tr>
</tbody>
</table>
### 4. COMMON TRANSLOCATIONS IN SOFT TISSUE SARCOMAS

<table>
<thead>
<tr>
<th>Histological classification</th>
<th>Translocated Chromosomes</th>
<th>Genes Fused</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALVEOLAR Rhabdomyosarcoma</td>
<td>t(2;13)(q35;q14)</td>
<td>PAX3/FKHR</td>
</tr>
<tr>
<td></td>
<td>t(1;13)p36;q14</td>
<td>PAX7/FKHR</td>
</tr>
<tr>
<td>Ewing's/PNET</td>
<td>t(11;22)(q24;q12)</td>
<td>FLI1/EWS</td>
</tr>
<tr>
<td></td>
<td>t(21;22)(q22;q12)</td>
<td>ERG/EWS</td>
</tr>
<tr>
<td></td>
<td>t(17;22)(q12;q12)</td>
<td>E1A/EWS</td>
</tr>
<tr>
<td></td>
<td>t(7;22)(p22;q12)</td>
<td>ETV1/EWS</td>
</tr>
<tr>
<td>DSRCT</td>
<td>t(11;22)(p13;q12)</td>
<td>WT1/EWS</td>
</tr>
<tr>
<td>Myeloid leukaemia</td>
<td>t(16;21)</td>
<td>TLS/ERG</td>
</tr>
<tr>
<td>Myxoid liposarcoma</td>
<td>t(12;16)(q13;p11)</td>
<td>CHOP/TLS</td>
</tr>
<tr>
<td>Malignant melanoma of soft parts (Clear cell sarcoma)</td>
<td>t(12;22)(q13;q12)</td>
<td>ATF1/EWS</td>
</tr>
<tr>
<td>Myxoid chondrosarcoma</td>
<td>t(9;22)(q22;q12)</td>
<td>CHN/EWS</td>
</tr>
<tr>
<td></td>
<td>t(9;15)(q22;21)</td>
<td>CHN/TFC12</td>
</tr>
<tr>
<td>Congenital fibrosarcoma/congen. mesoblastic nephroma</td>
<td>t(12;15)(p13;q25)</td>
<td>ETVG(TEL)/NTRK3</td>
</tr>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>t(X;17)(p11;q25)</td>
<td>TFE3/ASPL</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>t(X;18)(p11;q11)</td>
<td>SYT/SSX1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SYT/SSX2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SYT/SSX4</td>
</tr>
<tr>
<td>Inflammatory myofibroblastic tumour</td>
<td>t(1;2)(q25;p23)</td>
<td>TPM3/ALK</td>
</tr>
<tr>
<td>Dermatofibrosarcoma protuberans</td>
<td>t(2;19)(p23;q13)</td>
<td>ALK/TPM4</td>
</tr>
<tr>
<td>Endometrial stromal sarcoma</td>
<td>t(17;22)(q22;q13)</td>
<td>ALK/CLTC</td>
</tr>
<tr>
<td></td>
<td>t(7;17)(p15;q21)</td>
<td>COL1A1/PDGFB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JAZF1/JIAZ1</td>
</tr>
</tbody>
</table>
5. THE GRADING OF NRSTS

The grading of NRSTS represents one of the most debated and complex subjects concerning the information that the pathologist must give to the clinician.

The grade of malignancy usually describes the aggressiveness of the tumour and its natural history. It is determined by a combined assessment of histological features 1) degree of cellularity, 2) cellular pleomorphism or anaplasia, 3) mitotic activity, 4) degree of necrosis. Generally, low grade tumours usually have local aggressiveness but low tendency to metastatic spread. High grade tumours are more frequent and have a more invasive behaviour with high propensity to metastasise. Some histotypes (i.e. synovial sarcoma, alveolar sarcoma, angiosarcoma) should be considered as high grade independently from mitotic index, necrosis and cellularity.

Different grading systems (generally three-grade systems) have been defined over the years by paediatric and adult oncologists for predicting clinical course and prognosis, and defining a risk-adapted treatment. Unfortunately, a universally accepted grading system does not exist. The most used grading systems (POG System for paediatric sarcomas and FFCLCC System for adult sarcomas) suffer from many limitations due to their low reproducibility and the high rate of error. Furthermore recent advances in classification of some entities such as infantile hemangiopericytoma, now included in the group of myofibroma-myofibromatosis, are not taken into account in the POG classification.

The application of any grading system must take into account the following considerations:
- Grading should be used only in pre-treatment tumours
- Samples must be well preserved and representative of the whole lesion. Tru-cut biopsies represent a limitation and can give only a “minimum” grade due to sampling.
- Grading must be applied only after a precise diagnosis of histotype. The grading cannot be used instead of a correct diagnosis of histotype. In fact for some histotypes the diagnosis per se identifies an high grade neoplasia and does not need further grading. Other sarcomas (such as Epithelioid sarcoma, Alveolar soft part sarcoma, Clear cell sarcoma, Angiosarcoma, extraskletal myxoid chondrosarcoma) have a biological course not predictable by any morphological parameter evaluated by the classic grading systems.

For the purpose of this study both the POG and the FFCLCC grading systems will be evaluated. Moreover, a new “proposed” EpSSG grading system will be evaluated to compare with other grading schemes. This will not be used for patient stratification in this trial.

?? For patient stratification, the FFCLCC grading system will be used
POG (Pediatric Oncology Group) (Parham et al. Modern Pathol 1995;8:705-710)

3 grades based on histopathologic subtype, amount of necrosis, number of mitoses, and cellular pleomorphism

**grade 1**
- myxoid and well-differentiated liposarcoma
- well-differentiated or infantile (age < 4 yrs) fibrosarcoma
- well-differentiated or infantile (age < 4 yrs) hemangiopericytoma
- well-differentiated malignant peripheral nerve sheath tumour
- angiomatoid malignant fibrous histiocytoma
- deep seated dermatofibrosarcoma protuberans
- myxoid chondrosarcoma

**grade 2**
- soft tissue sarcomas in which:
  - <15% of the surface area shows necrosis
  - mitotic count < 5/10 high power fields using a 40x objective
  - nuclear atypia not marked
  - tumour not markedly cellular

**grade 3**
- pleomorphic or round cell liposarcoma
- mesenchymal chondrosarcoma
- extraskeletal osteogenic sarcoma
- malignant triton tumour
- alveolar soft part sarcoma
- any other sarcoma not in grade 1, with > 15% necrosis, or > 5 mitoses/10 HPF using a 40x
FNCLCC (French Federation of Cancer Centers Sarcoma Group)

**Differentiation**

1 – well-differentiated liposarcoma, well-differentiated fibrosarcoma, well-differentiated malignant schwannoma, well-differentiated leiomyosarcoma, well-differentiated chondrosarcoma

2 – myxoid liposarcoma, conventional fibrosarcoma, conventional malignant schwannoma, well-differentiated malignant hemangiopericytoma, myxoid malignant fibrous histiocytoma, pleomorphic malignant fibrous histiocytoma, conventional leiomyosarcoma, myxoid chondrosarcoma, conventional angiosarcoma

3 – round-cell liposarcoma, pleomorphic liposarcoma, dedifferentiated liposarcoma, poorly differentiated fibrosarcoma, poorly differentiated malignant schwannoma, epithelioid malignant schwannoma, malignant triton tumour, conventional malignant hemangiopericytoma, giant cell and inflammatory malignant fibrous histiocytoma, poorly differentiated/pleomorphic/epithelioid leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, mesenchimal chondrosarcoma, poorly differentiated/epithelioid angiosarcoma, extraskeletal osteosarcoma, Ewing’s sarcoma/pPNET, alveolar soft tissue sarcoma, epithelioid sarcoma, malignant rhabdoid tumour, clear cell sarcoma, undifferentiated sarcoma

**Mitotic index**

1 (0-9 mitoses per 10 HPF)
2 (10-19)
3 (>19)

**Tumoural necrosis**

0 – no necrosis on any examined slides
1 <50% of necrosis
2 >50% of necrosis

grade 1 – score 2-3
grade 2 – score 4-5
grade 3 – score 6-8
**EpSSG proposal**

**Low Grade Tumours (Intermediate Malignancy)**

- Infantile Fibrosarcoma
- Myxoid Liposarcoma without round cell component
- Myxoid Chondrosarcoma
- Giant-cell Fibroblastoma/ Dermatofibrosarcoma protuberans
- Angiomatoid Fibro-histiocytic tumour
- Plexiform Fibro-histiocytic tumour
- Low grade myofibroblastic sarcoma
- Inflammatory Myofibroblastic tumour

**High Grade Tumours**

- Ewing Sarcoma/PNET
- Mesenchimal Chondrosarcoma
- Intraabdominal desmoplastic small round cell tumour
- Extra-renal rhabdoid tumour
- Epithelioid Sarcoma-proximal type
- Myxoid liposarcoma with round cells (>25% round cells)

**Tumours “graded” according to FFCLCC**

- “Adult” Fibrosarcoma
- Leiomyosarcoma
- Malignant Peripheral Nerve Sheath Tumour
- Undifferentiated polymorphic sarcoma
- Monophasic Synovial Sarcoma

**Tumours not “graded” (with metastatic potential)**

- Alveolar Soft Part Sarcoma
- Epithelioid Sarcoma- “Classic type”
- Biphasic Sinovial Sarcoma
- Low-Grade Fibro-myxoid Sarcoma
- Angiosarcoma
- Epithelioid Hemangioendothelioma
6. HANDLING OF SPECIMENS

The type of surgical procedure influences the handling of the specimen and the extent of information that can be gained from its pathological examination.

**Important** - Please note, specimens should be received fresh in the laboratory. It is important that the surgeon/oncologist liaises with the pathologist to ensure that fresh specimens can be received fresh in the laboratory.

**Biopsy**
Open biopsy is recommended to ensure sufficient material is available for:
1. Diagnosis
2. Molecular characterisation/research (see schematic diagram)

**Resected Specimens** (read surgical guidelines for definition of primary resection - primary re-operation - secondary operation)

All primary and post-chemotherapy resection specimens need margins to be evaluated by the pathologist.

- Surface of specimen should be inked before incision.
- Specimen should be weighed and measured (in 3 dimensions).
- Orientation of specimen is important – this may need to be done with the surgeon. The distance of tumour from the minimum nearest resection margin is important. In resected specimens tumour depth e.g. dermal, subcutaneous, subfascial, intramuscular, needs to be specified macroscopically and microscopically.
- Ideally the specimen should be photographed, including the cut surface, and a block guide prepared.
- At least a block per centimetre of greatest tumour diameter needs to be sampled. However, it is strongly recommended that, where feasible, the entire specimen should be processed to ensure adequacy of excision, and in post-chemotherapy specimens to assess percentage of necrosis.
- The cut surface(s) should be examined and the pathologist should sample as above as well as taking blocks from areas which look macroscopically different in consistency or texture from other areas, in particular take note of nodularity and sample.
- Document macroscopic % of necrosis – sample areas of necrosis.
- The pathologist should assess what tissue has been kept for molecular diagnostics/research. This can be done in one of two ways, either A – do a frozen section from the cut surface to assess i) tumour is present and ii) tumour is not necrotic, or B – a paraffin section, identified as representative section of tissue sent for molecular diagnostics/research can be taken and assessed as per frozen section.
- Lymph nodes - please note – site of lymph nodes sampled should be documented as this is important in staging. All lymph nodes received by the pathologist should be examined. The entire lymph node or lymph nodes should be processed to ensure accurate assessment. Multiple levels need to be examined to exclude micro metastases.
- Molecular characterisation (see schematic diagram)
6.1. HANDLING OF SPECIMENS

1. Fresh Biopsy

Send Tissue to Biology Laboratory

- Tissue culture for karyotyping
- Tissue to RNase-free microtubes for RNA extraction
- Touch preps: fresh cut surface of tumours touched onto clean glass slides and air dried for >2 hours then fixed for 10 min. in methanol for use as FISH target
- Snap freeze for long term storage in liquid nitrogen

Fix in formalin for histology, Immunohistochemistry (see Pathology Guidelines)

In some national groups pathology and biology labs may be organised differently than in other countries and this may influence the procedures for optimising biological studies and/or collection and storage of specimens

NB: The pathologist needs to document what tissue has been sent for molecular diagnostic/research. The pathologist should be informed by the oncologist if consent has been obtained for storage of material for research. We strongly recommend that each centre has a system set up whereby the pathologist is informed in writing that consent has been given. It is up to individual centres to ensure that this is taking place. We also strongly recommend that consent is obtained prospectively and not retrospectively.

In most cases the pathologists will receive biopsy material. It is important that such specimens are received fresh, promptly in the laboratory and handled only by pathologists who will decide on how the specimen can be divided. Please note treatment depends on good histological diagnosis and therefore this should not be compromised for molecular studies. This, however, is at the discretion of the local pathologists.
6.2. HANDLING OF SPECIMENS

2. Resected Specimens

- Tissue culture for Karyotyping
- Tissue to RNase-free microtubes for RNA extraction
- Touch preps: fresh cut surface of tumours touched onto clean glass slides and air dried for >2 hours then fixed for 10 min. in methanol for use as FISH target
- Snap freeze for long term storage in liquid nitrogen

(priorities may vary depending on the tumour type)

Please note, inking of specimens is very important to assess margins. This needs to be done before material for molecular characterisation is taken.

NB: The pathologist needs to document what tissue has been sent for molecular diagnostic/research. See item 8 under handling of specimens. The pathologist should be informed by the oncologist if consent has been obtained for storage of material for research. We strongly recommend that each centre has a system set up whereby the pathologist is informed in writing that consent has been given. It is up to individual centres to ensure that this is taking place. We also strongly recommend that consent is obtained prospectively and not retrospectively.

In resected specimens, inking of the surface, with photograph and documentation of blocks taken will be necessary. Please note treatment depends on good histological diagnosis and therefore this should not be compromised for molecular studies. This, however, is at the discretion of the local pathologists.
HANDLING OF SPECIMENS

3. AMPUTATION OR DISARTICULATION FOR SOFT TISSUE SARCOMAS

PROCEDURE INCLUDES:

Macroscopy

1. Review radiological investigations if available.
2. Measure and describe limb (include measurement between major joints).
3. Measure circumference at level of tumour.
4. Examine skin surface for presence of tumour.
5. Orientate the specimen and cut through the centre of the specimen coronally, sagittally or transversely to give the largest surface area.
6. Measure and describe the tumour with special reference to:
   - Size
   - Encapsulation
   - Colour
   - Consistency
   - Necrosis (estimate %)
   - Gross margins (measured in mm.). Note distance of tumour from the amputation margins.
     Assess involvement of the compartments i.e. muscle groups/fascia etc.
   - Satellite lesions
7. Photograph the cut specimens.
8. Cut perpendicular to original cut noting appearance and closest margins.

Blocks for Histology

1. Take blocks of vessels at amputation margin and sample any lymph nodes present.
2. Sample and record position of closest margin (minimum of posterior, anterior, lateral and medial)
3. Sample tumour including necrotic areas (one block per cm. of tumour)
4. Sample skin to include biopsy tract.
5. Sample neurovascular tissues if present.

Wide Resections – Please note the above descriptions can also be used when dealing with wide resections. In these cases it is extremely important to assess margins macroscopically and microscopically.
7. THE PATHOLOGY REPORT

The following need to be included:

? Macroscopic

Specimen type
- Biopsy – excision or trucut – please state
- Primary resection
- Primary re-operation
- Secondary operation (post-chemotherapy)

Specimen site
- Head/neck
- Bladder/prostate
- Genitourinary (not bladder/prostate)
- Cranial
- Extremity
- Orbit
- Parameningeal
- Other- specify (include trunk, retroperitoneum etc.)
- Not specified

Laterality (as appropriate)

Tumour size
- Three dimensions – specify maximum diameter

? Microscopic

Histologic type
- Example: Congenital infantile fibrosarcoma
- Synovial sarcoma – biphasic
- Synovial sarcoma – monophasic
- Alveolar soft part sarcoma

Sarcoma, not otherwise specified (NOS). Please note this is not a diagnostic group. It indicates that a specific diagnosis cannot be made. This usually arises when the biopsy is very small, but the pathologist can exclude other tumours.

Anaplasia
- Absent
- Focal
- Diffuse
- Indeterminate
Necrosis
Absent
Present
Extent %

Mitotic rate
(x40 objective)
-1/10 high power fields

Regional lymph nodes
None sampled
No regional lymph node metastases
Regional lymph node metastases – specify:
  Site of lymph node
  Number examined
  Number involved

Margins
Cannot be assessed
No tumour at margins – please give distance of sarcoma to nearest margin in mm.
Margins involved by sarcoma – specify.

Note: see the definitions of margins given in the “Surgical section”: > 1 cm of healthy tissue around the tumour in all directions (when the tissue is a muscle), > 1 mm of healthy tissue around the tumour when the tissue is periostium, vessel sheath, epineurium, muscular fascia.

Venous/lymphatic invasion
Present
Absent
Cannot be assessed

Grading of Soft Tissue Sarcoma
Use FNCLCC system

Molecular characterisation
Please note: if molecular characterisation has been undertaken, then this should either be included in the main body of the report or set out as a separate report. A copy of this report needs to be sent to the national coordinator together with the copy of the histology report and form.

Post-chemotherapy specimens
Same procedure as above. It is important to specify the following:
% of necrosis
% of fibrosis
% of viable tumour
8. MATERIAL TO BE SENT TO NATIONAL CO-ORDINATORS

1. In the case of trucut biopsies, both primary and post-chemotherapy, 1 H&E and 15uss (or the loan of the block).

2. In the case of open biopsies/resected specimens, including post-chemotherapy specimens – 1 H&E from each block, and at least 20 uss from representative block(s) (or the loan of the blocks).

3. The uss should be on coated slides to be used for immunohistochemistry.

4. It is important that material from primary biopsy/resection and post-chemotherapy biopsy/resection and biopsy/resection of metastases is sent for review by the local co-ordinator.

5. If in the case of a very small biopsy there is not sufficient material left in the block, please send 1 H&E to be kept by the local co-ordinator and the original H&E and immunohistochemistry slides, which will be returned.

6. It is understandable that these requests create more work for the pathologist and laboratory staff. Therefore, it is possible to send blocks to the local co-ordinator. These will be returned.

7. The local pathologist report and the form need to be sent with the slides.

8. The national co-ordinators and panel of pathologists are offering real time review.

9. The slides/block and forms should be sent directly to the national co-ordinators.

NB: It is very important that we collect prospectively the results of the molecular diagnostics. Each oncology centre/pathology lab. should ensure that, if this cannot be carried out in their centre/lab., arrangements should be made with other laboratories to ensure that, whenever possible, molecular diagnostics are carried out.

In cases where there is a discrepancy between the local pathologist’s evaluation and the molecular diagnostic result, then rapid pathology review is recommended. All results will be sent to the referring pathologist and in case of discrepancy cases will be discussed with the referring pathologist.
References

**EpSSG NRSTS 2005 protocol: Biological aspects**

**EpSSG Biology Committee**
Angelo Rosolen (Italy) – coordinator
John Anderson (UK)
Soledad Gallego (Spain)

**BIOLOGICAL CHARACTERIZATION OF PAEDIATRIC NON-RHABDOSARCOMA SOFT TISSUE SARCOMAS**

**General considerations.**
The knowledge of biological phenomena involved in solid tumours is becoming increasingly relevant for the understanding of the behaviour of a variety of cancers. This, together with the availability of recent powerful technologies and new reagents for cellular and molecular biology studies, makes the field of sarcoma biology particularly attractive and challenging.

Recent molecular studies have contributed to an expanding list of genetic abnormalities in paediatric solid tumours, including chromosomal translocations and inversions, amplification of proto-oncogenes and gene-deregulation.

The group of malignancies known as “small round cell tumours” of childhood are still a diagnostic problem due to the relative lack of differentiation of these tumours, but other less frequent entities still represent a challenge both from the diagnostic and therapeutic perspectives, as well. Among them, tumours such as desmoplastic small round cell tumour (DSRCT), synovial sarcoma (SS) and congenital infantile fibrosarcoma (CIFS) are to be considered.

Cytogenetic studies of several childhood sarcomas have identified reciprocal chromosomal translocations which correlate with specific tumour types. Molecular cloning of the translocation breakpoints has identified fusions between genes located at the breakpoints of each partner chromosome that result in the expression of chimeric oncoproteins.

From a clinical perspective, some of the genetic abnormalities represent tumour associated markers that can be used to confirm the histological diagnosis or to assess biological characteristics that may have clinical impact. Furthermore, they can be used as tumour markers to detect minimal dissemination of disease with a much higher sensitivity than standard histopathological approaches.

**Common molecular targets in paediatric sarcomas**
Several RT-PCR protocols were recently established to specifically detect transcripts that can be used for the identification of paediatric sarcomas. Among others, the ETV6-NTRK3 chimeric transcript is found in congenital infantile fibrosarcoma (CIFS); EWS-WT1 in desmoplastic sarcoma (DSRCT) and SYT-SSX1 and SYT-SSX2 are characteristic of synovial sarcoma (SS).

This situation has some similarity to the genetic alterations of alveolar rhabdomyosarcoma and Ewing’s sarcoma family tumours, where reciprocal translocations have been well characterized. Moreover, new molecular markers may be identified in the future that could have clinical applications and may further improve our knowledge of soft tissue sarcomas of childhood.
The table below summarizes the most frequent genetic targets that are currently used in most laboratories for the characterization of paediatric sarcomas, excluding rhabdomyosarcoma and Ewing/PNET and their association to the specific histological subtype.

<table>
<thead>
<tr>
<th>Tumour</th>
<th>Chromosomal translocation</th>
<th>Transcript</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS</td>
<td>t(X;18)(q11;q11)</td>
<td>SSX1-SYT</td>
</tr>
<tr>
<td></td>
<td>t(X;18)(q11;q11)</td>
<td>SSX2-SYT</td>
</tr>
<tr>
<td>CIFS</td>
<td>t(12;15)(p13;q25)</td>
<td>ETV6-NTRK3</td>
</tr>
<tr>
<td>DSRCT</td>
<td>t(11;22)(q13;q12)</td>
<td>EWS-WT1</td>
</tr>
<tr>
<td>Liposarcoma</td>
<td>t(12;16)(q13;p11)</td>
<td>TLS-CHOP</td>
</tr>
<tr>
<td>Clear cell sarcoma</td>
<td>t(12;22)(q13;q12)</td>
<td>EWS-ATF1</td>
</tr>
<tr>
<td>Extraskeletal chondrosarcoma mixoid</td>
<td>t(9;22)(q22;q12)</td>
<td>EWS-TEC</td>
</tr>
<tr>
<td>Dermatofibroma protuberans</td>
<td>t(17;22)(q22;q13)</td>
<td>COL1A1-PDGFB</td>
</tr>
</tbody>
</table>

**Role of biological studies in paediatric sarcomas**

The new clinical trials of the European paediatric Soft Tissue Sarcoma Study Group (EpSSG) represent a unique opportunity to conduct prospective clinical and biological studies in the context of uniform diagnostic and therapeutic strategies. Moreover, the relatively large patient accrual in reasonable time periods, would give biologists and clinicians the possibility of translating into the clinical setting any relevant findings that may emerge from collaborative studies. Thus, a great effort is warranted by all the national participating groups and each clinical Institution in collecting biological samples to conduct selected and potentially relevant biological studies.

A Biology Subcommittee has been created in which representatives from each national groups should participate and collaborate both in identifying specific priorities and methods to make the collaboration most fruitful and translatable into clinical relevant information as well as in collecting biological samples for further studies.
Cytogenetics
Although characteristic genetic abnormalities have been reported in specific types of sarcomas, in some cases no specific genetic tumour marker can be identified. For this reason cytogenetic analysis should be performed in any solid tumour and results should be collected prospectively: this will allow us to learn about yet unknown genetic alterations that may be associated to specific tumours or subgroups of patients and to identify recurrent complex alterations that cannot be determined by molecular methods. Cytogenetic studies are only possible on fresh tumour tissue.

FISH
Fluorescent-in-situ hybridization is a rather recent technique that, making use of specific labeled DNA fragments, can detect genetic abnormalities both with regard to gene/chromosome structure and number. By this technique specific chromosomal translocations, including reciprocal translocations of the most common paediatric sarcomas, can be identified. Amplification or loss of genetic material can also be determined. Similarly to cytogenetics, fresh tumour tissue or cells are the optimal starting material for the assay.

Reverse transcriptase polymerase chain reaction (RT-PCR) for chimeric transcripts
Cytogenetic studies of childhood sarcomas have identified chromosomal translocations associated with specific tumour types. These genetic abnormalities give rise to fusion genes that are transcribed into specific chimeric RNA that can be revealed by RT-PCR. Chimeric transcripts may thus represent tumour associated markers that can be exploited as diagnostic tools.
In most instances, the prognostic implications of the presence or absence of specific reciprocal translocations are not known.

Storage of biological material for further analysis
Although we can plan studies on specific biological issue that would appear meaningful at present, there might be more important questions with clinical consequences that may become evident as our clinical and biological knowledge of the tumour progress. Furthermore, the availability of new technologies may render it possible to answer critical questions that are not approachable with the current scientific and technical resources.
For this reasons it is necessary that, whenever possible, biological specimens can be collected and stored appropriately for further studies as scientific priorities or feasibility become evident.
A clear example of this is the study of gene expression profile in tumours, by gene arrays, which is ongoing in many laboratories and that may indeed represent a significant improvement compared to previous approaches.

HANDLING OF SPECIMENS
FRESH OPEN BIOPSY OR TRU-CUT
Note: In some national groups pathology and biology laboratories may be organized differently than in other Countries and this may influence the procedures for optimizing biological studies and/or collection and storage of specimens.
A. INTRODUCTION
The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Medical research involving human subjects includes research on identifiable human material or identifiable data. It is the duty of the physician to promote and safeguard the health of the people. The physician’s knowledge and conscience are dedicated to the fulfillment of this duty.
The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient."
Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects. In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society.
The primary purpose of medical research involving human subjects is to improve prophylactic, diagnostic and therapeutic procedures and the understanding of the aetiology and pathogenesis of disease. Even the best proven prophylactic, diagnostic, and therapeutic methods must continuously be challenged through research for their effectiveness, efficiency, accessibility and quality.
In current medical practice and in medical research, most prophylactic, diagnostic and therapeutic procedures involve risks and burdens.
Medical research is subject to ethical standards that promote respect for all human beings and protect their health and rights. Some research populations are vulnerable and need special protection. The particular needs of the economically and medically disadvantaged must be recognized. Special attention is also required for those who cannot give or refuse
consent for themselves, for those who may be subject to giving consent under duress, for those who will not benefit personally from the research and for those for whom the research is combined with care. Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human subjects in their own countries as well as applicable international requirements. No national ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set forth in this Declaration.

B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH

It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subject. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation.

Appropriate caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol. This protocol should be submitted for consideration, comment, guidance, and where appropriate, approval to a specially appointed ethical review committee, which must be independent of the investigator, the sponsor or any other kind of undue influence. This independent committee should be in conformity with the laws and regulations of the country in which the research experiment is performed. The committee has the right to monitor ongoing trials. The researcher has the obligation to provide monitoring information to the committee, especially any serious adverse events. The researcher should also submit to the committee, for review, information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest and incentives for subjects.

The research protocol should always contain a statement of the ethical considerations involved and should indicate that there is compliance with the principles enunciated in this Declaration.

Medical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given consent.

Every medical research project involving human subjects should be preceded by careful assessment of predictable risks and burdens in comparison with foreseeable benefits to the subject or to others. This does not preclude the participation of healthy volunteers in medical research. The design of all studies should be publicly available.

Physicians should abstain from engaging in research projects involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians should cease any investigation if the risks are found to outweigh the potential benefits or if there is conclusive proof of positive and beneficial results.

Medical research involving human subjects should only be conducted if the importance of the objective outweighs the inherent risks and burdens to the subject. This is especially important when the human subjects are healthy volunteers. Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.

The subjects must be volunteers and informed participants in the research project. The right of research subjects to safeguard their integrity must always be respected. Every precaution should be taken to respect the privacy of the subject, the confidentiality of the patient's information and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.

In any research on human beings, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail. The subject should be informed of the right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. After ensuring that the subject has understood the information, the physician should then obtain the subject's freely-given informed consent, preferably in writing. If the consent cannot be obtained in writing, the non-written consent must be formally documented and witnessed.

When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship with the physician or may consent under duress. In that case the informed consent should be obtained by a well-informed physician who is not engaged in the investigation and who is completely independent of this relationship.

For a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorized representative in accordance with applicable law. These groups should not be included in research unless the research is necessary to promote the health of the population represented and this research cannot instead be informed on legally competent persons.
When a subject deemed legally incompetent, such as a minor child, is able to give assent to decisions about participation in research, the investigator must obtain that assent in addition to the consent of the legally authorized representative.

Research on individuals from whom it is not possible to obtain consent, including proxy or advance consent, should be done only if the physical/mental condition that prevents obtaining informed consent is a necessary characteristic of the research population. The specific reasons for involving research subjects with a condition that renders them unable to give informed consent should be stated in the experimental protocol for consideration and approval of the review committee. The protocol should state that consent to remain in the research should be obtained as soon as possible from the individual or a legally authorized surrogate.

Both authors and publishers have ethical obligations. In publication of the results of research, the investigators are obliged to preserve the accuracy of the results. Negative as well as positive results should be published or otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of interest should be declared in the publication. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects. The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method exists. At the conclusion of the study, every patient entered into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by the study.

The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient-physician relationship.

In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.
Information sheet / Consent forms

The following text is a suggested form of information suitable for parents of children with NRSTS. Local Research Ethical Committees may demand differing levels of written information as a part of the process of obtaining informed consent. The EpSSG NRSTS 2005 protocol is an observational study and the provision of written consent is a matter for individual institutions to agree in the context of their local ethical approval policies. It is also advisable to have the family consent to the storage of biological material for future studies according to the rules existing in different countries.

A1 - INFORMATION SHEET FOR PARENTS

Your child has recently been diagnosed with a tumour included in the group of the so-called Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS). This is a very heterogeneous group of tumours with different biology and clinical behaviour. These tumours can occur at any age, almost anywhere in the body. Usually, they are characterized by local aggressiveness, but sometimes they can provoke distant metastases. Their clinical behaviour is directly correlated to their grade of malignancy: generally, low-grade tumors usually may have local aggressiveness but low tendency to metastatic spread. High-grade tumors have a more invasive behaviour with higher propensity to metastasize (in particular at the lung). Other variables are important to predict the clinical outcome, particularly the tumour size and the extent to which the tumour can be removed by operation at the start of treatment.

The treatment of children with NRSTS is complex and necessitates multidisciplinary approach. Surgery is the mainstay of treatment, but in some cases tumour resection is not enough, because there is a high risk of local or metastatic relapse: therefore, adjuvant treatments as chemotherapy (anti-cancer drugs) and radiotherapy (x-ray treatment) are necessary. Moreover, in some cases the complete removal of the tumour is not possible and chemotherapy is administered in the view to shrink the tumour and make it resectable. Many children with NRSTS can be cured but it is still necessary to collect further information about the treatment they have received, whether that is chemotherapy, surgery or radiotherapy to learn more about the best way of treating such patients in the future.

1. What is the purpose of this study?
The purpose of this study is to treat children in a systematic way according to an internationally agreed treatment protocol and to document their response to treatment in order to identify in a large number of patients, how their treatment can be optimised.

2. Why has my child been chosen?
Your child has been diagnosed with a NRSTS and fulfils the eligibility criteria for this study.

3. Does my child have to take part?
It’s up to you and your child whether or not to take part. If you decide to take part you will be given these information sheets to keep and asked to sign a consent form. If you and your child...
decide to take part, you are free to withdraw at any time without having to give a reason. Your
doctor may wish to withdraw your child from the study if it is felt to be in their best interest. A
decision to withdraw or not take part at all will not affect the standard of your child’s care or the
relationship with your child’s doctor. You may take part in the clinical study without agreeing to
have your child’s tumour stored for a biological study (details to be given in an attached sheet).

4. What will happen to my child if we take part?
Your child will be treated according to the EpSSG protocol appropriate for your child’s tumour
depending on the extent to which the tumour has been (or can be) removed by operation, whether it
has spread, how large it is and what histological grade of malignancy it has. All treatments have
side effects. Your doctor will discuss these in detail with you. Surgery might cause physical,
functional or aesthetic damages. The commonest side effect of chemotherapy is a temporary poor
functioning in the bone marrow. This caused an increased susceptibility to infection for the whole
duration of treatment. You will be instructed what to do if your child has a fever or appears unwell
during this time. This side effect is temporary and your child’s ability to fight infection will return
to normal by six months from the end of treatment. Your child may also need blood and platelets
transfusions during the course of treatment. There are also some drug specific side effects, some of
which can be permanent (e.g. kidney damage from ifosfamide, cardiotoxicity for doxorubicin) but
the risk of these problems is low and your doctor will explain them in more detail. Moreover, there
may be a possibility of infertility in later life. Radiotherapy may cause fibrosis, bone and soft tissues
growth retardation, and other sequelae in relation to the site of the tumour and the age of your child.
Second malignancies also might occur in patients treated with chemotherapy and in particular with
radiotherapy, but the risk is very low. Your doctor will discuss your child’s individual risk of these
problems.
For all children with NRSTS we would like to store a small piece of tumour that is left over after
making the diagnosis and/or at a further operation to remove the tumour after treatment. Also frozen
and standard pathology wax blocks of tumour will be stored. These stored specimens will be used
for scientific research to improve our understanding of NRSTS. Any research studies using your
child’s sample will only be undertaken once they have received full ethical approval.

5. Will there be any inconveniences?
We do not anticipate there will be any inconveniences over and above the normal treatment for
NRSTS from taking part in this study.

6. What are the possible benefits of taking part?
Whether or not you decide to take part your child will receive the best possible medical care. By
taking part in this study, we will learn about how best to treat it in the future. We hope to learn
more about why some tumours do well and where for those who do less well to improve treatment
for children with NRSTS in the future. We are asking your permission to keep records of your
child’s treatment.

7. What are the possible risks of taking part?
There are usually no extra risks involved in collecting data or samples for storage for research. We
are asking your permission to collect detailed information about your child’s treatment.

8. Will my child taking part in the study be kept confidential?
With your consent we will be informing your doctor about your child’s participation in the study.
Information on all patients entered into this study will be kept at the National Coordinator Data
Center. Data including your child’s initials, date of birth, their diagnosis and the extent of their
tumour, details of the treatment, any side effects and tumour response, and whether tissues have
been stored will be recorded. Information relating to your child’s treatment will then be forwarded electronically to an international database in Italy. No personally identifiable information will be released in this way. Only limited clinic information on your child diagnosis and response to treatment will be sent to the central tumour office, in accordance with normal standards of medical confidentiality and data protection.

9. What will happen to the results of the research study?
The results of this study will be published in a medical journal once the study has been completed and all patients who have been followed up for at least one year. Your child will not be identified in any publication.

10. Who is organising and funding the research?
This research is being organised by the European paediatric Soft Tissue Sarcoma Study Group. This group includes experts from a number of countries throughout Europe who have considerable experience in the treatment of this tumour.

11. What if I have any other concerns?
If you have any concerns or other questions about this study or the way it has been carried out you should contact your doctor or you may contact the hospital complaints department.

Thank you for taking the time to read this information sheet and for taking part in the study if you agree to do so.

A2 - INFORMATION SHEET FOR OLDER PATIENTS
You have recently been diagnosed with a tumour called soft tissue sarcoma. This is a form of cancer that can occur almost anywhere in the body and of which there are many different types. The treatment you will need is influenced by several factors including the exact subtype of the tumour, its size and whether it can be removed by operation at the start of treatment. Surgery is the mainstay of treatment, but in some cases tumour resection is not enough, and adjuvant treatments are necessary; anti-cancer drugs (chemotherapy) and/or x-ray treatment (radiotherapy) may be useful for cure you.

We would like to collect information about the treatment you receive, whether that is chemotherapy, surgery or radiotherapy to learn more about the best way of treating patients like you in the future.

1. What is the purpose of this study?
For many patients the purpose is to treat the tumour in a systematic way according to a treatment protocol that has been agreed in many different countries. If the response to treatment is documented in a large number of patients, it is hoped that we will better understand how the treatment of soft tissue sarcomas can be improved.

2. Why have I been chosen?
You have a soft tissue sarcoma and are therefore eligible for this study.
3. Do I have to take part?
It is up to you whether or not you take part. If you decide to take part you will be given these information sheets to keep and asked to sign a consent form. You are free to withdraw from the study at any time without having to give a reason. Your doctor may also want to withdraw you from the study if it is felt to be in your best interest. A decision to withdraw or not take part at all will not effect the standard of your care or your relationship with your doctor and nurses.

4. What will happen to me if I take part?
You will be treated according to the protocol appropriate for your type of tumour, depending on the exact subtype of the tumour, how large it is, whether it has spread and whether it can be removed by operation.
All treatments have side effects, and your doctor will discuss these with you in details. All treatments have side effects. Your doctor will discuss these in detail with you. Surgery might cause physical, functional or aesthetic damages. The commonest side effects of chemotherapy are loss of hair and a temporary poor functioning in the bone marrow. This then reduces your ability to fight infection throughout your whole treatment. You will be told that if you have a temperature or you feel unwell that you must contact your doctor straight away. This is temporary side effect and once the treatment is finished your ability to fight infection will return to normal within 6 months. You may also need blood and platelet transfusions during the treatment because your bone marrow will not be making these properly. There are other specific side effects some of what can be permanent e.g. infertility or kidney damage from the ifosfamide but the risk of these problems is low and your doctor will explain them in more detail. You may also receive radiotherapy or further surgery depending on the size and place of your original tumour. The details of the surgery and radiotherapy will again be explained to you by the treating doctor.
For all people included in the protocol, we would like to store a small piece of the tumour that is left over after making the diagnosis and / or a further operation to remove the tumour. These stored specimens will be used for scientific research to improve our understanding of these neoplasms. Any research studies, using your sample will only be undertaken once they have received full ethical approval.

5. Will there be any inconveniences?
We do not anticipate any inconveniences over and above the normal treatment for soft tissue sarcomas from taking part in this study. We simply want to record the details of your treatment at a central database.

6. What are the possible benefits of taking part?
Whether or not you decide to take part, you will receive the possible medical care. By taking part in this study, we hope that we will learn more about how to best treat it in the future. We are asking your permission to keep your records although these will be anonymised outside this hospital.

7. What are the possible risks of taking part?
There are usually no risks involved in collecting data or samples for storage for research.

8. Will my taking part be kept confidential?
We will be letting your doctor know that you are taking part in this study with your consent and if you agree, your notes may be inspected by authorised professionals other than those directly involved in your care. Information on all patients entered into this study will be kept at the National Coordinator Data Center, where it is kept and anonymised. Information relating to your treatment will then be forward electronically to an International Database in Italy. No personally identifiable
information will be released in this way (i.e. it will all be anonymised). Only limited clinical information on your diagnosis and response to treatment will be sent to the Central Tumour Office, in accordance with normal standards of medical confidentiality and data protection.

9. What will happen to the results of the research study?
The results of this study will be published in a medical journal once the study has been completed and all patients who have been followed up for at least one year.

10. Who is organising and funding the research?
This research is being organised by the European paediatric Soft Tissue Sarcoma Study Group. This group includes experts from a number of countries throughout Europe who have considerable expertise in the treatment of this tumour.

11. What if I have any other concerns?
If you have any concerns or questions about this study or the way it has been carried out you should contact the investigator in your centre or you may contact the hospital complaints department. Thank you for taking the time to read this information sheet and for taking part in the study if you agree to do so.

A3 - INFORMATION SHEET FOR YOUNGER PATIENTS

This information sheet can be given or read to children as appropriate

Dear Patient

You have a lump or tumour called a sarcoma. We do not know why it has happened to you but we do know ways of trying to make you better. You need an operation that aims to remove the tumour; some children with this disease sometimes need treatments as medicines called ‘chemotherapy’ or x-ray treatment called ‘radiotherapy’.

We are trying to make the treatment for sarcoma better by lots of doctors in Europe working together to plan the best treatment for this tumour. We keep a register of all the children having treatment for sarcomas. Some of the information from your treatment will also be sent by a computer to Italy.

If you want to know about the details of treatment, you can ask your nurse, doctor or your mum or dad to explain it some more.